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Abstract 
 
Malignant hyperthermia (MH) is a potential fatal hereditary skeletal muscle disorder 
that occurs upon exposure to certain anaesthetic agents. Susceptibility is 
predominantly conferred by variants in the RYR1 gene encoding the type 1 ryanodine 
receptor (RYR1). A common feature observed in MH susceptible patients and in 
animal models, is a RYR1-leak dependent elevation in the intracellular Ca2+ 
concentration ([Ca2+]i) in the non-triggered state. However, it is not fully understood 
whether extracellular Ca2+ entry plays an important role in maintaining this elevated 
resting [Ca2+]i. It is also becoming increasingly evident that RYR1 variants can 
produce different MH phenotypes, for example the variant p.G2434R (c.7300G>A) is 
the major MH variant found globally, but has a weaker clinical phenotype relative to 
rarer variants such as p.R2454H (c.7361G>A).  
 
Live-cell calcium imaging was used to examine different aspects of the molecular 
mechanisms underlying RYR1-associated MH. The first was to use HEK293 cells to 
explore the caffeine sensitivity of novel potentially pathogenic RYR1 variants. Next 
skeletal muscle myotubes derived from MH patients with p.G2434R or p.R2454H, 
were found to have an enhanced sensitivity to caffeine, and a TRPC3/6 mediated 
increased sarcolemmal cationic influx relative to non-susceptible controls. There was 
no significant difference between the two MH associated RYR1 variants. 
 
Myotubes from a novel MH mouse model containing the equivalent variant to human 
p.G2434R, were also found to have an elevated sensitivity to RYR1 agonists. This 
model has further confirmed that the TRPC3/6 mediated enhanced cationic entry is 
conserved between the two species, and this entry can be reduced to control levels 
by blocking the RYR1-dependent leak.  
 
Taken together, the data presented in this thesis furthers our understanding of the 
molecular mechanisms that underlie the perturbed Ca2+ handling observed in MH 
tissue, and provides new avenues of research into MH and related RYR1 disorders 
as well as a potential target for novel therapies. 
 
 
 iii 
 
Table of Contents 
 
Acknowledgements…...............................................................................................i 
Abstract.....................................................................................................................ii 
Table of Contents.....................................................................................................iii 
List of Tables…..……..............................................................................................xii 
List of Figures………..............................................................................................xiii 
List of Abbreviations ............................................................................................xvi 
 
 
1 Introduction………................................................................................................1 
1.1 Malignant Hyperthermia................................................................................1 
1.1.1 Clinical Manifestations………………………………………..…...……….…1 
1.1.2 Epidemiology………………………………………………………..…………2 
1.1.3 Diagnosis of MH………..……………………………………………………..3 
1.1.3.1 Clinical Grading Scale…………………………………….………….…3 
1.1.3.2 IVCT…………………………..………………………………………..…3 
 
1.2  Genetics of MH…………………………………………………………..………..7 
1.2.1 Inheritance……………………………………………………………..………7 
1.2.2 Phenotypic Diversity……………….…………………………………….……8 
1.2.3 Molecular Genetics of the Susceptibility to MH……………….……….…..9 
1.2.3.1 Genetic Testing for MH…………………..……………………..….…..9 
1.2.3.2 Investigating Novel Variants………………….…………………..…..10 
1.2.3.3 Characterising RYR1 Variants………………………………..………11 
1.2.4 Related Skeletal Muscle Disorders…………………………………….….12 
1.2.4.1 Exertional Heat Illness…………..…………………………………....12 
1.2.4.2 Central Core Disease…………..…………………………………..…12 
 
1.3 Treatment of MH and Related Disorders…………….………………....……13 
 
1.4 Skeletal Muscle…………………………………………….………...……..……14 
1.4.1 Muscle Regeneration……………………..…………………..…..…..….…14 
1.4.2 Physiology………………………………...…………………………….…....15 
1.4.3 RYR1………………………………………………………………...…..……16 
1.4.4 RYR1 Regulatory Molecules and Proteins………………………….…….18 
 iv 
1.4.4.1 Small Molecules…………….…………………………….….………..18 
1.4.4.2 Proteins…………………………...……...……………………....…….19 
1.4.5 Cav1.1………………………….…………………………………….….……20 
1.4.6 STAC3……………………………………………………….………..….…..22 
1.4.7 TRPC Channels………………………………………….……………..…...22 
1.4.8 Extracellular Calcium Entry Mechanisms………………………...…...….23 
1.4.8.1 ECCE………………………………………………………………..…..23 
1.4.8.2 SOCE…………………………………………………….....…………..24 
1.4.8.3 RCaE……………………………………………………………...………25 
1.4.9 MH and Ca2+ Handling……….………………………………….……….…26 
 
1.5 Thesis Aims and Objectives…………………………………….….………….27 
1.5.1 Aims…………………………………………….…………………………..…27 
1.5.2 Objectives………………………………………………………..…………...28 
 
 
2 Methods.…………………………………………………………………………….…..29 
2.1 Generation of p.G2435R Mice……………………………………….…..…….29 
 
2.2 General Cell Culture Methods………………………………..…………….…30 
2.2.1 Isolation of Human Myoblasts…………………………………….….….…30 
2.2.2 Isolation of Mouse Myoblasts………………………………………………31 
2.2.3 Matrix Coating of Plates………………………………………...…………..32 
2.2.4 Differentiation of Human and Mouse Myoblasts…………………...…….32 
2.2.4.1 Live Cell Calcium Imaging Experiments…………………………….32 
2.2.4.2 Immunocytochemistry Experiments………………………………....32 
2.2.4.3 RT-PCR Experiments………………………………………………....32 
2.2.5 Passage and Cryostorage of Cells……………………………......……....33 
2.2.6 Cell Counting and Viability Assays………………………………………...33 
 
2.3 General Molecular Biology Methods……………………………….………...34 
2.3.1 DNA Extraction……………………........….……………………………......34 
2.3.2 PCR and Agarose Gel Electrophoresis……….....…………..…….…......34 
2.3.3 Direct PCR…………………………………………………….………..........35 
2.3.4 Sanger Sequencing…………………………………....……………...........35 
 
 
 v 
2.4 General Bacterial Methods……………...…....…..…..…..…..…...................36 
2.4.1 Bacterial Growth………..............…………………...……...……………....36 
2.4.2 Plasmid Maxi Preparation………………………………………….............36 
2.4.3 Production of Glycerol Stocks………….........………………………….....36 
 
2.5 Immunocytochemistry…………………………………….…………...............37 
 
2.6 Live-Cell Calcium Imaging…………………………………………….............38 
2.6.1 Perfusion System………………………………….………..……...............38 
2.6.2 Experimental Solutions…………………………..……………..................39 
2.6.2.1 Buffers………………………………………………...........................39 
2.6.2.1.1 Imaging Buffer……………………………................................39 
2.6.2.1.2 Manganese Buffer……………………………....………...........39 
2.6.2.2 Drugs…………………………………………………..…...................39 
2.6.2.2.1 Caffeine and Other Compounds……………………...............39 
2.6.2.2.2 KCl………………………………………...................................40 
2.6.2.2.3Halothane………………………………………..........................40 
2.6.3 Epifluorescence Imaging………….…….………………..........................41 
2.6.3.1 Dye Loading……………………….……….……..............................41 
2.6.3.2 Calcium Release..……………………………. …............................42 
2.6.3.3 Extracellular Cationic Entry…………………..…….........................43 
2.6.3.4 Statistics……………………………………………...........................43 
2.6.3.4.1 Calcium Release....………………………………….…….........43 
2.6.3.4.2 Manganese Quench………………………………....................44 
 
 
3 Studying Novel RYR1 Variants in HEK Cells…………......................................45 
3.1 Introduction…………………………………………………............................45 
3.1.1 Assessment of Novel Genetic Variants Associated with MH.................45 
3.1.2 Functional Studies using HEK Cells……………………..........................46 
3.1.3 MH Variants……………………………………………..............................47 
3.1.3.1 p.D1056H……………………………………………….......................47 
3.1.3.2 p.R2355W………………………………………………......................47 
3.1.3.3 p.D3986E……………………………………………..........................48 
3.1.4 pTUNE expression system…………………………….............................49 
3.1.5 AICAR………………………………………………....................................50 
 
 vi 
3.2 Aims………………………………………………............................................51 
 
3.3 Methods………………………………………….............................................51 
3.3.1 Characterising the Kinetics of the Perfusion System.............................51 
3.3.1.1 Flow Rate and Residual Well Fluid Volume…................................51 
3.3.1.2 Caffeine Perfusion…………………………………...........................51 
3.3.1.3 Curcumin Perfusion……………………………….............................52 
3.3.2 pTUNE RYR1 Constructs…………………………...................................53 
3.3.2.1 Generation and Sequencing of pTUNE RYR1 Plasmids................53 
3.3.2.2 Plasmid Isolation…………………………………..............................53 
3.3.3 Transient Transfections of HEK cells………….......................................53 
3.3.3.1 Maintenance, Passage and Cryopreservation of HEK Cells..........53 
3.3.3.2 Transient Transfections and Induction of pTUNERYR1.................53 
3.3.3.3 Inducing the Expression of pTUNERYR1……................................54 
3.3.3.4 Treatment with AICAR……………………………............................54 
3.3.4 Caffeine-induced Calcium Release Experiments…...............................54 
3.3.4.1 Experimental Solutions……………………......................................54 
3.3.4.2 Calcium Imaging…………………………………..............................54 
3.3.4.3 Statistics…………………………………..........................................55 
 
3.4 Results…………………………………..........................................................56 
3.4.1 Kinetics of the Perfusion System……....................................................56 
3.4.1.1 Flow Rate and Residual Well Fluid Volume...................................56 
3.4.1.2 Caffeine Perfusion…………………….............................................57 
3.4.1.3 Curcumin Perfusion…………………...............................................58 
3.4.2 Caffeine Responses of RYR1 Variants in HEK cells..............................59 
3.4.2.1 AUC………………..........................................................................59 
3.4.2.2 Peak……….....................................................................................61 
3.4.3 Acute AICAR Treatment.........................................................................63 
3.4.3.1 AUC Response………....................................................................63 
3.4.3.2 Peak Response………...................................................................63 
3.4.4 Chronic AICAR………............................................................................66 
3.4.4.1 AUC Response………....................................................................66 
3.4.4.2 Peak Response………...................................................................66 
 
 
 vii 
3.5 Discussion…………….................................................................................68 
3.5.1 Perfusion System……............................................................................68 
3.5.2 Caffeine Responses of RYR1 Variants in HEK Cells.............................69 
3.5.2.1 WT RYR1……….............................................................................69 
3.5.2.2 p.D1056H……….............................................................................69 
3.5.2.3 p.D3986E ………............................................................................70 
3.5.2.4 p.R2355W ………...........................................................................71 
3.5.3 The Effect of AICAR on RYR1 Channels...............................................71 
 
3.6 Conclusion……............................................................................................72 
 
 
4 Investigating the p.G2434R and p.R2454H Variants in Human MH................73 
4.1 Introduction…….........................................................................................73 
4.1.1 The p.G2434R Variant...........................................................................73 
4.1.2 The p.R2454H Variant...........................................................................74 
4.1.3 Structure Activity Relation of RYR1 Variants.........................................74 
4.1.4 Genotype and Phenotype Correlations..................................................75 
4.1.5 Genotype and Phenotype Discordance.................................................77 
4.1.6 Extracellular Ca2+ Entry in MH...............................................................78 
 
4.2 Aims.............................................................................................................80 
 
4.3 Methods.......................................................................................................81 
4.3.1 Experimental Cells.................................................................................81 
4.3.1.1 Human Myoblasts...........................................................................81 
4.3.1.2 Confirmation of RYR1 Variants......................................................81 
4.3.2 Immunocytochemistry............................................................................82 
4.3.2.1 Desmin Staining.............................................................................82 
4.3.2.2 Myosin Heavy Chain Staining........................................................82 
4.3.3 Live-Cell Calcium Imaging.....................................................................82 
4.3.3.1 Experimental Solutions..................................................................82 
4.3.3.2 Calcium Release............................................................................82 
4.3.3.3 Extracellular Cationic Entry............................................................82 
4.3.4 Statistics.................................................................................................83 
4.3.4.1 Calcium Release............................................................................83 
4.3.4.2 Manganese Quench.......................................................................83 
 viii 
4.4  Results.........................................................................................................84 
4.4.1 Human Pedigrees of Human Cell Samples............................................84 
4.4.2 Confirmation of Variants in Samples......................................................86 
4.4.3 Generation of Myotubes.........................................................................87 
4.4.4 p.R2454H Myotubes Have an Enhanced Sensitivity to Caffeine……....90 
4.4.5 p.G2434R Myotubes Have an Enhanced Sensitivity to Caffeine….......95 
4.4.6 Genotype-Phenotype Comparisons with Caffeine…..............................98 
4.4.7 Attenuated Peak Responses in MHS Myotubes…...............................100 
4.4.8 Human MHS Myotubes Exhibit an Enhanced RCaE ….........................102 
4.4.9 RCaE is Mediated by Non-Specific Cationic Channels …......................105 
4.4.10 RCaE is Mediated by TRPC Channels…………...................................107 
 
4.5 Discussion……………...............................................................................109 
4.5.1 Sensitivity to Caffeine in Human MHS Myotubes………………...........109 
4.5.1.1 Culture and Production of Myotubes……………..…………..........109 
4.5.1.2 Enhanced Sensitivity to Caffeine…………...………......................110 
4.5.1.3 Lower Peak SR Ca2+ Release.……………...................................114 
4.5.2 RCaE in Human Human MHS Myotubes……………..............................114 
4.5.2.1 Enhanced RCaE in Human MHS……………..................................115 
4.5.2.2 TRPC Channels Mediate the Enhanced RCaE…….......................115 
 
4.6 Conclusion…………...…………….....…………...…………….…………......117 
 
 
5 The Immortalisation of Human Skeletal Myoblast..........................................118 
5.1 Introduction…………………...……………..…………….............................118 
5.1.1 Skeletal Muscle Stem Cells…………………...……………………..……118 
5.1.2 The Regenerative Potential of Myoblasts………………………....…….119 
5.1.3 Retroviral Gene Delivery…………………...……………..……………....120 
5.1.4 Models of MH……………………...………………………………...........121 
 
5.2 Aim…………………………………….……..………………………………......122 
 
 
 
 
 ix 
5.3 Methods………………………………..….……………………………………..123 
5.3.1 Isolation of Human Skeletal Muscle Myoblasts………………………....123  
5.3.2 Fluorescence Activated Cell Sorting of Myoblasts....……………..……123 
5.3.3  The Immortalisation of Myoblasts………………………………………..124 
5.3.3.1 Plasmid Maxi-Preparation………………......………………………124 
5.3.3.2 Antibiotic Selection Assays……………………………...…...……..124 
5.3.3.3 Generation of Viral Particles…………………...……………………125 
5.3.3.4 Transduction of Myoblasts…………………………..………………125 
5.3.4 Immunocytochemistry………………………………....…......……………125 
5.3.4.1 Desmin Staining…………………………….……………………......126 
5.3.4.2 Myosin Heavy Chain Staining…………………………..…………..126 
5.3.5 RT-PCR for RyR1……………………………......….…...........................126 
5.3.5.1 RNA Extraction.………………………………………………………126 
5.3.5.2 RT-PCR……………….……………………………………………....127 
5.3.5.3 PCR and Agarose Gel Electrophoresis….…………………………127 
5.3.6 Statistics………………………………………………………….………....127 
 
5.4 Results………………………………………………………………….………..128 
5.4.1 The Immortalisation Process………………………....…………………..128 
5.4.2  FACS Isolation of Human Myoblasts……………….........…................129 
5.4.3 Purity of Myoblasts…………………………………….…………………..132 
5.4.4 Skeletal Muscle Cell Toxicity Assays………………….…………………135 
5.4.5 J-Retroviral Immortalisation…………………...…………………………..137 
5.4.5.1 GFP Transduction…………………………………………...............137 
5.4.5.2 hTERT and CDK4 Transduction……………………......................138 
5.4.6 Additional Purification of Immortalised Cells………………….….…......140 
5.4.7 Characterisation of Immortalised Cells……………......………………...142 
 
5.5 Discussion………………………………………....……………..……………..145 
5.5.1 A Regenerative Pool of Human MH Cells ………………………….......145 
5.5.2 Purification of Myoblasts…………………………………………....……..145 
5.5.3 Myoblast Immortalisation ……………………………………………..…..147 
 
5.6 Future Directions……………………………………………..…….................149 
 
 x 
6 Investigating p.G2434R RYR1in a Mouse Model…………………...…..………151 
6.1 Introduction…………………………………………..……..…………….........151 
6.1.1 The p.G2434R Variant………………………………………………….....151 
6.1.2 MH models…………………………………………………..…………......151 
6.1.3 Enhanced Extracellular Ca2+ Entry …………………………..................152 
 
6.2 Hypothesis and Aims……………………………………………..………......153 
6.2.1 Hypothesis………………………………………………........................153 
6.2.2 Aims……………………………………………………...........................153 
 
6.3 Methods…………………………………………………....…..........................154 
6.3.1 Experimental Cells and Solutions……………………...…………………154 
6.3.2 Epifluorescence Imaging………………………..…………………………154 
6.3.2.1 Calcium Release………………………………………….................154 
6.3.2.2 Extracellular Cationic Entry………………………………..…..……154 
6.3.2.3 Statistics……………………………………………..........................154 
6.3.2.3.1 Calcium Release………………………………….……............154 
6.3.2.3.2 Manganese Quench…………………………….………….......154 
 
6.4 Results…………………..……………………..……………............................155 
6.4.1 Myoblasts Isolation…………………………….……………….…............155 
6.4.2 Enhanced Sensitivity to Caffeine………………………………..………..155 
6.4.2.1 Responses Measured Using AUC…………………………............157 
6.4.2.2 Responses Measured Using the Peak Height.........………..........159 
6.4.3 Enhanced Sensitivity to Halothane………………………….……………161 
6.4.4 Enhanced Sensitivity to KCl…………………………………….………...163 
6.4.5 p.G2435R-Hom Myotubes Have an Elevated RCaE……………....…....167 
6.4.6 RCaE is Mediated by Non-Specific Cationic Channels…………….……169 
6.4.7 RCaE in p.G2435R MHS is Mediated by TRPC Channels……...………171 
6.4.7.1 BTP2……………………………………….......................................171 
6.4.7.2 SAR7334……………………………………………….....................173 
6.4.7.3 OAG..............................................................................................175 
6.4.7.4 Hyperforin………………………………….………..........................177 
6.4.8 RYR1 Leak Contributes to the Enhanced RCaE…………….………......179 
 
 
 
 xi 
6.5 Discussion …………………………..………………………….......................181 
6.5.1 The Validation of the Novel p.G2435R KI Mouse Model of MH……....182 
6.5.2 Increased RYR1 Leak Drives an Enhanced Entry of Extracellular  
Ca2+ in p.G2435R……………….…..…………….......................................186 
6.5.2.1 Extracellular Ca2+ Entry is Enhanced in MHS-Hom….…………...186 
6.5.2.2 TRPC Channels Mediate the Enhanced RCaE………………….....188 
6.5.2.3 RYR1 Leak Drives the Enhanced RCaE………………………........190 
 
6.6 Conclusion…………………………………………………….........................191 
 
 
7. General Discussions........................................................................................192 
7.1  Overview and Importance........................................................................192 
7.2 Findings and future Progress..................................................................192  
7.2.1 Are the p.D1056H, p.R2355W and p.D3986E RYR1 Variants 
Functionally Pathogenic?.....................................................................192 
7.2.2 The Immortalisation of MHS Human Myoblasts...................................193 
7.2.3 RCaE in Human and Mouse MH Cells………………………...................194 
7.2.4 A Model for Enhanced RCaE in p.G2435R MHS-HOM Myotubes….....195 
 
7.3 Final Summary...........................................................................................197 
 
 
References…….....................................................................................................198 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xii 
 
 
 
 
 
 
 
 
 
List of Tables 
 
Table 6.1 - Summary of EC50 for KCl and caffeine in myotubes from the p.G2435R 
and p.R163C mouse models………...……………………………………..……183 
 
Table 6.2 - Intracellular [Ca2+] measured using direct microelectrodes in different 
mouse model of MH………………………………………………….……………183 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiii 
List of Figures 
 
Figure 1.1 - Representative IVCT traces for MHN and MHS……………………………5 
Figure 1.2 - UK MH protocol for IVCT testing……………………………………………..6 
Figure 1.3 - The EMHG diagnostic variants within the RYR1 protein ………..……...…8 
Figure 1.4 - EC coupling in skeletal muscle cells ……………………………..………..16 
 
 
Figure 2.1- Measurement of halothane concentrations in imaging buffer……………41 
 
 
Figure 3.1 - The pTUNE system for the inducible expression of RYR1.....……...……50 
Figure 3.2 - Flow rates within the perfusion system at different pressures.……...…56 
Figure 3.3 - Perfusion system kinetics assessed using caffeine………………………57 
Figure 3.4 - Perfusion kinetics assessed using curcumin…………..…………………58 
Figure 3.5 - Caffeine concentration response curves using AUC in p.D1056H, 
p.R2355W, p.D3986E and WT...……….………..………………………60 
Figure 3.6 - Caffeine concentration peak response curves in p.D1056H, p.R2355W,      
p.D3986E and WT.………..…………………………………….…………62 
Figure 3.7 - The effects of acute AICAR treatment on the RYR1 AUC responses…64 
Figure 3.8 - The effects of acute AICAR treatment on the RYR1 peak responses…65 
Figure 3.9 - The effects of chronic AICAR treatment on the RYR1 AUC and peak 
responses in p.D1056H and WT…...……………...…………................67 
 
 
Figure 4.1 - Family pedigree of MHN and MHS samples used with the p.G2434R 
variant..................................................................................................84 
Figure 4.2 - Family pedigree of MHN and MHS samples used with the p.R2454H 
variant………….……………………..…..…………………………..….....85 
Figure 4.3 - Confirmation of p.R2454H sequence ………...…....………..…....………86 
Figure 4.4 - The purity of myoblasts in samples from p.R2454H MHS and MHN 
humans………..……………………………………………………………88 
Figure 4.5 - Effects of extracellular matrix composition and duration of differentiation 
on myotube formation in p.R2454H MHS and MHN samples…..……...89 
Figure 4.6 - The enhanced effect of caffeine on p.R2454H MHS myotubes…………91 
Figure 4.7 - An enhanced sensitivity to caffeine in MHS p.R2454H myotubes using 
AUC...……………………………………………………………………….92 
 xiv 
Figure 4.8 - An enhanced sensitivity to caffeine in MHS p.R2454H myotubes using 
peak responses………….…………………………………………………94 
Figure 4.9 - Enhanced sensitivity to caffeine in MHS p.G2434R myotubes using 
AUC...……………………………………………………………………….96 
Figure 4.10 - Enhanced sensitivity to caffeine in MHS p.G2434R myotubes using 
peak responses……………...………………………………………..…97 
Figure 4.11 - Enhanced sensitivity to caffeine in MHS p.R2454H and p.G2434R 
myotubes using AUC……………….………………...…………………99 
Figure 4.12 - Reduced SR calcium release in MHS myotubes………………………101 
Figure 4.13 - Sarcolemmal cationic permeability in MHS and MHN myotubes….…103 
Figure 4.14 - Enhanced RCaE in MHS myotubes is independent of the RYR1 variant.. 
...... ...... ...... ....................……………………………...............………………………104 
Figure 4.15 - The cationic entry is mediated by non-specific cationic channels……106 
Figure 4.16 - MHS myotubes have an enhanced sensitivity to SAR7334…………108 
 
 
Figure 5.1 - Schematic for the process of immortalising human skeletal myoblasts....  
.........................…..…………………......………………………………………...128 
Figure 5.2 - CD56 based FACS analysis of MHS skeletal muscle cells……………129 
Figure 5.3 - The expression of CD56 in different MHS and MHN patient samples… 
.... .... ......……………………………………………...............………………….131 
Figure 5.4 - ICC staining for desmin in preplated primary human skeletal muscle 
cells………………………………………………………………………..133 
Figure 5.5 - ICC staining for desmin in preplated and CD56+ FACS sorted  
primary human skeletal muscle cells.…..………………………………134 
Figure 5.6 - The effects of antibiotics and transduction agents on human myoblast 
growth...……………………………………...........................................136 
Figure 5.7 - Muscle cells transduced with the pBABE-GFP plasmid…………….…137 
Figure 5.8 - Antibiotic selection of immortalised human skeletal muscle cells…….138 
Figure 5.9 - The immortalisation of MHS and MHN human skeletal muscle cells…139 
Figure 5.10 - The isolation of CD56+ and CD82+ immortalised cells………………...141 
Figure 5.11 - Immortalised cells variably differentiate into multinucleated myotubes 
………....………………………………………………………………………..….142 
Figure 5.12 - Immortalised cells express RYR1 mRNA and myosin heavy chain 
…..….....……………………………………………………………………………143 
Figure 5.13 - The expression of myosin heavy chain in immortalised cell lines……144 
 
 xv 
Figure 6.1 - Myotube images……………………………………………………………156 
Figure 6.2 - The enhanced effect of caffeine in MHS myotubes……………………158 
Figure 6.3 - The enhanced sensitivity MHS myotubes to caffeine using AUC……...160 
Figure 6.4 - The enhanced sensitivity MHS myotubes to caffeine using peak 
responses.…………..………………………………………………....…162 
Figure 6.5 - The enhanced sensitivity of MHS myotubes to halothane………..........164 
Figure 6.6 - The response of myotubes from the three genotypes to potassium 
chloride.….………………………………………………………………..165 
Figure 6.7- Gene-dose dependent enhanced sensitivity of MHS myotubes to KCl..166 
Figure 6.8 - The presence of a RCaE in MHS and MHN myotubes…………………...167 
Figure 6.9 - MHS-Hom myotubes exhibit an enhanced RCaE……………………..…168 
Figure 6.10 - The RCaE is mediated by non-specific cationic channels……..………170 
Figure 6.11 - MHS myotubes have an enhanced sensitivity to BTP2………….……172 
Figure 6.12 - MHS myotubes have an enhanced sensitivity to SAR7334…………..174 
Figure 6.13- TRPC3/6 channels mediate the RCaE .………….……………………....176 
Figure 6.14 - TRPC6 partly mediate the RCaE………….…..……………….……........178 
Figure 6.15 - The RYR1 leak mediates an enhanced RCaE………………………...…180 
 
 
Figure 7.1 - Model for the enhanced RCaE in p.G2435R MHS-HOM myotubes….....195 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvi 
List of Abbreviations 
 
[Ca2+]i  Intracellular calcium concentration 
[Ca2+]E Extracellular calcium concentration 
[Ca2+]SR Sarcoplasmic reticulum calcium concentration 
°C Degree centigrade 
6-TM Six transmembrane 
7-AAD 7-Aminoactinomycin D  
95% CI  95% confidence interval 
aa Amino acid 
AAV Adeno-Associated Virus 
ACh Acetylcholine 
AChR Acetylcholine receptor 
ACMG American College of Medical Genetics and Genomics  
ADP Adenosine diphosphate 
AFU Arbitrary fluorescence unit 
AICAR 5-Aminoimidazole-4-Carboxamide Ribonucleoside 
AKI Acute kidney injury 
AM Acetoxymethyl ester 
ANOVA  Analysis of Variance 
APC Allophycocyanin 
ATP Adenosine triphosphate 
AUC Area under the curve 
bp Base pairs 
BSA Bovine serum albumin 
Bsol B solenoid domain 
C score Combined Annotation Dependent Depletion Tool Score  
C-terminal Carboxy-terminal 
c. Coding sequence number 
Ca2+ Calcium ion 
 xvii 
CACNA1S Human alpha-1 subunit of the dihydropyridine receptor gene  
CADD Combined Annotation Dependent Depletion Tool 
CaM Calmodulin protein 
Cas  CRISPR associated proteins 
CASQ1  Human calsequestrin-1 protein 
Cav1.1  Alpha-1 subunit of the L- type voltage gated calcium channel 
Cav1.1 complex Skeletal muscle L- type voltage gated calcium channel 
CCD Central core disease 
CD34 Cluster of differentiation number 34 
CD56 Cluster of differentiation number 56/NCAM 
CD82 Cluster of differentiation number 82 
CD146 Cluster of differentiation 146 (also known as MCAM) 
CDK4 Cyclin dependent kinase 4 protein 
cDNA Complementary DNA 
CGS Clinical grading scale 
CHCT Caffeine Halothane Contracture Test 
CK Creatine kinase 
cm Centimetre 
CPVT Catecholaminergic polymorphic ventricular tachycardia  
CRISPR Clusters of regularly interspaced short palindromic repeats 
Cryo-EM Cryogenic electron microscopy  
Csol C solenoid domain 
CSQ Calsequestrin 
Ct Cycle threshold 
CTD C-terminal domain  
DAPI 4',6-diamidino-2-phenylindole 
DEAE-D Diethylaminoethyl dextran  
DHSB Developmental studies hybridoma bank 
DMEM Dulbecco's modified essential media 
DMSO Dimethyl sulfoxide 
 xviii 
DNA  Deoxyribonucleic acid  
dNTPs Deoxyribonucleotide triphosphates  
E.coli  Escherichia coli 
ECC Excitation-contraction coupling 
ECCE Excitation coupled calcium entry 
ECF Extracellular fluid 
ECL Entactin- collagen IV- laminin 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetate 
EGTA Ethylene glycol tetraacetic acid 
EHI Exertional heat illness 
EHS Exertional heat stroke 
EMHG European Malignant Hyperthermia Group 
ER Endoplasmic reticulum 
ETCO2 End tidal carbon dioxide 
ExAC Exome Aggregation Consortium 
FACS Fluorescence activated cell sorting 
FBS Foetal bovine serum 
FGF-b Basic fibroblast growth factor 
FITC Fluorescein isothiocyanate 
FKBP12 FK506-binding protein 
fps Frames per second 
FSC Forward scatter 
g Force of gravity 
G1 Gap 1 (phase of the cell cycle) 
GCS Glasgow coma scale 
Gd3+ Gadolinium ion 
GFP Green fluorescent protein 
GP2 Retroviral packaging cell line derived from HEK293 cells 
GTP Guanosine triphosphate 
 xix 
H+ Hydrogen ion 
H2O Water 
H2O2 Hydrogen peroxide 
HEK Human embryonic kidney cells 293 
HEK-FT Hek fast growing with sv40 large t-antigen 
hr Hour 
hTERT Human telomerase reverse transcriptase protein  
ICC Immunocytochemistry 
IVCT In-vitro contracture test 
iPSCs Induced pluripotent stem cells 
IPTG Isopropyl β-d-1-thiogalactopyranoside 
IQR Interquartile range  
IU   International unit  
IVCT In vitro contracture test 
kb Kilobase 
KCl Potassium chloride 
kDa Kilodalton 
KI Knock-in 
LacL Lactose operon repressor protein 
LB Lysogeny broth 
M Molar 
MAF Minor allele frequency 
MCAM Melanoma cell adhesion molecule (also known as cd146) 
MCU Mitochondrial ca2+ uniporter 
Mg2+  Magnesium ion 
MgSO4 Magnesium sulphate 
MH  Malignant hyperthermia 
MHE   Malignant hyperthermia equivocal 
MHN   Malignant hyperthermia non-susceptible 
MHS Malignant hyperthermia susceptible 
 xx 
MHSc   Malignant hyperthermia susceptible to caffeine only 
MHSh   Malignant hyperthermia susceptible to halothane only 
MHShc   Malignant hyperthermia susceptible to halothane and caffeine 
MICU1 Mitochondrial induced calcium uptake protein 1 
min Minute 
MLV Murine Leukaemia virus  
mM Millimolar 
MmD Multi-minicore disease 
Mn2+ Manganese 
mRNA Messenger RNA 
MYH Myosin heavy chain 
N-CAM Neuronal cell adhesion molecule (also known as CD56) 
N-terminal Amino-terminal 
NAM Native American Myopathy  
NGS Next generation sequencing 
NIH National institutes of health 
nm Nanometer 
nM Nanomolar 
NO Nitric oxide 
NOS Nitric oxide synthase 
nt Nucleotide 
NTD N-terminal domain 
O2 Oxygen 
O2∙- Superoxide anions 
ORAI1 Calcium release-activated calcium channel 1  
OXPHOS Oxidative phosphorylation 
p. Protein amino acid number 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
 xxi 
PE Phycoerythrin 
PEG Polyethyleneglycol 
pen Penicillin 
psi Pounds per square inch 
RCaE Resting calcium entry 
RINe RNA integrity number  
RNA Ribonucleic acid 
RNS Reactive nitrogen species 
ROI Region of interest 
ROS Reactive oxygen species 
RT-PCR Reverse transcriptase pcr 
RYR1 Ryanodine receptor 1 gene 
RYR1 Ryanodine receptor 1 protein (skeletal muscle isoform) 
RYR2 Ryanodine receptor 2 protein 
s Second 
S Synthesis (phase of the cell cycle) 
S6 Sixth helix 
SDS Sodium dodecyl sulfate 
SERCA Sarco/endoplasmic reticulum Ca2+-ATPase 
shRNA Short hairpin RNA 
siRNA Short inhibitory RNA 
SNP Single nucleotide polymorphism 
SOCE Store operated calcium entry 
SR Sarcoplasmic reticulum 
STAC3  Sh3 and cysteine rich domain 3 gene  
Stac3  Sh3 and cysteine rich domain 3 protein  
STIM-1 Stromal interaction molecule 1 
STIM1L  Stromal interaction molecule 1 splice variant protein  
strep Streptomycin 
T-tubule Transverse tubule 
 xxii 
TAE  Tris-acetate-EDTA buffer 
TE Tris EDTA 
TEMED N,n,n',n'-tetramethylethane-1,2-diamine  
TF Transcription factor 
tetR Tetracycline repressor gene module 
TetR Tetracycline repressor proteins 
TIVA Total intravenous anaesthesia  
TRPC Transient receptor potential canonical 
TRPC3 Transient receptor protein canonical 3 
TRPC6 Transient receptor protein canonical 6 
TRPV1 Transient receptor potential channel subfamily v member 1  
U Units 
UV Ultraviolet 
v/v Volume per volume % 
VGNC Voltage gated sodium channel 
VSD Voltage sensing domain 
VSV-G Vesicular stomatitis virus glycoprotein 
VUS Variants of unknown significance 
w/v Weight per volume % 
WT Wild-type 
 
 
  
 
1 
Chapter 1. Introduction 
 
1.1 Malignant Hyperthermia 
1.1.1 Clinical Manifestations 
Malignant hyperthermia (MH) is a progressive, potentially fatal hypermetabolic 
reaction that is triggered following exposure to all volatile halogenated general 
anaesthetic (GA) agents, and the depolarising muscle relaxant suxamethonium 
(Denborough, 1998; Hopkins, 2011). The exposure occurs in genetically susceptible 
individuals and results in profound skeletal muscle calcium (Ca2+) dysregulation 
(Kalow et al., 1970; Lopez et al., 2018). There is massive unregulated Ca2+ release 
from intracellular stores, the physiological attempt to manage this Ca2+ discharge and 
regain the Ca2+ homeostasis underlies the signs observed during an MH reaction. 
These signs include tachypnoea, tachycardia, together with an increase in oxygen 
(O2) consumption and carbon dioxide (CO2) production, the latter two cause a 
hypoxaemia and hypercarbia, respectively (Gupta and Hopkins, 2017). A 
hyperthermia also develops, although this tends to be witnessed later during the 
reaction (Gupta and Hopkins, 2017). The excess intracellular Ca2+ causes tonic 
skeletal muscle contractions which are observed as masseter spasm and generalised 
skeletal muscle rigidity, and leads to rhabdomyolysis. As the reaction progresses, 
there is an increase in creatine kinase, metabolic acidosis, hyperkalaemia, 
dysrhythmias, disseminated intravascular coagulation, and eventually death 
(Rosenberg et al., 2015). 
 
The first reported case by Denborough et al., (1962) of what was eventually called 
MH summarises the aforementioned clinical features, as well as the underlying 
hereditary element which will be discussed later. The reaction occurred in a 21-year 
old male patient with a history of ten deaths in the family that was attributable to GA 
under ether or ethyl chloride. The previously healthy patient was listed for an 
orthopaedic procedure and thus underwent GA using halothane as an ether 
substitute. 15 minutes (min) into anaesthesia he developed the aforementioned signs 
of a hypermetabolic state, which on this occasion were treated by stopping the 
halothane, rapidly ceasing the operation and actively cooling the patient. The patient 
survived. Further investigations of this family highlighted that the condition was 
compatible with an underlying dominant hereditary element which also had an 
incomplete penetrance, as the grandmother of the proband had not suffered an MH 
reaction despite having a triggering GA (Denborough et al., 1962). 
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1.1.2 Epidemiology 
The estimated incidence of an MH reaction is between 1 in 10 000 to 1 in 250 000 
(Ording, 1985; Brady et al., 2009; Rosenberg and Rueffert, 2011), whereas the 
prevalence of the genetic variants associated with MH can be as high as 1 in 2000 
individuals (Monnier et al., 2002; Riazi et al. 2018). The findings that resolve the 
discrepancies in these figures include that only a small proportion of the general 
population are exposed to a GA, furthermore susceptible patients do not necessarily 
have an MH reaction during their first or subsequent triggering anaesthetics (Gupta 
and Hopkins, 2017; Ibarra Moreno et al., 2019). Two models have been proposed to 
account for the latter; the first states that the variants have a reduced penetrance 
within a Mendelian autosomal dominant model due to the influence of modifying 
genetic and/or environmental factors (Shaw and Hopkins, 2019). The second is that 
the likelihood of triggering is dependent on the cumulative effects of several “weaker” 
genetic variants within a threshold non-Mendelian genetic model (Robinson et al., 
2000; Shaw and Hopkins, 2019). The features that have been shown to increase the 
likelihood of triggering include male sex, younger age, and the use of suxamethonium 
(Brandom and Larach 2002; Migita et al., 2007; Hopkins, 2011; Gupta and Hopkins, 
2017; Ibarra Moreno et al., 2019). 
 
A poorly/untreated MH reaction results in significant morbidity and mortality, with a 
case fatality of around 70 % (Denborough, 1998). Fortunately, early detection and 
prompt treatment with dantrolene can reduce this to less than 5 % of cases 
(Denborough, 1998). However, recent studies in North America have shown a 6.6-
fold increase in the relative risk of deaths from MH from the period between 1987-
2006 to 2007-2012 (Larach et al., 2010 and 2014). A suggested reason for this is the 
is the loss of awareness of MH by anaesthetists (Kaura et al., 2018). Evidence for the 
latter comes from the publication of a review article in a leading journal in anaesthesia 
where it was suggested that MH was a disease of the past, as well as a 
misrepresentation as halothane hepatitis (Sneyd, 2017). MH and halothane hepatitis 
are two completely different entities (Ray and Drummond, 1991), furthermore 
evidence from the UK MH unit reveals that all known volatile anaesthetic agents 
cause MH, with isoflurane being the most common triggering agent since the 1970s 
(Kaura et al., 2018). In order to reduce the morbidity and mortality from MH, it is 
pertinent that clinicians are trained in understanding the aetiopathogenesis and 
management of this condition. Improvements in the mechanistic understanding of 
MH, together with enhanced diagnostic tests can help reduce the mortality and 
morbidity even further.  
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1.1.3 Diagnosis of MH 
1.1.3.1 Clinical Grading Scale 
The clinical grading scale (CGS) was first proposed by an international panel of 
experts in MH using the Delphi method to reach consensus (Larach et al., 1994). It 
was introduced in order to primarily help researchers qualitatively diagnose an acute 
MH reaction in the absence of specialist diagnostic tests, as well as to guide the 
management of patients. A major deficiency of the CGS is that it has a subjective 
element whereby clinicians judge whether the clinical signs are appropriate for a 
patient’s medical condition, anaesthetic technique and surgical procedure; this can 
lead to a bias in the diagnosis (Hopkins, 2000). Consequently, the CGS is not usually 
used to diagnose susceptibility to MH in the UK, instead this is done by genetic testing 
for diagnostic variants, or through the in vitro contracture test (IVCT). 
 
1.1.3.2 IVCT  
The IVCT was developed to help identify the presence of abnormal skeletal muscle 
Ca2+ handling in response to type 1 ryanodine receptor (RYR1) agonists. Early 
reports found that biopsies of skeletal muscle from patients with MH had an elevated 
contracture strength when exposed to caffeine and halothane relative to normal 
controls (Kalow et al., 1970; Ellis et al., 1971; Ellis and Harriman, 1973). The 
European Malignant Hyperthermia Group (EMHG) then published a standardised 
protocol (EMHG, 1984) which has since been used as a gold standard by the group 
members, and it is updated regularly (Urwyler et al., 2001; Hopkins et al., 2015). The 
CGS has been used to validate the IVCT which has a specificity of 94 % and a 
sensitivity of 99 % (Ording et al., 1997), although some have questioned the latter 
and suggested it is actually 100 % (Hopkins et al., 2015).  
 
The IVCT utilises a standardised piece of skeletal muscle from the quadriceps (vastus 
medialis or lateralis), fibres are electrically stimulated, those that meet the viability 
criteria are then exposed to increasing concentrations of caffeine or halothane. The 
strength of the contractures are measured as a change from the pre-dose tension to 
the plateau at that concentration of agonist (Figure 1.1). A threshold concentration is 
defined for each agonist by identifying the lowest concentration of caffeine or 
halothane that produces a contracture of ≥ 2 mN. The diagnosis of MH susceptibility 
(MHS) is made depending on whether the threshold concentration is met at ≤2 mM 
caffeine and/or ≤2 % halothane. When both criteria are met, the diagnosis is MHShc, 
if only the former is met it is MHSc, the latter MHSh, and if none are met the patient is 
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classed as MH non-susceptible (MHN) (Hopkins et al., 2015). Other parameters are 
also recorded and these include the maximal contractures achieved at 2 mM caffeine, 
and 2 % halothane. For the purposes of the IVCT, the EMHG defines the halothane 
concentrations used in the test as 0.11 mM for 0.5 % halothane, 0.22 mM for 1.0 % 
halothane and 0.44 mM as 2 % halothane (Urwyler et al., 2001; Hopkins et al., 2015).   
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Figure 1.1: Representative IVCT traces for MHN and MHS. Muscle specimens are loaded 
onto an IVCT set-up and maintained in carboxygenated Krebs buffer at 37 ºC, pH 7.35-7.45. 
The sample is stretched to a force of 2 mN, the optimal length (l0) is determined, and the 
muscle is electrically stimulated and allowed to rest until the drugs are added. The initial force 
immediately prior to the application of drug/halothane is called the pre-dose tension, this forms 
the baseline from which all responses to the increasing concentration of halothane (0.5 %, 
1 % and 2 %) are measured against. (A) In MHN patients, the application of halothane does 
not result in an increase in the tension in the muscle fibres. In MHS patients (B), the application 
of halothane results in a concentration dependent increase in muscle tension. A similar 
process is used for caffeine. 
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The IVCT is used in two instances, the first is to diagnose susceptibility to MH in a 
patient with a high likelihood of an MH reaction from a new family that is not known 
to have MH. This index case is known as the proband. The second is to assess 
individuals in a family known to have MHS, but in whom no EMHG classified 
diagnostic variants have been identified. Figure 1.2 shows the current pathway that 
is used to assess MH susceptibility in the UK. 
 
 
 
Figure 1.2: UK MH protocol for IVCT testing. The first patient within a family to have a 
clinical suspicion of MH is referred to as the proband. The proband will have Next Generation 
Sequencing (NGS) of their DNA to assess for the presence of an EMHG diagnostic mutation. 
Any patients with a diagnostic mutation are classed as MHS and other members in the family 
offered genetic testing. If there is insufficient time for the genetic testing of the proband, they 
have an IVCT, if this is positive, their family will be screened for variants for future research. 
A proband with a negative IVCT result, ceases further MH testing in the family. 
 
In North America, an alternative test known as the caffeine/halothane contracture test 
(CHCT) is used. Here 3 % halothane is added to muscle biopsies and in another set 
of experiments caffeine (0.5, 1 and 2 mM) is added incrementally, MHS is diagnosed 
when a contracture ≥7 mN to halothane or ≥3 mN to caffeine is observed (Rosenberg 
et al. 2002).  
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1.2 Genetics of MH 
1.2.1 Inheritance 
In humans, MH has been classically referred to as an autosomal dominant disorder, 
however as discussed earlier, the variable clinical penetrance highlights that the 
genetic complexity of this condition is much greater than would be expected within a 
simple Mendelian genetic model (Robinson et al., 2000). The non-genetic factors that 
are thought to contribute to the variable penetrance have been discussed in the 
preceding sections. There is evidence for genetic factors also contributing to this 
altered penetrance through mechanisms such as allele specific gene upregulation, or 
due to the presence of other genes acting as modifiers (Robinson et al., 2000; 
Grievink and Stowell, 2010).  
 
Two genes have thus far been proven to be associated with MH susceptibility; the 
~15 kilobase (kb) RYR1 gene found on chromosome 19q13.2 that encodes the type 
RYR1, and CACNA1S on chromosome 1q32.1 which encodes the alpha 1s subunit 
of the skeletal muscle voltage gated calcium channel (Cav1.1 complex) (Tanabe et 
al., 1987; Fuji et al., 1991; Monnier et al., 1997). The genes STAC3 and TRPV1 have 
also been recently reported to be associated with MH (Horstick et al., 2013; Abeel et 
al., 2018), but so far there is insufficient evidence to conclude whether variants in 
these genes are indeed diagnostic for MH. Of the two genes with diagnostic MH 
variants, mutations in RYR1 are implicated in up to 80 % of families, whereas those 
in CACNA1S in approximately 2  % of families (Robinson et al., 2006; Gillies et al., 
2008, Kraeva et al., 2011; Miller et al., 2018; Ibarra et al., 2019). The EMHG has 
classified 48 RYR1 and 2 CACNA1S variants as diagnostic for MH (www.emhg.org; 
accessed 01/12/19).  
 
 The majority of the diagnostic RYR1 variants are found inside 3 regions within RYR1 
that were classically referred to as MH hotspots (Figure 1.3), although this 
classification has now been deemed obsolete as next generation sequencing (NGS) 
techniques have found MH associated variants throughout RYR1 (Kim et al., 2015; 
Riazi et al., 2018).  
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Figure 1.3: The EMHG diagnostic variants within the RYR1 protein. Three traditional 
regions within RYR1 were identified as MH susceptibility regions 1-3 because they contained 
the majority of the initially identified MH associated variants. NGS techniques have since 
revealed that the variants associated with MH are distributed throughout the RYR1 gene. The 
two RYR1 variants that are fully described and studied later in this thesis are also shown. 
 
 
1.2.2 Phenotypic Diversity 
Variants in the RYR1 gene have been reported to lead to a significant amount of 
phenotypic diversity which was determined by the time for the onset of the clinical MH 
reaction, the responses on the IVCT, the intracellular calcium concentration [Ca2+]I, 
and associations with other skeletal muscle pathologies including central core 
disease and exertional heatstroke (Urwyler et al., 1994; Girard et al., 2001; Fiege et 
al., 2002;  Robinson et al., 2002 and 2006; Carpenter et al., 2009a; Kraeva et al. 
2015; Murayama et al., 2016). This phenotypic variability is not only seen in humans, 
but also in mouse MH models where it affects the post-natal survival, the presence 
of myopathic features, the responses to RYR1 agonists, and [Ca2+]i (Yang et al., 2006; 
Chelu et al., 2006; Yuen et al., 2011; Lopez et al., 2018). 
 
Human studies have revealed that the location and type of amino acid change seen 
with different RYR1 variants can either increase or decrease the magnitude of the 
IVCT response in MHS muscle (Girard et al., 2001; Fiege et al., 2002; Robinson et 
al. 2002; Carpenter et al., 2009a). For example, in the largest study examining the 
effects of the RYR1 variants on the IVCT phenotype, Carpenter et al. (2009) found 
that p.G2434R (c.7300G>A) had a significantly lower change in muscle tension 
relative to other variants including p.R2454H (c.7361G>A), when the muscle fibres 
were exposed to caffeine or halothane. p.G2434R is the most common variant seen 
in the UK MH population where it accounts for 16 % of UK MH families, whereas 
p.R2454H is much more rare with a presence in 2 % of UK families (Miller et al., 
2018). The study by Carpenter et al. (2009a) also revealed that the severity of the 
response on the IVCT had a strong association with a shorter onset in the clinical MH 
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reaction.  Furthermore, they suggested that  regions within RYR1 that are highly 
conserved between species appear to have a disproportionate number of MH 
associated variants, and thus proposed that such areas play an important role in 
regulating RYR1 activity and maintaining a normal calcium homeostasis (Carpenter 
et al., 2009a; Klingler et al., 2014). However, the exact mechanism by which these 
variants contribute to the MH reaction is not completely understood. 
 
Another interesting feature observed in the genetics of MH, is a RYR1 genotype and 
IVCT phenotype discordance (Adeokun et al., 1997; Fortunato et al., 1999). This is 
observed in 26.2 % of UK MH families that harbour a familial RYR1 variant (Miller et 
al., 2018). It usually seen by the presence of a phenotypic diagnosis of MHS on the 
IVCT, but in the absence of the familial RYR1/CACNA1S variant (negative genotype). 
The discordance can also manifest as genotype positive with an IVCT negative 
phenotype of MHN, although this is a less frequent occurence.  
 
 
1.2.3 Molecular Genetics of the Susceptibility to MH 
1.2.3.1 Genetic Testing for MH 
There has been a recent increase in the rate of identification and characterisation of 
diagnostic MH variants.  At the start of this project in 2016, the EMHG had published 
37 causative MH variants (www.emhg.org; accessed 25/11/16), however these have 
increased by 30 % in just over 3 years to 48 RYR1 and 2 CACNA1S (www.emhg.org; 
accessed 01/12/19). This has been driven by a major MH research goal of developing 
a genetic diagnostic panel for this condition. The underlying principle here is to reduce 
the burden to patients of undergoing invasive skeletal muscle biopsies due to the 
associated procedural risks as well as other inconveniences to the patient. The former 
includes pain, post-operative infection, bleeding, muscle weakness, paraesthesia, 
and deep venous thrombosis. In the UK biopsies are not usually performed until 
patients are at least 10 years old and this limits the availability of this test for younger 
potentially susceptible patients. Other problems with biopsies include the need for 
patients to take time off work for the procedure and its associated recovery, as well 
as having to travel long distances to a diagnostic centre. The centre in Leeds is the 
only MH unit in the UK and Ireland, moreover on the continent many Eastern and 
some Western European countries (Finland, Portugal, Greece) do not have an MH 
unit able to perform an IVCT.  
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Despite the objective to move to a fully genetic approach for the diagnosis of MH, 
research over the last 30 years has only produced 48 diagnostic RYR1 and two 
CACNA1S diagnostic variants. There are several problems that have hampered this 
progress. The first is the sheer number of variants that have been identified in both 
the RYR1 and CACNA1S genes; there are over 200 variants identified in the former 
alone (Riazi et al. 2018). The second is the genetic and allelic heterogeneity observed 
in MH which does not strictly follow what would be expected from a monogenetic 
autosomal dominant disorder (Carpenter et al., 2009a, Miller et al., 2018). It has been 
hypothesised that part of the variability observed in the MH phenotype is related to 
different gene interactions that can affect whether a variant functions as pathogenic 
or not (Robinson et al., 2000). The third is the increased difficulty posed when cloning 
and working on one of the largest receptor proteins in humans (Tong et al., 1997; 
Sato et al 2013; Roesl et al., 2014). 
 
 
1.2.3.2 Investigating Novel Variants 
NGS has revealed the presence of many variants within RYR1 and CACNA1S, with 
the two genes exhibiting an above average rate of variants compared to other genes 
(Fiszer et al., 2015, Kim et al., 2015). Moreover, many of these variants have an 
unknown significance and are rare with frequencies of lower than 1/1000; this minor 
allele frequency (MAF) is the same as that found in pathogenic variants (Fiszer et al., 
2015). Consequently, a low frequency itself cannot serve as a predictor of 
pathogenicity (Riazi et al., 2018). There is some benefit in utilising in silico prediction 
tools in identifying putative pathogenic variants (Kumar et al., 2009, Kircher et al., 
2014), however these tools themselves are not infallible. For example, it has been 
reported that up to 50 % of low-frequency or de novo missense variants that were 
thought to be deleterious using bioinformatics were found to have little or no effect on 
the clinical phenotype (Miosge et al., 2015). Comparably, in RYR1 a significant 
number of predicted pathogenic variants have also been found to be benign, probably 
benign or of unknown pathogenicity (Gonsalves et al., 2013, Riazi et al., 2018). These 
points highlight the difficulties faced in trying to identify novel diagnostic variants for 
MH and emphasise the need to functionally characterise the variants using in vitro 
assays. However, such assays can be time consuming in the absence of a high-
throughput screening system (Emanuel et al., 2017). 
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1.2.3.3 Characterising RYR1 Variants 
The EMHG has published an updated guideline on the characterisation of RYR1 
sequence variants (Hopkins et al., 2015). The process involves a full characterisation 
of the variant at a genetic and protein level, with co-segregation of the variant with 
the disease in the family. This should be accompanied by assessing the prevalence 
of the variant in a population by searching relevant genomic databases. Variants are 
classed as pathogenic when they have a MAF of <0.1 % (the guideline actually states 
1 % but this was a typographical error) based on a sample size > 150 individuals.  
 
The functional characterisation should be assayed in ≥1 system such as the human 
embryonic kidney-293 cells (HEK) system utilising rabbit RYR1 cDNA constructs 
(Tong et al., 1997; Brini et al., 2005), or dyspedic myotubes with the insertion of cDNA 
constructs containing the variant of interest (Yang et al., 2003). An alternative 
approach is the assessment of RYR1 function in ex vivo tissues through calcium 
measurement or ligand-binding in myotubes, microsomal sarcoplasmic preparations 
or lymphoblasts from patients. Due to the potential influence of alternative individual 
genetic factors when using cells derived from a single patient, the EMHG 
recommends that such experiments should utilise samples from at least two non-
related patients with the same mutation. Finally, the genetic and functional 
characterisation must be consistent with a pathological role in MH (Hopkins et al., 
2015). They also state that if an MH-associated RYR1 variant is identified in an index 
case, then the variant can be used for predictive genetic testing in the relatives of the 
patient. The EMHG has adapted the American College of Medical Genetics scoring 
matrix to assist in the classification of novel variants that are associated with MH as 
either pathogenetic or benign for MH susceptibility (EMHG, 
https://www.emhg.org/genetic-scoring-matrix, accessed 01/12/19).  
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1.2.4 Related Skeletal Muscle Disorders 
Mutations in RYR1 have been implicated in multiple other skeletal muscle disorders 
in addition to MH. Consequently, susceptibility to MH itself has also been shown to 
be associated with other pathologies including exertional heatstroke, rhabdomyolysis, 
chronically raised serum creatine kinase, and core myopathies such as central core 
disease (CCD) (Jungbluth et al., 2016; Carpenter et al., 2009a).  
 
1.2.4.1 Exertional Heat Illness 
Exertional Heat Illness (EHI) is a complex disorder whereby the failure of 
thermoregulatory systems induced by physiological, genetic and environmental 
factors leads to an excess of heat production that the body cannot effectively dissipate 
(Capacchione and Muldoon, 2009; Epstein and Roberts, 2011). The clinical 
presentation ranges from mild heat exhaustion to a more severe, life-threatening 
episode known as exertional heat stroke (EHS) (Capacchione and Muldoon, 2009). 
Symptoms of EHI include feeling dizzy, nauseous, weak, as well as headaches. In 
EHS there is neurological impairment with a core temperature exceeding 40 ºC, if left 
untreated this progresses to multi-organ failure and death (Binkley et al., 2002). There 
is evidence for an association between recurrent EHI and MH that appears to   
emanate from variants in RYR1 (Dlamini et al., 2013; Snoeck et al., 2016). This also 
may explain why skeletal muscle from 34 % of patients with EHI develop contractures 
during the IVCT (Gardner, 2018). 
 
1.2.4.2 Central Core Disease 
CCD belongs to a family of core myopathies that represent the most common type of 
the congenital myopathies (Brislin & Theroux, 2013). Their histopathological 
characterisation reveals prominent non-staining focal lesions within the fibre called 
‘cores’ which exhibit reduced oxidative enzyme activity (Brislin & Theroux, 2013). 
Patients with this disease typically present with hypotonia and motor delays in 
infancy, however a spectrum of presentation exists from akinesia in foetal life to 
muscle weakness in adulthood (Brislin & Theroux, 2013). CCD usually has an 
autosomal dominant inheritance pattern involving missense variants in RYR1, the 
majority of these variants are found around the pore forming and carboxyl-terminal 
domain of the RYR1 protein, whereas in MH there is a predominance of variants in 
the N-terminal and central domain of RYR1 (Wu et al., 2006). Interestingly, some 
have suggested that MH susceptibility may represent a sub-clinical myopathy with no 
obvious phenotypical expression until a triggering agent is introduced (Brislin & 
Theroux, 2013). 
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1.3 Treatment of MH and Related Disorders 
Dantrolene, a hydantoin derivative is the only drug that is licensed in the UK for the 
treatment of malignant hyperthermia, as well as for chronic severe spasticity of 
skeletal muscle in adults (BNF 78). It has also been suggested that dantrolene may 
have a role in the treatment of other pathological processes including exertional 
rhabdomyolysis, heat stroke, neuroleptic malignant syndrome, and ecstasy 
intoxication (Larner, 1992; Lopez et al., 1995; Grogan and Hopkins, 2002; Krauss et 
al., 2004). Dantrolene is known to be a direct skeletal muscle relaxant through 
blocking intracellular release of Ca2+, whether this is through a direct or indirect (or 
both) action on the RYR1 protein has remained elusive (Lopez et al., 1987; Lopez et 
al., 1992; Krauss et al., 2004). Part of the controversy has been fuelled by the results 
from studies using tissues, versus those using single channel reconstituted into 
bilayers, with some studies using the latter showing dantrolene did not have an effect 
on the RYR1 channel (Kolb et al., 1982; Nelson et al., 1996; Fruen et al., 1997; 
Palnitkar et al., 1999; Snetsi et al., 2001). However, Choi et al., (2017) recently 
reconciled these results by demonstrating that dantrolene increases the Mg2+ affinity 
of RYR1 (or stabilises the resting state of the channel), and an accumulation of Mg2+ 
was key for the action of dantrolene on this protein. Many of the single channel studies 
had an absence of Mg2+ in their buffers, thus abrogating the direct effects of 
dantrolene on RYR1 activity. 
 
The development of drugs that target RYR1 is an active avenue of research that may 
benefit some if not all of these pathologies, but may also be useful in diseases 
mediated by similar variants in RYR2 (Andersson & Marks, 2010; Dulhunty et al., 
2011).  Thus, a greater understanding of the molecular mechanisms that underlie the 
perturbed Ca2+ handling seen in MH will potentially provide new targets for future drug 
development in this and related diseases. 
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1.4 Skeletal Muscle 
Skeletal muscle forms one of the three major type of muscle found in the body. This 
striated muscle plays an important role in many physiological processes including 
locomotion, metabolism, and thermogenesis. It is composed of several bundles 
(fascicles) of muscle fibres that are bound tightly together. Each fibre is one skeletal 
muscle cell consisting of multiple nuclei, these originate from the fusion of several 
muscle cells (myoblasts) during development and regeneration.  
 
1.4.1 Muscle Regeneration 
Mauro (1961) first postulated that the sublaminar mononuclear cells found between 
the basal lamina and sarcolemma of skeletal muscle fibres were the resident 
progenitor cells for skeletal muscle regeneration. These satellite cells have since 
been found to primarily be involved in the postnatal growth, maintenance and repair 
of skeletal muscle (Wang and Rudnicki, 2011). The transcription factor (TF) paired-
box 7 (PAX7) is a marker of the quiescent satellite cells that have the ability to self-
renew, proliferate or undergo myogenic differentiation and fuse in order to restore 
damaged muscle (Seale et al., 2000).  
 
Satellite cells are a heterogenous population, the majority of which commit to 
proliferate as myoblasts, whereas approximately 10 % remain as self-renewing stem 
cells. The committed population proceed via the upregulation of the TF myogenic 
factor 5 (MYF5) and myoblast determination protein (MYOD) (Rudnicki et al., 1992 
and 1993).  A subsequent expression of myogenin and downregulation of PAX7 
causes the myoblasts to differentiate into myocytes, these can then fuse together to 
form new myotubes or fuse with existing fibres (Braun and Gautel, 2011). The new 
myotubes then undergo further maturation into myofibers. Media conditions 
containing high serum facilitate the proliferation of isolated myoblasts in vitro due to 
the presence of multiple growth factors (Richler and Yaffe, 1970; Inestrosa 1982). A 
reduction in the serum concentration with the consequential withdrawal of growth 
factors activates the terminal differentiation programme, this induces myoblast fusion 
which form multinucleated myotubes. These myotubes express RYR1 and the Cav1.1 
complex which are key proteins involved in excitation-contraction coupling (ECC) 
(Eltit et al., 2012). However, myotubes do not fully develop the specialised triad 
ultrastructure seen in mature skeletal muscle fibres under standard in vitro conditions.  
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1.4.2 Physiology 
Skeletal muscle fibres are excitable cells which contract through the process of ECC 
(Figure 1.3). Nerve impulses from the alpha motor neurone arrive at the 
neuromuscular junction and cause the release of acetylcholine (ACh) into the 
synapse.  The ACh binds to the post-synaptic nicotinic acetylcholine receptors 
(AChR) present at the motor end plate regions on the skeletal muscle membrane, 
and thus induces a depolarisation of the sarcolemma. This depolarisation wave is 
propagated along the sarcolemma and deep into the myofibrils through specialised 
invaginations known as the transverse (T)-tubules. The T-tubules are closely 
apposed to the terminal cisternae of the sarcoplasmic reticulum (SR) which together 
form an ultrastructure known as a triad. The change in the membrane potential is 
sensed by the Cav1.1 complex present within the T-tubule membrane. The complex 
subsequently undergoes a conformational change that leads to the activation of 
RYR1 channels on the SR membrane through a direct physical interaction (Rios and 
Brum, 1987; Tanabe et al, 1988; Tanabe et al, 1990; Nakai et al.,1998). RYR1 
activation releases intracellular SR stores of Ca2+ down its concentration gradient into 
the sarcoplasm.  
 
The released Ca2+ is utilised by the contractile units within the sarcomeres to mediate 
muscle contraction. The Ca2+ is simultaneously pumped back into the SR by the 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pumps, these together with the 
sodium calcium-exchangers (NCX) help maintain a low resting [Ca2+]i of 
approximately 100 nM in skeletal muscle (Parekh and Putney Jr, 2005; Eltit et al., 
2010). During ECC the [Ca2+]i increases to the high nanomolar and low millimolar 
range. The SR free Ca2+ concentration [Ca2+]SR is maintained at approximately 1 mM, 
with a total [Ca2+]SR estimated to be 11 mM (Murphy et al., 2009). The majority of the 
exchangeable pool of Ca2+ in the body is present in the extracellular fluid (ECF), and 
this which equates to around 30 mmol of Ca2+. Around 55 % of the extracellular Ca2+ 
is bound to proteins, consequently the ionised Ca2+ concentration found in the 
extracellular space [Ca2+]E is 1 mM (Brown and MacLeod, 2001).  
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Figure 1.4: ECC in skeletal muscle cells. ECC is initiated by the arrival of nerve impulses at the 
neuromuscular junction (1). This results in the release of synaptic acetylcholine (ACh) which 
through binding to the nicotinic acetylcholine receptors (AChR), induces the depolarisation 
sarcoplasmic membrane (2). The action potentials propagate along the membrane and deep within 
the myofibrils through specialised invaginations known as the transverse (T) tubules (3). The 
Cav1.1 complex present within the T-tubules senses the change in the membrane potential (4), 
undergo a conformational change which due to their close apposition to the SR RYR1 channels 
leads to the activation of the latter and the release of SR calcium (Ca2+)  (5). This close apposition 
occurs at specialised triadic junctions. The calcium is then utilised by the contractile unit within the 
muscle to mediate muscle contraction (6). Ca2+ is then driven back into the SR via 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pumps (7).  
 
1.4.3 RYR1 
There are three mammalian ryanodine receptor (RYR) isoforms which share 
approximately 66 % sequence identity. RYR1 is found predominantly in skeletal 
muscle, RYR2 in cardiac myocytes, and RYR3 primarily in the brain (Priori & 
Napolitano, 2005; Amador et al., 2013). However, each isoform is also found in other 
tissues for example RYR1 is present in the brain, pancreas, smooth muscle and B 
lymphocytes, and there is some RYR3 expression in skeletal muscle (Samso et al., 
2016). RYR1 and RYR2 have an 80 % amino acid sequence similarity, yet functionally 
they work in a different manner. In contrast to the physical activation of RYR1, RYR2 
is triggered by the influx of extracellular Ca2+ across the cardiac voltage gated Ca2+ 
channels (Cav1.2) in a process known as Ca2+ induced Ca2+ release (CICR) (Fleischer 
and Inui, 1988). In contrast, Ca2+ entry through Cav1.1 is not thought to play a 
significant role in skeletal muscle. Dayal et al., (2017) found a knock-in mouse model 
containing a non-conducting Cav1.1 pore, exhibited no major differences both in 
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terms of function or expression of key skeletal muscle proteins relative to wild type 
mice. Furthermore, although different isoforms of RYR are co-expressed in certain 
tissues, they cannot compensate for each other. This is highlighted in work by 
Takeshima et al., (1994), who found that RYR1 knock-out mice die perinatally from 
respiratory failure, and this could not be overcome by the expression of RYR2/3. 
 
RYR1 is a ~2.2 megadalton homotetrameric channel formed from four polypeptides 
each consisting of approximately 5000 amino acids with a molecular weight of ~565 
kilodalton (kDa) (Yan et al., 2015; Zalk et al., 2015).  Recent advances in cryogenic 
electron microscopy (cryo-EM) have allowed several structures of the RYR1 channel 
to be elucidated at 3.8-4.8 Armstrong (A) resolution (Yan et al., 2015; Zalk et al., 
2015; des Georges et al., 2016). The tetrameric RYR1 has a pyramidal appearance 
with a square base of 270 x 270 A and a height of 160 A (Yan et al., 2015). It has 
three major regions, the cytosolic ligand-binding domain, the cytosolic central domain 
which relays conformational signals to the transmembrane domain; the latter forms 
the pore for Ca2+ movement out of the SR. The majority of the protein (~80 %) is 
present in the cytosol and this contains nine distinct domains including the amino (N)-
terminal domain. The cytosolic component mediates ligand-sensing in the channel as 
well as providing a scaffold for modulatory interactions with a wide array of 
intracellular proteins including the Cav1.1 and small molecules (Hernández-Ochoa et 
al., 2015; Yan et al., 2015; Zalk et al., 2015; des Georges et al., 2016). The latter 
include caffeine, halothane, low concentrations of Ca2+ or magnesium (Mg2+), 
adenosine triphosphate (ATP), and Ca2+ released from nearby activated RYR1 
channels (Amador et al., 2013). 
 
The major physiological activation of RYR1 occurs through its physical coupling with 
Cav1.1, with this interaction thought to involve the SPRY2 domain on the former and 
the II-III loop on the latter. The exact mechanisms for this coupling has not been fully 
resolved, as although some studies have shown that this interaction does occur when 
utilising the main functional region of the SPRY2 domain, this was not reproducible 
with the full length of SPRY2 (Cui et al., 2009; Lau et al., 2014; Samso, 2017).  
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The cryo-EM structures have revealed that the solenoids contained in helical domains 
1 and 2 as noted by one group (Yan et al. 2015) or B solenoid (BSol) and C solenoid 
(CSol) by another group (Zalk et al., 2015; des Georges et al., 2016) are highly mobile 
and thus have a role in the long-range allosteric communication. These also interact 
with the SPRY2 domain found in nearby subunits, and this may affect the activation 
properties of the channel. Helical domain 1/BSol contains the p.G2434R, p.R2454H 
and p.R2355W variants which will be functionally evaluated in subsequent chapters 
(Yan et al., 2015; Zalk et al., 2015; des Georges et al., 2016). 
 
The pore forming domain consists of 6 transmembrane (TM) helices that span the SR 
membrane with an extraordinarily long conducting pathway of 90 A from the SR lumen 
to the cytosol, with a 1 Armstrong constriction point in the closed state (Yan et al., 
2015). The 6-TM helices have structural homology with other 6-TM ion channels such 
as the voltage gated sodium channel (VGNC) and the transient receptor potential 
channel subfamily V member 1 (TRPV1) channel (Yan et al., 2015). The 6th helix (S6) 
of the pore forming domain is thought to be important in the gating of the channel, 
and is rigidly connected to the C-terminal subdomain (CTD). The CTD also has 
extensive interactions with the central domain which is thought to act as the central 
transmitter of conformational changes from the ligand binding cytosolic portion to the 
channel forming components (Yan et al., 2015).  The central domain also contains 
EF hand motifs which are presumed to confer the Ca2+-sensing ability in RYR1; this 
occurs through a large conformational change that is triggered by the binding of Ca2+ 
to the core of the channel (Yan et al., 2015; Samso 2016).  
 
1.4.4 RYR1 Regulatory Molecules and Proteins 
1.4.4.1 Small Molecules  
The [Ca2+]i in skeletal muscle is approximately 100 nM, whereas the [Mg2+]i is 1 mM 
(Melzer et al., 1995). Ca2+ is known to have a biphasic effect on RYR1 activity; at low 
cytoplasmic µM concentrations it activates the channel, and inhibits it at higher 
concentrations (>100 µM). The bell-shaped activity suggests there are two Ca2+ 
binding sites on the cytosolic side of RYR1; a high-affinity activating and low-affinity 
inhibiting site (Chen et al., 1993; Lamb et al., 1995). There is also evidence for a 
luminal (SR) binding site for Ca2+ with activation at 100-250 µM, and inactivation at 
higher concentrations (Ma et al., 1988; Fill et al., 1990; Sitsapesan and Williams, 
1995; Herrmann‐Frank and Lehmann‐Horn, 1996; Sarkozi et al., 2004). In contrast, 
mM concentrations of ATP and Mg2+ on the cytosolic side activate and inhibit the 
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channel, respectively. The cytoplasmic Mg2+ is thought to modulate RYR1 activity 
through binding and competing at the Ca2+ activation and inhibition sites (Laver et al., 
1997; Lamb et al., 2000; Laver et al., 2004). At the latter site, both Mg2+ and Ca2+ are 
thought to bind with an affinity (Ki) of 0.1 mM and cause an inhibition (Melzer et al., 
1995; Laver et al., 1997 and 2004). However the higher [Mg2+]i means that this ion 
predominantly occupies the inhibitory site. On the other hand, the binding affinity is 
greater for Ca2+ (1 µM versus up to 100 µM for Mg2+) at the RYR1 activation site which   
permits Ca2+ to selectively activate RYR1. The importance of the inhibitory effects of 
Mg2+ on RYR1 is clearly seen in studies that investigated the effects of lowering 
[Mg2+]i in MHS and MHN samples; a reduction in [Mg2+]i caused MHN fibres to release 
SR Ca2+ in a similar fashion to that seen in MHS fibres with a higher [Mg2+]i (Duke et 
al., 2002, 2004, and 2006). 
 
1.4.4.2 Proteins 
Numerous cytosolic and SR proteins regulate RYR1 channel activity, these include 
FK506-binding protein (FKBP12), calmodulin, calsequestrin, junctin, and triadin 
(Prosser et al., 2011; Rios et al., 2015). Calsequestrin-1 (CASQ-1) is a SR luminal 
protein that is encoded by the CASQ1 gene. In the presence of high (~1 mM) [Ca2+]SR 
it polymerises into a multimeric complex that has a high buffering capacity for Ca2+ 
(Kawasaki and Kasai, 1994; Wang et al., 1998; Györke et al., 2004; Manno et al., 
2017). It is the main Ca2+ binding protein in the SR, functioning as a Ca2+ sensor, 
which at low [Ca2+]SR inhibits RYR1 activity via a triadin-junctin complex, and thus 
limiting SR Ca2+ depletion (Zhang et al., 1997; Beard et al., 2002; Györke et al., 2004).  
 
There are no variants in CASQ-1 that have so far been listed as diagnostic for MH. 
However, when CASQ1 null mice are exposed to halothane, elevated environmental 
temperatures (41 ºC) or strenuous exercise, a hypermetabolic reaction consisting of 
hyperthermia, severe rhabdomyolysis and contractures occurs (Dainese et al., 2009; 
Michelucci et al., 2017). Additionally, male CASQ1 null mice have a higher 
spontaneous death rate, this has also been noted in a novel knock-in mouse model 
of MH containing a variant that is equivalent to p.G2434R in human RYR1 (Protasi et 
al., 2011; Michelucci et al., 2017; Lopez et al., 2018). Although variants in CASQ1 
have been implicated in MH, none have been proven to be diagnostic thus far. 
CASQ2 is an isoform of CASQ1 that is predominantly found in cardiac muscle, 
variants in CASQ2 are diagnostic for catecholaminergic polymorphic ventricular 
tachycardia (CPVT). CPVT is an inherited disorder characterized by life threatening 
arrhythmias that are induced by physical and/or emotional stress (Marks et al., 2002).  
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CPVT is sometimes referred to as the cardiac equivalent of skeletal muscle MH, 
because certain variants in RYR2 that predispose to CPVT occur at the same 
residues in RYR1 that cause susceptibility to MH (Marks et al., 2002; MacLennan and 
Chen, 2009; Rios et al., 2015).  
 
Junctin and Triadin are SR transmembrane proteins present at the triads where RYR1 
and the Cav1.1 complex interact. They play a role in regulating RYR1 function through 
distinct binding sites, and are thought to mediate the regulatory effects of CSQ1 on 
RYR1 (Wei et al., 2009; Boncompagni et al. 2012). Triadin knock-out mice have 
revealed that the loss of such modulation causes an enhanced [Ca2+]i (Shen et al., 
2007). 
 
 
1.4.5 CaV1.1 
Recent studies have revealed several cryo-EM structures of the Cav1.1 complex at 
increasing resolution (Wu et al., 2015 and 2016), with the latest resolved in the 
presence of its prototypical ligands (Zhao et al., 2019). The Cav1.1 complex consists 
of a pore forming α1s subunit (176 kDa), as well as the auxiliary subunits α2δ (177 
kDa), β (56 kDa), and γ (34 kDa) that are involved in modulating the membrane 
trafficking, current kinetics, and gating properties of the channel (Samso et al., 2015; 
Wu et al., 2015; Zhao 2019). Cav1.1 comprises of four repeat units (I-IV) each of 
which contains 6-TM domains (S1-S6) (Hu et al., 2015). As with RYR1, the Cav1.1 
also has structural homology to other voltage gated ion channels and therefore S1-
S4 are thought to be the voltage sensing domains (VSDs). S5, S6 and the intervening 
segments from each repeat combine to form the ion-conduction pore domain (Yu et 
al., 2005; Bannister and Beam, 2013; Wu et al., 2015). The cytosolic β subunits are 
required for the tetrad-tetramer organisation between Cav1.1 and RYR1 at the 
specialised triadic junctions, and this is classically thought to interact with the residues 
between repeat I-II (Bannister and Beam, 2013), however more recent structural data 
suggest it binds to VSDII (Wu et al., 2016). The γ subunit is a transmembrane protein 
whereas the α2δ subunit is extracellular. The former was found to interact with the 
VSDIV and the latter with the extended extracellular loops of Cav1.1 (Wu et al., 2016). 
The residues present in the large loop between repeat II and III are called the II-III 
loop and amino acids within this, particularly residues 720-765, are critical for the 
physical interaction with RYR1 and ECC.  
 
  
 
21 
Experiments over the last three decades have revealed an exquisite bidirectional 
regulation exists between RYR1 and Cav1.1 (Tanabe et al., 1990; Nakai et al., 1996; 
Avila et al., 2001). Nakai et al., (1996) first provided evidence for retrograde signalling 
when they found that myotubes lacking RYR1 (dypedic) had  profoundly reduced L-
type currents through the Cav1.1 complex, and this was reversed on the reintroduction 
of RYR1. The anterograde signalling by the non-active Cav1.1 has also been shown 
to suppress spontaneous RYR1 activity at rest (Eltit et al., 2010). However even in 
this quiescent state, there is thought to be a degree of passive leak of SR Ca2+ 
through a proposed low conductance constitutively open conformation of RYR1, this 
occurs through a ryanodine-insensitive “Ca2+ leak” (Eltit et al., 2010). This leak is 
thought to play an important role in the regulation of the resting [Ca2+]i (Eltit et al., 
2010). The importance of this finely balanced bidirectional regulation is seen in 
experiments using myotubes from murine models of MH and human MHS. Here, MH 
variants associated with Cav1.1 and RYR1 have been shown to result in an elevated 
resting [Ca2+]i (Wehner et al., 2002; Ducreux et al., 2004; Yang et al., 2007; Eltit et 
al., 2011 and 2012).   
 
The two diagnostic variants in CACNA1S are p.R1086H (c.3257G>A) and p.R174W 
(c.520C>T), these have led to an increased understanding of the bidirectional 
signalling that is observed between the RYR1 and (Weiss et al., 2004; Eltit et al., 
2012). p.R174W is found in a highly conserved charged residue within S4 of VSDI 
(Eltit et al., 2012). This variant induced a near two-fold elevation in the [Ca2+]i, a 
reduction in the SR Ca2+ content, and a  significant enhanced sensitivity to volatile 
anaesthetics. It also abolished the activation of the L-type Ca2+ current but had little 
effect on ECC (Eltit et al., 2012). Clinically, this variant was associated with a positive 
IVCT, and thus MH susceptibility (Carpenter et al., 2009b).  
 
p.R1086H is found within III-IV linker has also been found to enhance the caffeine 
sensitivity of RYR1 and elevate the resting [Ca2+]i. However, the variant also caused 
a decrease in the L-type current density, with a shift in the SR Ca2+ release to more 
hyperpolarising potentials (Weiss et al., 2004). This suggests that p.R1086H caused 
a loss in the III-IV linker mediated negative allosteric modulation of RYR1 (Weiss et 
al., 2004).  
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1.4.6 STAC3 
The STAC3 gene found on chromosome 12q13.3 encodes the Src homology 3 and 
cysteine rich domain 3 (STAC3) protein which has recently been identified to be 
important for ECC (Stamm et al., 2008; Polster et al., 2016). It is involved in both 
trafficking Cav1.1 to the plasma membrane and stabilising the Cav1.1-RYR1 
interaction (Nelson et al., 2013; Polster et al., 2015 and 2016; Linsley et al., 2017). 
Recent crystal structures as well as functional studies show that the interaction 
between STAC3 and Cav1.1 occurs via the SH3 domain on the former and the II-III 
linker in the latter (Wong King Yuen et al., 2017; Polster et al., 2018). STAC3 has also 
been identified as a factor required for myogenic differentiation (Bower et al., 2012). 
Moreover, it has been proposed that certain variants in STAC3 may confer 
susceptibility to MH given that the p.W284S STAC3 variant has been functionally 
shown to be  pathogenic in a family with Native American myopathy (NAM) (Horstick 
et al., 2013). Horstick et al., (2013) used a genetic screen of zebrafish with impaired 
skeletal muscle activity to identify STAC-3 as important in ECC, and this then led to 
solving the p.W284S STAC3 variant as a cause of NAM. NAM is an autosomal 
recessive disorder characterised by congenital muscle weakness, delayed motor 
development, multiple joint plus skeletal muscle abnormalities, distinctive facies and 
susceptibility to MH (Bailey and Bloch, 1987; Horstick et al., 2013). Although this 
variant has subsequently been shown to not be unique to non-Native American 
individuals (Grzybowski et al., 2017; Zaharieva et al., 2018), it has  thus far not been 
adopted as an EMHG diagnostic variant for MH, as there is a lack of direct evidence  
linking MH and STAC3. NGS of the UK MH population has failed to identify any novel 
pathogenic STAC3 variants, but has found p.W284S in a homozygous proband (Miller 
et al., 2018).  
 
1.4.7 TRPC Channels 
The Transient Receptor Potential Canonical proteins (TRPC) channels are a group 
of non-selective cation channels that are permeable to the cations Ca2+ and Na+ with 
a greater permeability for Ca2+ (Bon and Beech, 2013). TRP proteins are primarily 
expressed on the plasma membrane as homo/heteromeric tetramers. Each monomer 
consisting of six transmembrane spanning domains, with the pore-forming loop 
resideing between the fifth and sixth segments (Wu et al., 2010). They have a 
structural homology to voltage gated potassium channels, except they lack the 
positive residues within the 4th transmembrane segment which are important for 
voltage sensing (Gailly, 2012; Fan et al., 2018).  
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The TRPC family contains TRPC1, TRPC3, TRPC4, TRPC5, TRPC6 and TRPC7 
(Bon and Beech, 2013). TRPC3/6/7 forms a subfamily that has a very high protein 
sequence homology, and these proteins can function as both store operated channels 
(SOC) or receptor operated channels (ROC) (Gailly, 2012; Fan et al., 2018). Although 
TRPC3/6/7 can form both heteromultimetric complexes with each other or with 
members of the TRPC1/4/5 subfamily (Bon and Beech, 2013),  skeletal muscle does 
not express the full complement of TRPC channels. TRPC1/3/6 are the major 
channels present in this tissue, with other TRP channels such as TRPV2/4 and TRP 
Melastatin 4/7 (TRPM4/7) also expressed (Brinkmeier, 2011; Gailly, 2012). ROC 
activation occurs through a direct interaction with diacylglycerol (DAG) which is the 
phospholipase C mediated cleavage product of the sarcolemmal phosphatidylinositol 
4,5-bisphosphate (Itsuki et al., 2012; Fan et al., 2018). In contrast, SOC activation 
occurs through interactions with other sarcolemmal and SR proteins such as stromal 
interaction molecule 1 (STIM1) and ORAI1; these have been shown to mediate store 
operated calcium entry (SOCE) (Feske et al., 2006; Park et al., 2009).  
 
1.4.8 Extracellular Calcium Entry Mechanisms 
Although ECC defines the classical method by which Ca2+ enters the sarcoplasm via 
RYR1, there have been increasing recent reports of other pathways involved in 
elevated Ca2+ entry into skeletal muscle cells. These include SOCE, excitation-
coupled calcium entry (ECCE) and resting calcium entry (RCaE) (Kurebayashi and 
Ogawa, 2001; Cherednichenko et al., 2004; Lyfenko and Dirksen, 2008; 
Cherednichenko et al., 2008; Dirksen, 2009; Estève et al., 2010; Cully et al., 2018). 
The importance of these pathways in initiation and/or propagation of the MH reaction 
is becoming increasingly apparent as we gain a greater understanding of their 
function, and as there is growing evidence to show that SR Ca2+ stores are insufficient 
to sustain an MH reaction (Kurebayashi & Ogawa 2001; Eltit et al. 2013).  
 
1.4.8.1 ECCE 
This pathway was first identified in skeletal myotubes, here it was found to be 
essential for sustaining the amplitude of the Ca2+ transient that are generated in 
response to the depolarisation of the sarcolemma by repetitive, or prolonged 
depolarisations (Cherednichenko et al., 2004; Hurne et al., 2005). ECCE has been 
found to be independent of the SR store content, and mediates a relatively small influx 
of extracellular Ca2+ during normal physiological activity (Cherednichenko et al., 2004; 
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Hurne et al., 2005).  However a significant potentiation of ECCE is observed in the 
p.R163C RYR1 MH mouse model (Cherednichenko et al., 2004; Cherednichenko et 
al., 2008; Bannister et al., 2009). ECCE may provide a putative mechanism through 
which suxamethonium, a depolarizing muscle relaxant that causes muscle 
fasciculation, could trigger or contribute to a MH reaction. ECCE is dependent on the 
proper functioning of the RYR1-Cav1.1 complex, with studies suggesting that the Ca2+ 
current occurs through the Cav1.1 complex without involving STIM-1 (Lyfenko and 
Dirksen, 2008; Bannister et al., 2009; Dirksen, 2009). Dayal et al., (2017) generated 
a mouse which had a non-conducting Cav1.1 to investigate the importance of the Ca2+ 
current that occurs through Cav1.1 during ECC. They found the Ca2+ influx via Cav1.1 
was not necessary for skeletal muscle performance in young and aged mice, thus 
suggesting ECCE is lest important in this context. Furthermore, there was a lack of 
upregulation of multiple key proteins involved in ECC or Ca2+ homeostasis, and this 
included those involved in SOCE. Nevertheless, the full molecular mechanisms 
underlying ECCE have yet to be determined. 
 
1.4.8.2 SOCE 
SOCE is the process by which ER/SR Ca2+ stores can be replenished following 
depletion. It was first described in T-lymphocytes, but has since been shown to be 
present in other cell types including skeletal muscle (Kurebayashi and Ogawa, 2001).  
Although SOCE is another route through which extracellular Ca2+ can enter skeletal 
muscle cells, it is only thought to responsible for a relatively small influx of 
extracellular calcium during normal physiological processes (Stiber and Rosenberg, 
2011; Trebak et al., 2013; Pan et al., 2014). In contrast, SOCE plays a more dominant 
role when the SR Ca2+ is severely depleted, and is only inactivated upon store 
repletion (Pan et al., 2002; Launikonis and Ríos, 2007; Duke et al., 2010). Such a 
store depletion can occur through the activation of leaky RYR1 channels as observed 
in RYR1-associated MH (Duke et al., 2010; Yarotskyy et al., 2013; Cully et al., 2018), 
or through the loss of the SR Ca2+ buffering capacity by the loss of CASQ1 (Zhao et 
al., 2010). Zhao et al., (2010) used short-hairpin RNA to reduce the SR Ca2+ buffering 
capacity by knocking-down CASQ1 in adult skeletal muscle fibres and found an 
enhanced rate of SOCE. When CASQ1 was overexpressed, SOCE was shown to be 
inhibited (Shin et al., 2010).  SOCE thus provides a putative mechanism whereby the 
high [Ca2+]i can be maintained during an MH reaction, and thus propagates the 
hypermetabolic and hypercontractile states. In line with this hypothesis, the absence 
of extracellular Ca2+ results in a markedly reduced contracture during the IVCT 
(Fletcher et al., 1990).  
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The exact receptors that underlie SOCE in skeletal muscle have not been elucidated, 
however the inhibitory actions of the putative TRPC antagonist BTP2 on skeletal 
muscle SOCE suggests that TRPC channels are involved (Zitt et al. 2004; Eltit et al. 
2013). The importance of both TRPC plus SOCE in the MH reaction is demonstrated 
by the findings that BTP2 pre-treatment can abolish MHS skeletal muscle responses 
to halothane on the IVCT (unpublished data from the Leeds MH unit). The TRPC 
channels are thought to mediate the extracellular Ca2+ entry through an indirect 
interaction with the RYR1 and/or their activation by intracellular secondary 
messengers such as inositol 1,4,5-trisphosphate (IP3) and DAG (Lee et al., 2006). 
TRPC3 has been shown to be a pre-requisite for the full gain of ECC, as well as the 
full activation of RYR1 by agonists (Lee et al., 2006). One hypothesis that links 
TRPC3/6 activity with SOCE is that the TRPC3/6 channels interact with the STIM-1-
Orai-1 complex in skeletal muscle, although the data supporting this is still 
contentious with some studies failing to find this interaction (Liao et al., 2007; Liao et 
al., 2008; Horinouchi et al., 2012; Eltit et al., 2013).  Part of this contention may be 
attributed to the difficulty of studying TRPC channels given they exist as hetero-
tetramers rendering it challenging to delineate the contribution of each subtype (Gaily, 
2012). Another reason could be that initial studies investigated the interaction of 
STIM1 with TRPCs rather than the more recently discovered splice variant STIM1L 
which is known to have a greater affinity for TRPCs (Liao et al., 2007; Horinouchi et 
al., 2012) 
 
1.4.8.3 RCaE 
The control of resting skeletal [Ca2+]i is understood to be through a balance of activity 
of channels, pumps and exchangers in both the SR and sarcoplasm. RYR1 has been 
found to account for more than half of the resting [Ca2+]i through two mechanisms that 
are mediated by the bidirectional communication between Cav1.1 and RYR1 (Eltit et 
al., 2012). The first is the aforementioned Ca2+ leak conformation, whereas the 
second is through RYR1 potentiating the basal sarcolemmal Ca2+ influx (Eltit et al., 
2010). Mutations in RYR1 have been shown to enhance both these processes and 
thus lead to an elevated [Ca2+]I (Eltit et al., 2012). The exact channels involved in the 
elevated [Ca2+]I have not been fully elucidated, but may involve the sarcolemmal 
Na+-Ca2+ exchanger operating in a reverse-mode, and TRPC channels (Eltit et al., 
2013; Altamirano et al., 2014). The increased resting permeability may not only 
account in part for the raised [Ca2+]i observed in RYR mutants, but may also contribute 
to the propagation of the hypercalcaemic state observed during an MH reaction 
(López et al., 2000; Altamirano et al., 2014). 
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1.4.9 MH and Ca2+ Handling 
The precise mechanisms by which triggering agents cause an MH crisis is not fully 
understood. What is known is that there is perturbed calcium handling within the 
skeletal muscle fibre which is primarily driven by an altered RYR1. In a porcine MH 
model, the isolated RYR1 receptor was found to have a prolonged duration in the 
open state, with the alteration postulated to be due to a defect in the low-affinity Ca2+ 
binding site (Fill et al., 1990). The consequence of a longer receptor open state is an 
enhanced release of SR Ca2+ which then leads to elevations in [Ca2+]i. Mouse knock-
in models of MH have revealed that the RYR1 channel has an enhanced sensitivity 
to RYR1 agonists, and an increased [Ca2+]i (Yang et al., 2006, Yuen et al., 2012; 
Lopez et al., 2018). Several mechanisms have been postulated regarding how the 
variants promote the leaky state of the channel, some evidence supports that the 
variants change the sensitivity of the channel to cytosolic Ca2+ and Mg2+, whereas 
others have suggested there is an enhanced sensitivity to a luminal Ca2+ activating 
site (Jiang et al, 2008; Chen et al., 2017). The latter has been termed store overload 
induced Ca2+ release (SOICR). This luminal activating site is thought to function 
through a raised luminal Ca2+ reducing the affinity to Mg2+ (Laver et al., 2004). 
 
The raised SR Ca2+ release is thought to trigger other mechanisms of Ca2+ entry such 
as SOCE, into skeletal muscle cells during an MH reaction, but less is known about 
the effects in the resting non-triggered state. Furthermore, much of the data 
presented on this theory so far has been gained through animal models of MH 
carrying RYR1 variants that are not commonly found in the UK MH population (Yang 
et al., 2006, Yuen et al., 2012; Lopez et al., 2018; Miller et al., 2018).  Therefore, there 
is a strong need for further work to investigate whether the findings from animal 
models are replicated in human MHN and MHS skeletal muscle, and if the magnitude 
of these responses is affected by the specific diagnostic RYR1 variants. 
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1.5 Aims and Objectives 
 
1.5.1 Aims 
This thesis aims to explore the molecular pathways involved in establishing the 
altered calcium handling that is observed in the MH phenotype, and to examine the 
modulating effects of different RYR1 variants. The work will focus on examining the 
importance of the extracellular entry of Ca2+ into skeletal muscle cells of both MHS 
patients as well as from a novel mouse model of MH which contains an RYR1 variant 
that is equivalent to the most common variant found in human MH. Accordingly, this 
thesis provides a unique opportunity to explore if the pathways involved in calcium 
handling are conserved between the two species using equivalent RYR1 variants. 
The project will also attempt to develop a system for the production of immortalised 
human MH cells, generating a unique resource for the editing of novel genetic variants 
associated with MH in human cell lines. The long-term aim of the project is to fully 
characterise the proteins involved in the perturbed calcium handling that is observed 
in skeletal muscle from MH susceptible patients. This enhanced understanding of the 
disorder would then lead to identification of putative novel targets for the treatment of 
MH and related conditions.  
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1.5.2 Objectives 
 
1.5.2.1 Investigate the Caffeine Sensitivity of Three RYR1 Variants in a 
Heterologous Expression System. 
In this chapter I will develop a perfusion system that will be used in the subsequent 
chapters to investigate the calcium handling mechanisms of human and mouse MH 
cells. I will also investigate the caffeine sensitivity of three human RYR1 variants that 
are associated with susceptibility to MH.  
 
1.5.2.2 Investigate the Genotypic-Phenotypic Correlations Between Two 
Human MH RYR1 variants.  
This chapter will assess whether there are any genotype-phenotype correlations 
observed in the caffeine sensitivity as well as rate of extracellular cationic entry in 
cells from patients with two different diagnostic RYR1 variants associated with MH. 
The variants have a different phenotypic response on the IVCT, and this chapter will 
assess if this is also observed in myotubes. 
 
 
1.5.2.3 Explore the Feasibility of Immortalising Human Skeletal Myoblasts. 
The limited ability of human myoblasts to replicate, restrict the ability to perform 
detailed studies into the molecular mechanisms underlying MH in human skeletal 
muscle cells. In this chapter the objective is to immortalise human myoblasts in order 
to produce a regenerative pool of MH cells for detailed mechanistic studies. 
 
1.5.2.4 Characterise the Calcium Handling in a Novel Mouse Model of MH. 
In this chapter, skeletal muscle cells from a novel knock-in mouse model harbouring 
the most common diagnostic RYR1 variant will be characterised to assess whether 
they have an enhanced sensitivity to RYR1 agonists. Studies will also assess whether 
the Ca2+ handing mechanisms seen in human MH cells are conserved in this mouse. 
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Chapter 2. Methods 
 
2.1 Generation of p.G2435R Mice 
The p.G2435R knock-in MH mice were created using homologous recombination in 
embryonic stem cells by the MRC Harwell Institute (UK). Below is the overall method 
used (from Lopez et al., 2018). The process involved site-directed mutagenesis 
(QuickChange Multi-Site-Directed Mutagenesis Kit; Stratagene, La Jolla, CA, USA) 
to mutate the glycine into an arginine at codon 2435 in the murine RyR1 protein. 
Position 2435 in the murine RyR1 protein is the counterpart to position 2434 in human 
RyR1, thus the p.G2435R in mouse is equivalent to human p.G2434R. A 5.86 kb 
fragment containing exons 40-47 of RYR1 and Notl restriction sites were isolated from 
a 129Sv/J mouse genomic library and used to construct the targeting vector 
harbouring the codon encoding an arginine at position 2435. The targeting vector also 
contained a bacterial locus of crossover in P1 (LoxP) recombination sites flanking the 
neomycin (G418) cassette which was inserted between the 1.9 kb downstream and 
3.9 kb upstream arm. 
 
The linearized targeting vector was introduced into 129Sv/J embryonic stem cells via 
electroporation, and G418 used to positively select for cells which had undergone 
homologous recombination with the vector. PCR was used to confirm homologous 
recombination at this location, and Sanger sequencing was used to confirm the 
presence of the mutation. A clone identified as containing the p.G2435R mutation 
was injected into C57BL/6 murine blastocysts and implanted into pseudo-pregnant 
mice. Male chimeric offspring were mated with female C57BL/6 mice, the presence 
of both agouti coat colour and PCR screening were then used to confirm germ-line 
transmission. The LoxP-flanked neo cassette was then excised through the mating 
of the mice with tissue-non-specific alkaline phosphatase promoter-driven Cre 
recombinase (Tnap-Cre) transgenic mice. The resulting offspring containing the 
p.G2435R mutation but not the neomycin cassette then underwent two-rounds of 
backcrossing with C57BL/6 wild type (MHN) mice, and then crossbred to produce 
mice carrying either one heterozygous (Het) or two homozygous (Hom) p.G2435R 
alleles. These p.G2435R carrying lines were maintained using either male Hom 
mating with female Hom, or Het males mating with Het female mice. Initial genotyping 
assays were performed by Charles River, and then by the animal house at the 
University of Leeds. 
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2.2 General Cell Culture Methods 
2.2.1 Isolation of Human Myoblasts 
Ethical approval for the use of human myoblasts was obtained from the National 
Research Ethics Service committee for Yorkshire and the Humber, Leeds East 
(reference 10/H1306/70), and all patients whose samples have been stored have 
given their written consent for this. The isolation of human myoblasts for the Leeds 
MH biobank had been previously performed by the technicians within the MH Unit. 
Excess human skeletal muscle tissue from IVCT experiments was stored overnight 
at 4 °C in a preplating medium containing Ham's F-10 nutrient mix with GlutaMAX 
(F-10; Gibco, USA), 20 % fetal bovine serum (FBS; Gibco, USA), 
4 x Penicillin/Streptomycin (pen/strep; Gibco, USA). On the following day the muscle 
was placed into a sterile petri-dish (Sarstedt, Germany), cut finely mixed with 
phosphate buffered saline (PBS) and then centrifuged at 300 x g for 6 minutes (min). 
The supernatant was removed, 3 mL of a Dispase II (2.4 units/mL) plus Collagenase 
D (1 mg/mL; Sigma-Aldrich, USA) mixture was added to the pellet, mixed then 
incubated at 37 °C for 1 hour with regular mixing. This was then washed in PBS 
containing 400 U/mL each of pen/strep, filtered through a 70 µm cell strainer and 
centrifuged at 300 x g for 6 min. The pellet was resuspended in proliferation medium 
containing Ham’s F-10 with 20% FBS, 400 U/mL pen/strep and 10 ng/mL human 
basic fibroblast growth factor (FGF-E; Peprotec, UK), then incubated at 37°C in 95% 
air/5% carbon dioxide (CO2) for one hour.  
To preferentially select for myoblasts the preplating technique of Rando and Blau 
(1994) was used. The cell supernatant was transferred into a new flask and incubated 
at 37°C in 95% air/5% CO2 for one hour, this was repeated twice.  After two 
preplatings, the supernatant was transferred to an entactin-collagen IV-laminin (ECL) 
cell attachment matrix (Merck Millipore, UK) coated flask (1.3 µg/cm2) and allowed to 
proliferate. Proliferating cells were maintained at 37 °C in 95% air/5% CO2, with 
complete proliferation medium changes every two to three days. Once the cells had 
reached 60-70 % confluence they were either split or stored in liquid nitrogen. During 
the first few passages, the myoblasts were maintained in the human proliferation 
medium with 400 Units/ml pen/strep, however after 4-5 passages, the concentration 
of the antimicrobials were reduced to 200 Units/ml each of pen/strep. 
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2.2.2 Isolation of Mouse Myoblasts 
Approval for the isolation of mouse skeletal myoblasts from the RY16 mice containing 
the variant was obtained from the UK home office (project number PB2FB5E95) 
under the Animals Scientific Procedures Act 1986. The University of Leeds animal 
welfare and ethical review committee also approved the project. Myoblasts were 
isolated from three wildtype (C57BL/6), three heterozygous for the p.G2435R RYR1 
and three C57BL/6 mice homozygous for this variant, after undergoing a Schedule 1 
killing. The mice were less than 8 weeks old with a mix of male and female animals.  
 
Total skeletal muscle from fore- and hindlimbs were isolated, weighed and finely cut 
in PBS at 4 °C. A Dispase II (2.4 units/mL) plus Collagenase D (1 mg/mL; Sigma-
Aldrich, USA) mix with 5 µM calcium chloride was added, the enzymatic digestion 
was left for 60-75 min at 37 °C. During this time, the tissue was triturated with a 5 mL 
pipette every 15 min. The digested slurry was then mixed with 2 x volume of the 
preplating medium before being passed through a 100 µm cell strainer. The filtrate 
was centrifuged at 300 x g for 10 min at room temperature, the ensuing pellet was 
resuspended in fresh preplating medium and a red cell lysis buffer added; this 
contained 155 mM ammonium chloride, 10 mM potassium bicarbonate, 1 mM 
Ethylenediaminetetraacetic acid (EDTA), pH 7.2.  This mixture was then filtered 
through a 40 µm cell strainer and the filtrate centrifuged at 300 x g for 6 min, the 
ensuing pellet resuspended in the preplating medium, plated onto 10 cm sterile petri 
dishes and placed in the incubator for 30 min at 37 °C in 95% air/5% CO2. After 
30 min, the medium was transferred to a new sterile petri dish and this repeated for 
at least six preplatings before the final medium was placed onto ECL (1.3 µg/mL) 
coated sterile petri dishes, then 2.5 ng/mL of FGF-E was added.  Further preplatings 
were performed over the ensuing days as required until a pure myoblast population 
was produced with the cells maintained in rat tail collagen (2 µg/cm2) coated petri 
dishes, using the mouse proliferation medium consisting of Ham’s F-10 with 20% 
FBS, 100 U/mL pen/strep and 2.5 ng/mL FGF-E. The medium was changed every 
two to three days, and when the cells reached 60% confluence, they were either split 
or stored in liquid nitrogen. 
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2.2.3 Matrix Coating of Plates  
ECL coating of plates was performed by incubating the plates/flasks with ECL 
(1.3 µg/cm2) for 60 min at 37 °C in 95 % air/5 % CO2 or overnight at 4 °C. Excess 
ECL was then removed and the plates gently rinsed with PBS. Collagen coating was 
achieved by incubating culture flasks with rat tail collagen (2 µg/cm2 dissolved in 
acetic acid) for 30 min at 37 °C in 95 % air/5 % CO2 or overnight at 4 °C, followed by 
a PBS rinse. Matrigel coating was completed by adding ice-cold Matrigel 
(11.3 µg/cm2) to the pre-cooled (4 °C) culture vessel, then placing on a plate shaker 
for 30 min at room temperature, followed by a further 30 min at 37 °C in 95 % air/5 % 
CO2, with excess Matrigel aspirated. 
 
2.2.4 Differentiation of Human and Mouse Myoblasts 
2.2.4.1 Live Cell Calcium Imaging Experiments 
Human and mouse myoblasts were plated at a density of 0.75-1.5 x 104 onto Matrigel 
coated 96-well imaging plates and left in proliferative medium containing 10 or 
2.5 ng/mL of FGF-E, respectively. On the next day, once the cells were >60 % 
confluent, the differentiation process was initiated by changing from the proliferative 
medium to differentiation medium consisting of DMEM with GlutaMAX and 4.5 g/L 
glucose, 2 % heat inactivated horse serum, and 100 U/mL pen/strep (all from Gibco, 
UK). Human myoblasts were differentiated for 10-13 days with the medium changed 
every 1-2 days, whereas mouse myoblasts were differentiated for 4-5 days.  
 
2.2.4.2 Immunocytochemistry Experiments 
Myoblasts were plated onto ECL-coated 8-chamber glass slides (Nunc, Lab-Tek, 
Sigma-Aldrich, USA) or 96-well imaging plates (Cat# 655090, Greiner bio-one GmbH, 
Germany) at a density of 1 x 104 and 5 x 104 cells per well in proliferation medium. 
After reaching >60 % confluence, they were differentiated as discussed in 2.2.4.1. 
 
2.2.4.3 RT-PCR Experiments 
Human myoblasts were plated onto ECL-coated plates or flasks and grown to >60 % 
confluence in proliferative medium.  The differentiation process was initiated as 
described above in 2.2.4.1.  
 
 
 33 
2.2.5 Passage and Cryostorage of Cells 
When myoblasts were >60 % confluent, the proliferation medium was discarded and 
the cells rinsed with PBS followed by the addition of 1 mL of 0.25 % trypsin-EDTA 
(Gibco, UK) per 25 cm2 of the culture vessel. The trypsin was incubated at 37 °C in 
95 % air/5 % CO2 for 3-5 min until the majority of cells were no longer adherent. Fresh 
preplating medium and PBS were added to stop the reaction, and the mix centrifuged 
at 300 x g for 6 min. The pellet was subsequently either resuspended in 20 mL of 
proliferation medium which was then split over two flasks for further growth, or it was 
resuspended in the cryopreservation solution. Human and mouse myoblasts were 
cryopreserved in a freezing mix either containing 10% dimethyl sulfoxide (DMSO; 
ThermoFisher, USA) and 90% preplating mixture for the immortalisation experiments, 
or 10% DMSO and 90 % FBS for the cells that were used for calcium imaging studies. 
The resuspended cells were then aliquoted into cryovials (Sarstedt, Germany), 
cooled slowly to -80 °C for short term storage and placed in liquid nitrogen for long-
term storage at -180 °C. 
 
2.2.6 Cell Counting and Viability Assays 
After the trypsinised cells had been treated with preplating or proliferation media, a 
10 µL aliquot of the cell solution was mixed thoroughly with 10 µL of trypan blue 
(Gibco, UK), a 10 µL aliquot of the ensuing mix was then loaded onto a 
haemocytometer. Viable cells (no trypan blue staining) were counted from 5 fields of 
view, these were averaged to determine the number of cells per mL of the 
resuspended cell mixture. 
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2.3 General Molecular Biology Methods 
2.3.1 DNA Extraction 
Myoblasts were plated and grown to >70 % confluence on ECL coated T25 flasks or 
10 cm plates (Sarstedt, Germany). Cells were trypsinised, and pelleted as described 
in 2.2.5. Cell pellets were resuspended in a lysis buffer (2% w/v sodium dodecyl 
sulphate and 25 mM EDTA) at 1 mL per 1 x 106 cells, and agitated gently. The 
proteins were precipitated by gently mixing with one third volume of 10 M ammonium 
acetate, this was then centrifuged at 3200 x g for 20 min. The supernatant was 
transferred to a new falcon tube containing 2.5 volumes of cold 100 % ethanol and 
the mixture incubated overnight at -20 ºC. The DNA precipitate was then centrifuged 
at 3200 x g for 15 min, the supernatant was discarded and the pelleted DNA washed 
with 70 % (v/v) ethanol, then centrifuged at 3200 x g for 15 min, and the supernatant 
discarded. The wash step was repeated twice, then the pellet was left to air dry for 
10-20 min at room temperature before finally being resuspended in Tris-EDTA (TE) 
buffer (ThermoFisher, USA). A NanoDrop 1000 spectrophotometer (ThermoFisher, 
USA) was used to quantify the DNA as per the manufacturers recommendations. The 
short-term storage of DNA was at -20 ºC, whereas long-term storage at -80 ºC. 
 
2.3.2 PCR and Agarose Gel Electrophoresis 
The primers used in the polymerase chain reactions (PCR) were designed using 
Primer Blast (using Primer3 and BLAST, US National Library of Medicine, Ye et al., 
2012), and synthesised externally by Integrated DNA Technologies (IDT). Lyophilised 
primers were resuspended in nuclease-free water (Ambion, UK) to 10 µM and diluted 
to the optimal concentration in each PCR reaction. PCRs were run in a thermal cycler 
(T100, BioRad, USA), the conditions are described in the subsequent chapters. For 
gel electrophoresis, a 10 µL aliquot of a PCR product was mixed with 2 µL 6 x loading 
buffer, this together with a 100 bp ladder were run on a 1% agarose gel containing 
0.01% ethidium bromide at 120 V for 45-60 min. An ultraviolet (UV) imaging station 
(U:Genius gel imaging system, Syngene, UK) was used to visualise the DNA bands. 
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2.3.3 Direct PCR  
70 % confluent myoblasts were trypsinised as described in 2.2.5, from this a 10 μL 
aliquot was added to 15 μL of nuclease-free water (Ambion, UK) and centrifuged at 
4000 x g for 6 min. The supernatant was removed, a further 200 μL of nuclease-free 
water added, with the mixture heated at 99 ºC for 10 min. Next proteinase-K 
(200 µg/mL; Sigma-Aldrich, USA) was added, the mixture was incubated at 56 ºC for 
30 min, after which the proteinase inactivated by incubating at 96 ºC for 10 min and 
the reaction placed on ice for 5 min. A 2.5 µL aliquot was added to 47.5 µL of an ice-
cold PCR reaction mix consisting of 18.25 µL nuclease free water, 1 x DreamTaq 
buffer, 200 µM dNTPs, 200 µM each of forward and reverse primers, 5 % DMSO, and 
1.25 Units Taq polymerase (DreamTaq). All reagents unless stated were from 
ThermoFisher (UK). 
 
2.3.4 Sanger Sequencing 
This was outsourced to a commercial company SourceBioscience (Cambridge, UK). 
5 µL per reaction of non-purified PCR products (10 ng/µL) together with 5 µL of the 
appropriate primers (3.2 μM) were sent by post for clean-up and Sanger sequencing. 
The sequencing results were analysed using 4Peaks software (Nucleobytes, 
Netherlands). 
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2.4 General Bacterial Methods 
2.4.1 Bacterial Growth 
Escherichia coli (E.coli)  containing the plasmids of interest were streaked onto agar 
plates containing 1 x ampicillin and grown at 37 qC overnight. Single colonies were 
then picked and inoculated into a 5 mL starter culture of liquid broth (LB) containing 
1 x ampicillin then placed in a shaking incubator at 37 qC for 6 hr. A 150-200 μL aliquot 
of the starter culture was used to inoculate 150-200 mL of LB containing 100 μg/mL 
ampicillin (Sigma-Aldrich, USA) and incubated in the shaking incubator at 37 qC 
overnight.  
 
2.4.2 Plasmid Maxi Preparation 
Bacterial cells that were grown overnight were then pelleted by centrifugation at 4000 
x g for 30 min, following which a QIAGEN (UK) maxi-prep assay was used according 
to the instructions of the manufacturer to isolate transfection-grade plasmid DNA 
which was free from bacterial endotoxins. The DNA pellet was then resuspended in 
Tris base, acetic acid and EDTA (TAE) buffer (ThermoFisher, USA), quantified using 
a nanodrop 1000 and then diluted to 1 Pg/mL with TAE buffer. 
 
2.4.3 Production of Glycerol Stocks 
Long-term storage of bacterial cultures was undertaken using glycerol stocks. Here, 
500 μL of the overnight culture was added to 500 μL 50% (v/v) glycerol, mixed and 
stored at -80 qC. 
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2.5 Immunocytochemistry 
Myoblasts were plated and differentiated as described in 2.2.4.2. After differentiation, 
the medium was discarded, slides were washed with PBS and then fixed with 4% 
paraformaldehyde (PFA) for 15 min at room temperature. Cells then went another 
PBS wash before being permeabilised with 0.1% Triton X-100 in PBS for 15 min, 
followed by further PBS washes.  Non-specific binding was blocked through a 10 min 
incubation with 5% normal donkey serum, following which they were incubated with 
the primary antibody of interest for either 1 hr at room temperature or overnight at 
4 °C in a humidified chamber. The antibodies were diluted in PBS containing 1% 
bovine serum albumin (BSA). Cells were then washed with PBS and incubated for 1 
hr at room temperature (or overnight at 4 °C) with the secondary antibody conjugated 
to the fluorophore of interest. After final washes, the slides were mounted with 
ProLong Diamond Antifade mountant containing 4',6-diamidino-2-phenylindole 
(DAPI; ThermoFisher, USA) for 24 hr at room temperature. Imaging was performed 
using a Carl Zeiss (Zeiss, Germany) or Nikon Eclipse T1e (Nikon, Japan) microscope 
using Texas Red, FITC and DAPI filter sets. 
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2.6 Live-Cell Calcium Imaging 
2.6.1 Perfusion System 
The system used for these studies was a valvebank 8 pinch valve perfusion system 
with 35 ml syringes with a thermoclamp inline heater (Figure 2.1) (Automate 
Scientific, USA). The thermoclamp attachment was connected via short perfusion 
tubing to a    borosilicate glass pipette which had been fashioned to produce a short 
dead space on the inlet channel. The inlet channel was approximately 3 mm longer 
then the outlet channel to maintain a constant volume of liquid in the well; this 
prevented cells from drying or an exposure to variable drug concentrations. The outlet 
channel was connected to a constantly running roller pump. The imaging buffer (IB) 
and drugs were perfused at 3 pounds per square inch (psi); IB for 10 s then drug for 
10 s followed by IB for 10 s unless otherwise stated in subsequent chapters. 
Myotubes were allowed to recover for 2 mins for the refilling of SR stores, during 
which time the light source was switched off to prevent cellular phototoxicity and dye 
bleaching. In the Mn2+ quench experiments due to the slower response kinetics, the 
drugs as well as IB were perfused for 30 s or longer at 0.5 psi.  
 
 
Figure 2.1: Perfusion system for calcium imaging. 
A valvebank 8 pinch valve perfusion system with 35 ml syringes and a thermoclamp inline 
heater was used for live cell fluorescence imaging. Syringes were loaded with the drugs of 
choice or IB, and a pinch valve controller used to rapidly administer these as per the 
experimental protocol. A constant well volume was maintained by continuous suction of any 
excess fluid using a roller pump. The pressure regulator was set to maintain a constant 
perfusion pressure throughout each experiment.  
Waste
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Syringes (8 x 35 mL) 
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Pinch valve
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2.6.2 Experimental Solutions  
2.6.2.1 Buffers 
2.6.2.1.1 Imaging Buffer 
The IB used in the myotube based calcium release experiments consisted of in mM: 
NaCl 133, KCl 5, MgCl2 1, CaCl2 2, glucose 5.5, 4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid (HEPES) 10, pH 7.40 at 25 °C. The solution was 
prepared as a 10X stock that was stored at 4 °C without MgCl2, CaCl2 or glucose, and 
these were added on the day of experiment.  
 
2.6.2.1.2 Manganese Buffer 
For the manganese (Mn2+) quench experiments, the manganese buffer (MnB) was 
similar to IB except 0.5 mM MnCl2 was used instead of the CaCl2 and MgCl2.  
 
2.6.2.2 Drugs 
2.6.2.2.1 Caffeine and Other Compounds 
Compounds used in the live-cell imaging experiments included caffeine, 250 nM 4-
[[(1R,2R)-2-[(3R)-3-Amino-1-piperidinyl]-2,3-dihydro-1H-inden-1-yl]oxy]-3-
chlorobenzonitrile dihydrochloride (SAR7334; TOCRIS, USA), 25 µM gadolinium 
chloride (GdCl3), 5 µM hyperforin, 1 mM 5-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR; Cell Signaling Technology, USA), 1 mM Tetracaine, 5 µM N-
[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl-1,2,3-thiadiazole-5-
carboxamide (BTP2; TOCRIS, USA) and 100 µM 1-Oleoyl-2-acetyl-sn-glycerol 
(OAG). All drugs are from Sigma-Aldrich (USA) unless otherwise stated. 
 
Most of the drugs were soluble in aqueous solutions, thus stocks were produced in 
de-ionised water and stored as per the manufacturer recommendations. On the day 
of experiment, stocks of drugs were dissolved in IB to produce the final desired 
concentration. BTP2 and OAG are not soluble in aqueous solutions and thus were 
dissolved in DMSO, aliquoted into small volumes to avoid frequent freeze-thaw cycles 
and stored at -20 °C. The final DMSO concentration within these drugs was ≤0.04%. 
In the experiments with BTP2, myotubes were pre-treated for 20 min with 5 µM BTP2 
in IB, before perfusing MnB containing 5 µM BTP2. The pre-treatment with 100 µM 
OAG occurred for 5 min in IB, before perfusing MnB containing 100 µM OAG. 
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2.6.2.2.2 KCl 
Experiments were performed to examine the response of myotubes to differing 
concentrations of KCl. The higher concentrations of KCl were achieved by reducing 
the concentration of NaCl in the IB to maintain a total cation (K+ + Na+) concentration 
of 138 mM. 60 mM KCl was also used to determine the presence of functioning EC 
coupling. 
 
2.6.2.2.3 Halothane 
Initial experiments were performed to identify the concentration of halothane in 
solutions that have been gassed using the IVCT experimental set-up. The 
concentration of halothane was measured using the UK MH unit/EMHG protocol for 
the analysis of the halothane concentrations in the IVCT solutions. Halothane was 
bubbled through 40 mL of IB at room temperature for 3 min, a 500 µL aliquot of the 
solution was then added to gas chromatography (GC) air tight vials containing 500 µL 
of carbon tetrachloride containing 1:50 chloroform, and vortexed vigorously. A 1 µL 
sample of this mixture was then run through a GC analyser (Shimadzu, Japan). A 
reference curve was used to determine the concentration of halothane in the sample. 
The procedure was repeated with aliquots of IB that had been freshly bubbled with 
halothane diluted to different degrees, and the halothane concentration measured. 
The experiments revealed that a dilution of 20-fold with IB consistently produced a 
solution that had a measured halothane concentration of 0.04 mM and a 10-fold 
dilution produced a halothane concentration of 0.11 mM (Figure 2.1); the latter is 
equivalent to 0.5 % as per EMHG protocol (Hopkins et al., 2015).  Thus, for the 
halothane experiments, freshly bubbled IB containing halothane were diluted 10 or 
20-fold with IB, the solution was vigorously shaken and kept in an air-tight container 
with virtually zero dead space until perfused over the myotubes. A fresh sample of 
the diluted halothane was produced and used after every 3 wells of imaging. 
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Figure 2.1: Measurement of halothane concentrations in imaging buffer. 
Imaging buffer (40 mL) was gassed for 3 minutes with 2% halothane using a standard IVCT 
set-up, the solution was then either diluted 20 or 10-fold with imaging buffer, thoroughly mixed, 
and analysed with gas chromatography as per the UK MH unit/EMHG protocol. The median 
and interquartile range are shown together with the individual data points. 
 
 
2.6.3 Epifluorescence Imaging 
2.6.3.1 Dye Loading 
Stock solution of Fluo-4AM and Fura-2AM (ThermoFisher, USA) were prepared in 
DMSO at 1 mM and stored in 3 PL aliquots at -20 qC. On the day of experiments these 
were diluted in imaging buffer to a final concentration of 5-20 PM and loaded into the 
cells (details of the loading conditions are presented in the relevant chapters). 
Following loading, the cells were washed 3 times with IB at room temperature and 
allowed 25 min to de-esterify prior to fluorescence imaging. In some experiments 
Pluronic acid F-127 (ThermoFisher, USA) was used to help with dye loading. Here a 
20 % (w/v) stock was produced by dissolving the compound in DMSO at 40 qC whilst 
vigorously shaking, this stock solution was kept in the dark in a dehumidified 
environment at room temperature. On the day of experiment this was mixed with the 
fluorescent dye in a ratio of 1:1 to produce a 10% working solution. The medium was 
aspirated from differentiated myotubes grown on 96-well imaging plates (see 2.2.4.1), 
the plates were washed twice with IB at 37 qC before the fluorescent dye was added. 
Following loading, excess dye was discarded, the cells washed three times with IB, 
then left for 25 min in IB in the dark at room temperature to allow the dye de-
esterification, before they underwent imaging on a Nikon Eclipse T2000 at room 
temperature. 
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2.6.3.2 Calcium Release. 
The Fluo-4 dye was excited using a short arc mercury lamp with an excitation filter of 
480 +/- 20 nm, and the emission measured at 535 +/- 25 nm using a 40x 1.3 NA 
objective. Images were captured using 4x4 binning at a rate of 20 fps through an 
intensified 12-bit digital intensified charge-coupled device (ORCA-ER) using IPLab 
software (BD Biosciences, USA). To prevent phototoxicity to the cells as well as dye 
bleaching, the cells were only exposed to the excitation light for 2 s prior to the drug 
being perfused, then for 10 s of the drug perfusion and 15 s during the drug washout. 
Furthermore, neutral density filters were used to lower the light intensity. The 
recorded images were then imported into FIJI software (Schindelin et al., 2012) using 
the IPLab plugin (Wayne Rasband, NIH, USA) and analysed. Regions of interest 
(ROI) were drawn within individual cells and a time series analyser plugin (Balaji J, 
Department of Neurobiology, UCLA, USA) used to determine the temporal changes 
in the fluorescent intensities. This data was exported to Prism 7 (GraphPad, USA) 
and this together with Microsoft Excel (version 16 for Apple, Microsoft, USA) were 
used to calculate the area under the curve (AUC), base and peak height for each 
response to caffeine/KCl/halothane. Myotubes were only included in the analysis if 
they responded to 60 mM KCl and therefore had functioning ECC (Cherednichenko 
et al., 2004). 
 
The AUC for each response in individual myotubes was calculated as the average 
fluorescence during the response to the challenge, minus the average baseline 
fluorescence for one second (s) immediately before the challenge. Because of 
variability in cells, the responses to caffeine at each concentration in every individual 
cell was normalised to the response observed with the highest concentration of drug 
applied in that cell.  
 
The peak fluorescence was calculated and normalised for each drug concentration 
within an individual cell using the equation:  
Peak F = (F-F0)/(Fmax-Fmax0) 
Here, F is the peak fluorescence following drug application, F0 is the baseline 
fluorescence pre-drug application, Fmax is the peak fluorescence after the maximum 
drug concentration is applied (e.g. 20mM Caffeine or 60mM KCl) and Fmax0 is the 
baseline fluorescence prior to Fmax. For the halothane experiments, the AUC and 
peak responses were normalised to 60 mM KCl as this was also used to check for 
EC coupling in each cell. 
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The data from the normalized responses observed at each caffeine concentration in 
each myotube were used to plot a concentration-response curve on a semi-log axis.  
A non-linear regression using a four parameters variable slope Hill equation was used 
to fit representative curves in each myotube for both the normalised AUC and peak 
height of the responses. The EC50 for each drug was then determined in each 
myotube, and these were then used for further statistical comparisons. 
 
2.6.3.3 Extracellular Cationic Entry 
After dye loading, the Fura-2 dye was excited at 360 +/- 5 nm with the emission 
measured at 510 +/- 40 nm using 40x 1.3 NA objective. Images were captured at 5 
fps with a 2x2 bin using the equipment described in 2.6.1. To prevent bleaching of 
the dye and damage to the cells, neutral density filters were used to reduce the 
intensity of the excitation light to very low levels which were close to the limits of the 
detection in the system. ROI in individual cells were analysed as above to determine 
the fluorescent intensities, and this data was exported to Prism 7. Prism was used to 
fit linear regression models (y=mx+c) for the basal signal in IB, and then 
independently in Mn2+-containing solutions (MnB) with and without treatment drugs. 
The specific rate of Fura-2 quenching induced by Mn2+ entry was calculated by 
subtracting the basal slope from the slope during the MnB application (i.e. net slope), 
and expressed as arbitrary fluorescence units (AFU) per second. The net slope was 
calculated in the absence and presence of treatment drugs. Cells with a positive net 
slope following the addition of MnB were excluded from the analysis, furthermore the 
slope was normalised to zero when the net slope was positive following treatment 
with a cation channel antagonist. 
 
2.6.3.4 Statistics 
2.6.3.4.1 Calcium Release. 
Parametric data are presented as mean with the standard error of the mean (SEM), 
non-parametric data as box plots showing the median with the interquartile range 
(IQR) and the whiskers representing the range. Statistical analysis and nonlinear 
curve fitting were performed using a four parameter [agonist] vs. response equation 
in Prism 7 (Graphpad, USA). The EC50 values were determined for each myotube 
from fits to Hill equations and all the EC50 values were compared between the groups 
using either parametric or non-parametric tests depending on the distribution of the 
data, with correction for multiple comparisons where necessary as indicated in the 
text. Significance was accepted as P < 0.05.  
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2.6.3.4.2 Manganese Quench 
Non-normally distributed data are presented as box plots showing all the data points, 
median and IQR with the whiskers representing the range. Normally distributed data 
are presented as bar charts with mean ± SEM. Statistical analyses were performed 
with Prism 7 using the non-parametric tests Mann-Whitney, Wilcoxon signed-rank test 
or Kruskal-Wallis with Dunn’s correction for multiple comparisons, and student’s t-test 
or one-way analysis of variance (ANOVA) for parametric data. Significance was 
accepted as p < 0.05. Non-parametric statistical tests were used for the data as the 
data could not be transformed into a normal distribution across all genotypes. 
 
Unless otherwise stated in the relevant chapters, blinding to the genotypes of cells or 
the treatment group was not performed due to logistical reasons in conducting the 
experiments. 
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Chapter 3. Studying Novel RYR1 Variants in HEK Cells 
 
3.1 Introduction 
3.1.1 Assessment of Novel Genetic Variants Associated with MH  
A major goal of recent research into MH has been the development of a genetic 
diagnostic panel for MH as discussed in chapter 1. The underlying principle here is 
to reduce the burden to patients of undergoing invasive skeletal muscle biopsies. 
Despite this, studies over the last 30 years into identifying diagnostic RYR1 mutations 
for MH have only produced 48 diagnostic RYR1 and two CACNA1S mutations 
(EMHG diagnostic mutations, accessed 01/12/2019), while over 200 variants have 
been identified in the former alone (Miller et al., 2018; Riazi et al., 2018). 
 
The aforementioned problems with assessing the large number of novel variants that 
are associated with MH can be partly overcome using bioinformatics tools. These can 
be used to predict the pathogenicity of variants based on the current knowledge of 
protein sequence information, putative structure, domain and inter-polypeptide chain 
interactions. This aids in the identification of which variants could be prioritised to 
undergo further functional assessments only, but are unable to categorically identify 
diagnostic mutations. The enormity of the task of functionally characterising all the 
variants is highlighted by a recent analysis of the UK MH database which identified 
that there were 25 potentially pathogenic RYR1 variants found in 555 UK MH families 
(Miller et al., 2018). 
 
Functional assessments can be performed using either primary ex-vivo patient 
samples or isolated B-lymphocytes (Girard et al., 2001). A problem with this approach 
is the potential for additional variants in RYR1 or other skeletal muscle proteins to 
alter the Ca2+ handling properties of the cells, which then makes it difficult to ascertain 
whether any changes detected are a sole consequence of the variant of interest. The 
presence of more than one pathogenic variant complicates this assessment, 
particularly as this occurs in 9.2 % of the families in the UK MH population when 
RYR1, CACNA1S and STAC3 were fully sequenced (Miller et al., 2018). \the problem 
with such heterogeneity can be overcome by using the same genetic background on 
which variants are introduced, for example by genetically editing primary or 
immortalised mouse/human skeletal myoblasts using CRISPR-Cas9 system, or the 
creation of KI mouse models. CRISPR-Cas9 editing is limited by both its relative 
infancy as a technique (Garneau et al., 2012), as well as the need for cells that are 
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able to undergo numerous cycles of replication in order to generate a viable cell line. 
The monetary and ethical costs of generating and maintaining KI animal models for 
every potentially pathogenic variant render this an expensive approach. An 
alternative approach is a technique has been established in MH research for the last 
30 years, which involves the heterologous expression of RYR1 in HEK cells.  
 
 
3.1.2 Functional Studies using HEK Cells  
HEK cells are the most commonly utilised system for functional studies into the 
physiological effects of novel potentially pathogenetic RYR1 variants that are 
associated with MH (Tong et al., 1997 and 1999; Brini et al., 2005; Murayama et al., 
2011 and 2016; Merritt et al., 2017). The majority of these studies achieve this by 
examining the effect of the variant on the response of the channel to RYR1 agonists 
caffeine, 4-chloro-m-cresol (4-CMC) and halothane. 
 
The advantages of using HEK cells as an expression system that expresses rabbit or 
human RYR1 is that they are easily available, proliferate rapidly plus reliably, they 
are more amenable to genome editing, and are relatively cheap for functional studies 
that include the overexpression of specific proteins (Graham et al.,1977; Lin et al., 
2014). In addition, as they are derived from Homo sapiens, they provide a relevant 
and potentially consistent genetic background. The major limitation is that they are 
not a skeletal muscle cell line, and therefore do not natively express the full range of 
proteins involved in ECC. Furthermore, they do not form the triadic ultrastructure, their 
endoplasmic reticulum (ER) has a different Ca2+ buffering capacity to that seen in 
skeletal muscle SR, and HEK cells are unable to rapidly pump Ca2+ from the cytosol 
into the ER (Thomas and Smart, 2005; Jiang et al., 2010). Site-directed mutagenesis 
experiments to introduce RYR1 variants can be very time-consuming as they require 
sub-cloning of RYR1 fragments due to the long coding sequence (>15 kb) (Merritt et 
al., 2017). HEK cells are also believed to be at risk of genotypic divergence as a 
consequence of the accumulation of errors in the genome over an increasing number 
of cell divisions, but evidence suggests that the HEK genome is in a steady-state 
under standard cell culturing conditions (Lin et al., 2014).  
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3.1.3 MH Variants 
in this chapter two potentially pathogenic RYR1 variants identified by the Leeds MH 
unit and one confirmed EMHG diagnostic variant underwent further studies in a HEK 
expression system (EMHG diagnostic mutations, 2019). This expression system was 
chosen as the advantages of this system outweighed its disadvantages, within the 
context of the experience and facilities that were available in the Leeds MH unit. 
 
3.1.3.1 p.D1056H 
The amino acid change of an aspartic acid (D) to a histidine (H) at position 1056 of 
human RYR1 is encoded by a change in the cDNA of c.3166G>C. It is a potentially 
pathogenic variant (based on a MAF of <0.001), that has not been classified as a 
diagnostic variant by the EMHG (Miller et al., 2018; EMHG diagnostic mutations, 
accessed 01/12/2019). p.D1056H was first identified in an MHS individual during 
exome sequencing of four MH families (Kim et al., 2013), and currently there are two 
MH families in the UK MH database have been found to harbour this variant (Miller 
et al., 2018). The variant was initially thought to also be associated with exertional 
heat stroke (Merritt, 2013), however the latter is now thought to be a false positive 
result which originated from a contaminated sample. The variant has a MAF of 
0/7 566 in the Exome Aggregation Consortium (ExAC) cohort (using the European 
non-Finnish cohort), however this MAF was not statistically significant at an 
uncorrected P value of 0.0012 due to the number of comparisons made (Miller et al., 
2018).  
 
In terms of the RYR1 structure, p.D1056H is found within the SP1a/ryanodine 
receptor domain 2 (SPRY2)  which was originally thought to be a major link with II-III 
loop of the Cav1.1, but recent work suggests that this domain is instead involved in 
interactions between RYR1 protomers through its contact with the Bsol in the 
adjacent protomer (Lau and Van Petegem, 2014; des Georges et al., 2016). BSol 
itself has been shown to be important in RYR1 channel gating (Yamamoto et al., 
2000; des Georges et al., 2016).  
 
3.1.3.2 p.R2355W 
This diagnostic MH variant occurs due to an amino acid substitution at position 2355 
from a basic positively charged amino acid (arginine; R) to a non-polar bulky side 
chain (tryptophan; W), this results in a greater steric hindrance. It is encoded by 
c.7063C>T. p.R2355W has been found in 11 families worldwide, 8 families in the UK, 
2 in New Zealand and 1 in Germany (Wehner et al., 2004; Schiemann et al., 2014; 
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Miller et al., 2018). An IVCT study has shown this variant does not cause a significant 
difference in static caffeine contracture, the static or dynamic halothane contracture, 
or the CK concentration relative to p.G2434R (Carpenter et al., 2009). Functional 
studies have shown p.R2355W causes an increased sensitivity to caffeine, 
halothane, and/or 4-CMC in either human skeletal myotubes or HEK cells (Wehner 
et al., 2004; Schiemann et al., 2014; Merritt et al., 2017). The EC50 determined by 
Merritt et al., (2017) using the peak response was 1.4 ± 0.6 mM caffeine versus 
3.8 ± 0.6 mM in wild type (WT). Consistent with the increased channel sensitivity to 
these RYR1 agonists, p.R2355W is found within the BSol region which is involved in 
long range allosteric communications within RYR1 (Yamamoto et al., 2000; des 
Georges et al., 2016). This variant was chosen to confirm whether the results 
produced in this study were consistent with those reported by others, as well as to 
use as a comparative variant for the effects of AICAR. 
 
3.1.3.3 p.D3986E 
This variant, is a substitution of an aspartic acid (D) to glutamic acid (E) amino acid 
at position 3986 which is encoded by c.11958C>G. Both amino acids are negatively 
charged, however an extra methyl group is present within the side chain of the latter. 
p.D3986E is found in the CSol within the central domain of RYR1, and forms part of 
the channel activation module that facilitates pore dilatation (des Georges et al., 
2016). CSol also interfaces with the BSol domain (des Georges et al., 2016). 
 
The p.D3986E variant is not currently on the EMHG diagnostic list, although it is 
classed as likely pathogenic using bioinformatic analysis, and thus is used 
diagnostically in the UK MH unit (EMHG diagnostic mutations, 2019). It has been 
identified in 10 MHS individuals (7 MHShc and 3 MHSh) across 6 MH families that 
were referred for investigations in the Leeds MH unit. Furthermore, it has not been 
seen in any MHN individuals sequenced thus far, and is classed as a rare variant with 
a minor allele frequency of 0/66 312 ExAC (Miller et al., 2018). Skeletal muscle from 
MHS patients carrying the p.D3986E variant was found to have both a significantly 
higher static caffeine contracture and an elevated CK concentration relative to 
p.G2434R (Carpenter et al., 2009). Increases in CK are associated with greater 
muscle damage and turnover (Carpenter et al., 2009). The only published study of 
this RYR1 variant found that in HEK cells there was no significant increase in the 
caffeine EC50 compared with WT RYR1 (Merritt et al., 2017). 
 
 
 49 
3.1.4 pTUNE expression system 
The pTUNE expression system is a tuneable genetic switch that has been engineered 
so that repressor proteins and RNA interference (RNAi) are coupled to allow the tight 
inducible expression of a gene of interest (Figure 3.1; Deans et al., 2007). Not only 
does this arrangement allow investigations into the functional role of the gene of 
interest, but the tuneable elements facilitates studies examining whether there is a 
threshold response to changes in gene expression.  
 
The system is based on the repression at the lactose operon (lac) described by Jacob 
and Monod (1961), and builds upon this by adding a tetracycline (tet) controlled 
promoter with RNAi. In the resting uninduced state the LacI repressor proteins are 
constitutively expressed and thus bind to their target sites on the lac operator (lacO) 
sites in the module containing the gene of interest (e.g. RYR1). LacI repressor 
proteins also bind to the lac sites on the tetR repressor module which inhibits the 
transcription of TetR protein. Repression of TetR allows the transcription of shRNA 
by a U6 promoter and this binds complementarily to the synthetic target sequence 
located on the 3’ untranslated region (UTR) of the mRNA for the gene of interest (i.e. 
RYR1 in this case). Thus, the shRNA acts to inhibit any leakage in the expression of 
the gene of interest resulting in undetectable expression of that gene (Deans et al., 
2007).  
 
The expression of the gene of interest is induced by the addition of Isopropyl β-d-1-
thiogalactopyranoside (IPTG) which is a non-hydrolysable analogue of allolactose (a 
metabolite of lactose), it binds to and causes a conformational change in the LacI 
proteins. In doing so IPTG prevents the Lacl repressor proteins from binding to the 
lacO sites thus allowing the expression of the gene of interest. There is a 
simultaneous loss of TetR repression. TetR can then inhibit the production of the 
shRNA by binding to the tet operator site in the U6 promoter of the RNAi module, and 
this consequently stops the shRNA repression of the gene of interest. The activity of 
this system is dependent on the concentration of IPTG used as shown by Dean et al. 
(2007) and therefore provides greater control in the expression of the gene of interest.  
 50 
 
Figure 3.1: The pTUNE system for the inducible expression of RYR1. 
This system utilises a lac operon repressor combined with a shRNA repressor for the tight 
regulation of a gene of interest (RYR1). (A) In the ‘OFF’ mode which occurs in the absence of 
Isopropyl β-d-1-thiogalactopyranoside (IPTG), the Lacl repressor proteins (yellow) are 
constitutively expressed and these bind to Lac operator (lacO) sites on two modules; a 
transgene module (purple) and a tetracycline repressor (tetR) module (blue). Binding to these 
prevents the target gene expression and causes transcriptional repression of TetR. TetR 
repression allows the shRNA to be transcribed which then targets a synthetic target sequence 
next to RYR1, this stops any leaked expression of RYR1. (B) In the ‘ON’ induced state, IPTG 
binds to the Lacl proteins, and prevents them from binding to lacO sites thus permitting the 
transcription of RYR1 and tetR. TetR binds to a tet operator site on the promoter for the RNAi 
module, and this prevent the transcription of shRNA. Adapted from Deans et al., (2007). 
 
3.1.5 AICAR 
AICAR is an activator of the adenosine monophosphate (AMP)-activated protein 
kinase (AMPK). This kinase is activated by increases in the AMP to ATP ratio, and 
thus functions as a sensor of cellular energy (Lanner et al., 2012). Cells convert 
AICAR to 5-aminoimidazole-4-carboxamide ribonucleoside (ZMP) which is then able 
to mimic AMP and thus activate AMPK. Lanner et al. (2012) found that acute 
treatment with AICAR prevents heat-induced sudden death in the p.Y524S RYR1 
knock-in mice (Chelu et al., 2006, Durham  et al., 2008, Boncompagni et al., 2009). 
p.Y524S is equivalent to human p.Y522S which is associated with MH and central 
core disease (Quane et al., 1994). The mechanism underlying the effects of AICAR 
in p.Y524S was found to be through a reduction in Ca2+ leak, together with a reduced 
production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
(Lanner et al., 2012). Both ROS and RNS have been shown to potentiate the 
enhanced sarcoplasmic resting Ca2+ in p.Y524S (Durham  et al., 2008), as well as 
lead to a greater RYR1-mediated Ca2+  leak during the ageing of skeletal muscle 
(Andersson et al., 2011). 
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3.2 Aims 
1. To investigate the kinetics of the perfusion system used in live-cell calcium 
imaging experiments. 
2. To examine the caffeine sensitivity of the RYR1 variants p.D1056H, 
p.D3986E and p.R2355W: 
a. The primary outcome is the AUC of the responses. 
b. The secondary outcome is the peak responses.  
3. To examine the effects of acute and chronic AICAR treatment on the 
caffeine sensitivity of p.D1056H variants, and acute treatment on p.R2355W 
and p.D3986E variants using the AUC and peak responses. 
 
3.3 Methods 
3.3.1. Characterising the Kinetics of the Perfusion System  
3.3.1.1 Flow Rate and Residual Well Fluid Volume 
The flow rates within the perfusion system were tested by perfusing IB for 30 s at 
2-4 psi and measuring the volume of IB that had been used. A total of 3 repeats were 
performed. To determine the residual well volume, the perfusion system was set-up 
as it is for a live cell experiment with the suction on. IB was perfused into an empty 
well for 30 seconds, and the final volume of IB in the well measured using a P200 
pipette (Gilson, USA). This was repeated 10 times. 
 
3.3.1.2 The Measurement of Caffeine and its Perfusion  
Caffeine (0.1 mM, 0.5 mM and 20 mM; solution set A) made in IB, was perfused at 
2 psi for 2 s into a well on a 96-well plate, and the plate covered with Parafilm (Sigma, 
USA) to prevent any dehydration prior to analysis. The samples (solution set B) were 
then analysed as per EMHG protocol for caffeine concentration measurement. For 
this, 50 ml of a 1 % (w/v) caffeine standard in 0.1 M HCl was made, and diluted down 
to produce 1 in 500 and 1 in 1000 dilutions of the caffeine standard solution. The 
samples obtained from the perfusion of 0.1, 0.5 and 20mM caffeine (solution set B) 
were diluted with 0.1M HCl by 0, 5 and 250-fold respectively (diluted solution set B). 
This was also done for the 0.1, 0.5 and 20mM stock caffeine solutions used in the 
perfusion system (diluted solution set A). These dilutions were performed as the 
ultraviolet (UV) absorbance of caffeine is not a linear function of concentration.  
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The UV absorbance measurements of the solutions were made using a Nanodrop 
1000 spectrophotometer (ThermoFisher, USA) at the peak caffeine absorption 
wavelength of 272 nm (Mejri et al., 2009). The readings were initially zeroed using 
0.1mM HCl, then 3 readings were made for each of the diluted caffeine concentrations 
(diluted solution set A and B), as well as the 1 in 500 and the 1 in 1000 caffeine 
standards. The Beer-Lambert law was then used to calculate the molar extinction 
coefficient (H) of 1% caffeine using the 1 in 500 and 1 in 1000 caffeine solutions. 
 
(𝟏) 𝑨 = 𝝃𝑪𝒍  this can be re-arranged to (2) 𝝃 = 𝑨/𝑪𝒍 and (3) C= 𝑨/𝝃𝒍 
 
Where A= absorbance i.e optical density at 272 nm x dilution factor, C = concentration 
of sample, l = length of light path (0.1 cm). The two values H were averaged and used 
to calculate the concentrations in g/L of caffeine in the diluted solution sets A and B 
using the formula 3, above. To convert from g/L to mM, the former was multiplied by 
5.15 (as 1 gram/194.2 the molecular weight of caffeine = 5.15 mM). This was 
repeated 5 times for each concentration. Comparisons were then made between the 
measured caffeine concentrations applied in the perfusion system, and that obtained 
in the well after the 2 s of 2 psi perfusion. 
 
3.3.1.3 Curcumin Perfusion  
Curcumin is a bright yellow compound found in turmeric, as well as in yellow food 
colouring. It fluoresces under the excitation and emission wavelengths of a standard 
green fluorescent protein (GFP) filter-set. ‘Tesco Yellow Food Colouring’ (Tesco, UK) 
was added to water at a concentration of 1:200 (v/v). The protocol for this experiment 
involved no perfusion initially (to determine the background fluorescence), then 10 s 
of perfusion with water, followed by a 16 s perfusion with the IB containing curcumin 
and finally by 22 s of water. For this experiment, the microscope images were 
captured using IPLab software with an 8 x 8 bin at a rate of 33 frames per s. 
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3.3.2. pTUNE RYR1 Constructs 
3.3.2.1 Generation and Sequencing of pTUNE RYR1 Plasmids 
All cloning used to generate the pTUNE plasmids containing the p.D1056H, 
p.D3986E, p.R2355W and WT RYR1 used in this chapter, were generated and 
sequenced by Dr Alan Merritt; the generation of these are extensively described in 
Merritt (2013). 
 
3.3.2.2 Plasmid Isolation 
Plasmids containing the pTUNE-RYR1 variants of interest and WT were isolated as 
described in section 2.4.2. However, plasmids were isolated using the QIAGEN-Tip 
500 plasmid maxi kit instead of the QIAGEN HiSpeed plasmid maxi kit. The plasmids 
were eluted in 10 mM Tris-ethylenediaminetetraacetate (TE) buffer at pH 8.01 
(QIAGEN, USA), and subsequently quantified using a NanoDrop 1000 
spectrophotometer (ThermoFisher, USA). 
 
 
3.3.3 Transient Transfections of HEK cells 
3.3.3.1 Maintenance, Passage and Cryopreservation of HEK Cells  
HEK fast growing with SV40 large T-antigen (HEK-FT) cells were maintained in 
DMEM with GlutaMAX containing 4.5g/L glucose, 10 % FBS and 100 Units/ml 
pen/strep (all from Gibco, USA). Passaging, cell counting and cryopreservation was 
performed as described in section 2.2. 
 
3.3.3.2 Transient Transfections and Induction of pTUNERYR1  
HEK-FT were plated at 2 x 104 cells per well in a 96-well imaging plate (Greiner, 
Germany) coated with ECL (Millipore, USA) at a final concentration of 2 μg/cm2. Cells 
were allowed to adhere overnight, on the following day they were transfected with a 
mixture of 200 ng of the desired plasmid construct that had been incubated with 0.4 µl 
of P3000 reagent and 0.3 μl of lipofectamine 3000 (LF3000, ThermoFisher, USA). 
Both DNA:P3000 and LF3000 were first diluted with 5 μl of Opti-MEM,  then 
combined, mixed gently and allowed to incubate at room temperature for 15 min.  The 
DNA:lipid complexes were then added to each well  in small aliquots, and mixed 
gently. The 96-well plate was returned to the incubator for 6 hours at 37 ºC, in a 95% 
air/5% CO2 environment. 
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3.3.3.3 Inducing the Expression of pTUNERYR1  
After 6 hours of transfection, the media was exchanged with fresh growth media 
containing 25 µM IPTG (ThermoFisher, USA), and this was then refreshed every 24 
hours until caffeine-induced calcium release experiments were performed. 
 
3.3.3.4 Treatment with AICAR  
Chronic treatment was performed by an overnight exposure to 1 mM AICAR (Cell 
Signalling Technology, USA), this was added to the growth media prior to imaging 
experiments. Control cells had the same volume of the water vehicle added to the 
growth media. In the acute AICAR treatment paradigm, 1 mM AICAR was added to 
the imaging buffer during the 30 min de-esterification phase after Fluo4-AM had been 
loaded into the cells. 
 
 
3.3.4 Caffeine-Induced Calcium Release Experiments 
3.3.4.1 Experimental Solutions  
Solutions and drugs were made as described in section 2.6.2, except the IB buffer 
consisted of 125mM NaCl, 5mM KCl, 2mM CaCl2, 1.2mM MgSO4, 6mM glucose, 
25mM HEPES, adjusted to pH 7.40 at 25 °C with 1 M HCl. IB was perfused at 1 psi 
for 10 s then caffeine for 5 s followed by IB for 10 s. Cells were allowed to rest for 1 
minute during which time they were kept in the dark and had intermittent perfusion of 
IB. The pressure was reduced from 2 psi because initial experiments revealed that 
higher pressures led to sheets of HEK cells peeling off. All experiments were 
undertaken at room temperature. 
 
3.3.4.2 Calcium Imaging  
Imaging was performed 72 hours after transfection as described in section 2.6.3, 
except HEK cells were washed with IB 3 times, loaded with 20 µM Fluo4-AM for 20 
min, following which the cells were washed 3 times, and allowed to rest for 30 min at 
room temperature. Cells were then visualised with a 20 x 0.75 NA dry lens (Plan Apo, 
Nikon, Japan).  Images were captured using 2x2 binning at a rate of 5 fps. Image 
analysis was performed ImageJ software (NHLBI, USA). Regions of interest were 
drawn around individual HEK cells, a Red HOT look up table add-on (FIJI, NIH, USA) 
was used to identify the intensity of the Ca2+ response. 25 stable HEK cells with the 
brightest intensity in their responses to caffeine were used from each transfection, 
where this was not possible the maximum number of cells available were used (this 
was between 10-24 cells per transfection). The response to increasing concentrations 
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of caffeine were analysed as described previously in section 2.6.3.2. The EC50 was 
determined from the log concentration response curve constructed for each 
transfection (i.e. well) per variant. The mean EC50 for each well was then averaged to 
calculate the overall caffeine EC50 for each plasmid. The data for each variant was 
collected over 4-7 separate days. 
 
3.3.4.3 Statistics 
Blinding of the investigators was not undertaken due to practical reasons in 
performing the experiments.  The number of planned repeats was determined by the 
results previously reported with these constructs by Merritt (2013), with HEK cells 
(Tong et al., 1997) and with AICAR Lanner et al., (2012). Parametric data are 
presented as mean ± SEM, non-parametric data as box plots displaying the median 
with the interquartile range (IQR), and the whiskers representing the range. Where 
the mean difference has been reported, this is presented with the 95% confidence 
interval. Two-tailed unpaired t-tests were used to compare the EC50 between variants 
and WT, and Kruskal-Wallis with Dunn’s multiple comparisons test for the responses 
to 1 mM caffeine, as these were not normally distributed.  
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3.4 Results 
3.4.1 Kinetics of the Perfusion System 
As this was a new perfusion system, the kinetics of the system were assessed in 
the system described section 2.6.1.  
 
3.4.1.1 Flow Rate and Residual Well Fluid Volume 
The rate of perfusion of the buffer was examined at different pressures (Figure 3.2). 
The mean flow ± SEM increased from 13.3 ± 0.67 ml/min at 2 psi, to 16.3 ± 0.33 
ml/min at 3 psi, and 20 ± 0 ml/min at 4 psi; a 1.23-fold difference in the flow for each 
psi. Increasing the pressure enhanced the flow (P<0.0001, one-way ANOVA, n=3 
wells per group). The residual volume of fluid in the well was assessed after perfusing 
each well for 10 s at 2 psi. The mean ± SEM volume of the residual buffer in the well 
was 68 ± 2.8 µl (n=10 wells). After a 5 s period of perfusion at 2 psi together with a 
residual buffer volume of 68 µl per well, there would be a calculated 16 volume 
changes in the well. The number of volume changes would increase with longer 
periods of perfusion.  
 
 
Figure 3.2: Flow rates within the perfusion system at different pressures.  
The bars represent the mean ± SEM for the flow (ml/min) within the perfusion system. Note 
the linear relation between the pressure applied and flow achieved. Increasing the pressure 
significantly increased the flow. **P<0.001, ****P<0.0001, one-way ANOVA with Tukey's 
multiple comparisons test, n=3 wells per group. 
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3.4.1.2 Caffeine Perfusion 
Next, in order to examine the concentration of caffeine present in the wells in the 
setting of a minimal perfusion time, the concentration of caffeine was measured after 
a 2 s perfusion at 2 psi.  Under these perfusion conditions there would be sufficient 
flow to allow 6.5 working volume changes. The caffeine concentration in the wells 
was calculated by examining the absorbance at 272 nm as described in 3.3.1.2. This 
was then compared to the measured concentration of caffeine present in the stock 
solutions prior to perfusion (Figure 3.3). The mean (± SEM) % of the measured 
caffeine concentrations after the perfusion relative to the stock concentrations of 
caffeine applied were 95.0 ± 6.1% (0.1 mM caffeine), 92.2 ± 5.3%, (0.5 mM caffeine), 
and 93.2 ± 1.8% (20 mM caffeine), n=5 wells per group. Under these conditions the 
perfusion system was able to achieve >92% of the applied concentration of caffeine 
at all concentrations tested (P=0.088, one-way ANOVA with Tukey's multiple 
comparisons test, n=5 wells per group). 
 
 
 
Figure 3.3: Perfusion system kinetics assessed using caffeine. The measured caffeine 
concentrations in the well after a 2 s perfusion at 2 psi following the application of various 
different caffeine concentrations. The concentrations were normalised to concentration of the 
stock solution applied. The bars represent the mean % of the stock concentration ± SEM. A 
2 s perfusion was sufficient to achieve concentrations that were within 8% of that applied at 
both low and high concentrations of caffeine. There was no significant difference between the 
three groups, P=0.088, one-way ANOVA with Tukey's multiple comparisons test, n=5 wells 
per group. 
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3.4.1.3 Curcumin Perfusion 
To test whether the caffeine data were consistent with other assays, yellow food 
colouring containing curcumin was used in the perfusion system due to its 
fluorescence characteristics described in 3.3.1.3. Figure 3.4 shows the effects of 
applying the dye in 6 different wells. There was a change in fluorescence within the 
first 0.7 s, this suggests a 0.7 s lag in the perfusion system at a pressure of 2 psi. The 
major increase in the fluorescence occurred rapidly within the first 2 s where it had 
reached 84% of the maximum, this then slowed down with 92% and 97% of the 
maximum fluorescence reached by 5 s and 10 s, respectively. The wash out of the 
dye also started to occur within 0.7 s of changing to water, with this returning to within 
10% of baseline after a 10 s perfusion.  
 
 
 
 
Figure 3.4: Perfusion kinetics assessed using curcumin.  
Recording from 6 wells showing the kinetics of the perfusion system using a curcumin. The 
experiment was performed at 2psi, for the first 2 s there was no perfusion, then water was 
perfused from 2-12 s, followed by the dye at 12-28 s, and then water at 28-50 s. The data was 
captured at 33 fps.  
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3.4.2 Caffeine Responses of RYR1 Variants in HEK cells. 
HEK cells were transfected with full-length WT RYR1 and the three RYR1 variants 
which are either diagnostic for, or potentially associated with MH. The pTUNE 
expression system was induced using 25 µM IPTG, as this has previously been 
shown to be the optimum concentration for the variants being studied (Merritt, 2013). 
In the four transfected cell lines treated with IPTG, a caffeine-induced calcium release 
was observed using the Ca2+ sensitive dye Fluo4 (Figure 3.5 and 3.6). The responses 
exhibited a caffeine concentration dependence. The primary and secondary 
outcomes will be discussed separately below. 
 
3.4.2.1 AUC 
The mean ± SEM EC50 of HEK cells transfected with WT RYR1 was 5.1 ± 0.5 mM 
caffeine (Figure 3.5 A-C, n=10 transfections). The results for each of the variants 
showed a left-ward shift in the concentration-response curves. The caffeine EC50 was 
significantly lower in two of the three variants investigated relative to WT; it was 39 % 
less at 3.1 ± 0.5 mM in p.D1056H (P=0.017, n=8, Figure 3.5A), and 59 % lower in 
p.D3986E at 2.2 ± 0.6 mM (P=0.010, n=4, Figure 3.5B). The EC50 of 3.1 ± 0.7 mM in 
p.R2355W was not significantly lower than WT (P=0.060, n=4, Figure 3.5C). 
 
The response to 1 mM caffeine was assessed for each of the variants relative to WT. 
This caffeine concentration was used as it was found to be the threshold 
concentration at which a response greater than 10 % was observed in the RYR1 
variants studied (Figure 3.5D). As the responses were not normally distributed 
between all the variants, non-parametric statistics were used. The presence of an 
RYR1 variant had a significant effect on the response to 1 mM caffeine (P=0.011, 
Kruskal-Wallis test, n=4-10). Dunn’s multiple comparisons test revealed the median 
(and IQR) response to 1 mM caffeine was significantly greater in p.D1056H at 17.3 % 
of the normalised fluorescence  (IQR 11.2 - 24.1 %, P=0.036, n=8), and 37.9 % 
(16.9 - 56.0%, P=0.0095, n=4) in p.D3986E, relative to 4.3 % (1.1 - 8.8%) in WT 
(n=10, Kruskal-Wallis with Dunn’s multiple comparisons test).  In contrast, the median 
response in p.R2355W to 1 mM caffeine of 11.0 % (3.0 - 23.0 %) was not greater 
than  that seen in WT (P=0.851, n=4, Kruskal-Wallis with Dunn’s multiple 
comparisons test). Similar results were also observed with 2mM caffeine (data not 
shown). 
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Figure 3.5: Caffeine concentration response curves using AUC in p.D1056H, p.R2355W, 
p.D3986E and WT. The mean EC50 for caffeine in WT RYR1 relative to p.D1056H (A) , 
p.D3986E (B), and p.R2355W (C). Data points are the mean ± SEM of the normalised 
response measured using the AUC. (D) The response to 1 mM caffeine in the three variants 
and WT RYR1 displayed as a box-plot showing the median and range. *P<0.05, unpaired two-
tailed t-test or Kruskal-Wallis with Dunn’s multiple comparisons test, n= 4-10 transfections, 
each with 10-25 HEK cells, with the transfections performed over 4-7 separate days. 
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3.4.2.2 Peak 
The mean ± SEM EC50 for HEK cells transfected with WT RYR1 was 4.4 ± 0.5 mM 
caffeine (Figure 3.6 A-C, n=10 separate transfections). Each RYR1 variant exhibited 
a left-ward shift in the concentration-response curves for caffeine, but the EC50 was 
only significantly lower in p.D1056H and p.D3986E relative to WT. The EC50 was 
2.2 ± 0.3 mM in p.D1056H (P=0.003, n=8, Figure 3.6A), 1.9 ± 0.6 mM in p.D3986E 
(P=0.017, Figure 3.6B), and  2.5 ± 0.6 mM in p.R2355W (P=0.051, n=4, Figure 3.6C). 
The EC50 for caffeine in p.D1056H and p.D3986E was 50 % and 67 % less than that 
in WT. 
 
The response to 1 mM caffeine was also compared between each of the variants and 
WT RYR1 (Figure 3.6D). The presence of an RYR1 variant had an effect on the 
response (P=0.020, Kruskal-Wallis test, n=4-10). Dunn’s multiple comparisons test 
revealed the median response to 1 mM caffeine was significantly greater in p.D3986E 
at 44.6 % of the normalised peak response (IQR is 21.3 - 67.1 %, P=0.012, n=4), and 
p.D1056H at 25.7 % (18.1-38.9 %, P=0.015, n=8), relative to 7.7 % (2.2 - 15.8 %) in 
WT (n=10).  The response in p.R2355W of 18.2 % (5.9 - 28.6 %) was not significantly 
different from WT (P>0.999, n=4, Kruskal-Wallis with Dunn’s multiple comparisons 
test).  
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Figure 3.6: Caffeine concentration peak response curves in p.D1056H, p.R2355W, 
p.D3986E and WT. The mean EC50 for caffeine in WT RYR1 relative to: (A) p.D1056H (B) 
p.D3986E and (C) p.R2355W. Data points are the mean ± SEM of the peak normalised 
response. (D) The response to 1 mM caffeine in the three variants and WT RYR1 displayed 
as a box-plot showing the median, quartiles and range. *P<0.05, **P<0.01, unpaired two-tailed 
t-test or Kruskal-Wallis with Dunn’s multiple comparisons test, n=4-10 transfections each with 
10-25 HEK cells, with the transfections performed over 4-7 separate days. 
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3.4.3 Acute AICAR Treatment 
This set of experiments was performed to examine the effects of AICAR on the 
caffeine sensitivity observed with WT and the three different variants. 1 mM AICAR 
has previously been shown to restore the caffeine sensitivity in a mouse model of MH 
(Lanner et al., 2012). Furthermore, previous work in the MH unit in Leeds has also 
revealed that an overnight treatment with 1 mM AICAR significantly reduced the 
caffeine sensitivity of p.D1056H, p.R2355W and p.D3986E RYR1 variants (Merritt, 
2013). This set of experiments aimed to test whether similar effects were also seen 
with an acute 1 mM AICAR treatment.  
 
3.4.3.1 AUC Response 
Acute 30 min treatment with 1 mM AICAR did not have an effect on the caffeine-
induced calcium release in WT, or the three RYR1 variants (Figure 3.7A-D).   
The mean caffeine EC50 in WT was 5.1 ± 0.5 mM in untreated and 4.5 ± 0.8 mM in 
AICAR treated cells, with a mean difference of -0.6 (-2.6 to 1.4) mM (Figure 3.7A, 
P=0.540, n=10 and 6). In p.D1056H the EC50 was  3.1 ± 0.5 mM and then 
2.4 ± 0.5 mM following 1 mM AICAR treatment, the mean difference 
was -0.8 (-2.2 to 0.7) mM (Figure 3.7B, P=0.282, n=8 and 7). The EC50 in p.D3986E 
was 2.2 ± 0.6 mM in untreated HEK cells and 4.7 ± 1.0 mM after AICAR treatment, 
with a mean difference of 2.5 (-0.4 to 5.3) mM (Figure 3.7C, P=0.078, n=4). In 
p.R2355W the EC50 was 3.1 ± 0.7 mM in untreated and 3.7 ± 0.6 mM in treated cells, 
the mean difference was 0.7 (-1.7 to 3.0) mM (Figure 3.7D, P=0.521, n=4).  
 
3.4.3.2 Peak Response 
The results of the normalised peak responses to AICAR mirrored those seen with 
AUC. An acute 30 min application of 1 mM AICAR did not have an effect on the 
caffeine-induced calcium release in all samples (Figure 3.8A-D).   
The mean EC50 in WT cells was 4.4 ± 0.5 mM prior to AICAR and 3.9 ± 0.8 after 
treatment, the mean difference was -0.5 (-2.4 to 1.5) mM (Figure 3.8A, P=0.617, 
n=10 and 6). In p.D1056H it was 2.2 ± 0.3 mM and 1.6 ± 0.4 mM following AICAR 
treatment, with a mean difference of -0.5 (-1.7 to 0.6) mM (Figure 3.8B, P=0.2334, 
n=8 and 7). The EC50 in p.D3986E 1.9 ± 0.6 mM in untreated HEK cells to 
4.2 ± 0.8 mM after a 30 min acute AICAR treatment, the mean difference was 
2.3 (-0.2 to 4.8) mM (Figure 3.8C, P=0.068, n=4). Finally in p.R2355W the EC50 was 
2.5 ± 0.6 mM in untreated and 2.3 ± 0.3 mM in treated cells, with a mean difference 
of -0.2 (-1.7 to 1.3) mM (Figure 3.8D, P=0.789, n=4). 
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Figure 3.7: The effects of acute AICAR treatment on the RYR1 AUC responses. 
AICAR had no significant effect on the EC50 of caffeine in (A) WT, (B) p.D1056H, 
(C) p.D3986E, or (D) p.R2355W. Data points are the mean ± SEM of the normalised AUC 
response. P>0.05, two-tailed t-test. n= 4-10 transfections, each with 10-25 HEK cells, with the 
transfections performed over 4-7 separate days. 
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Figure 3.8: The effects of acute AICAR treatment on the RYR1 peak responses.  
AICAR had no significant effect on the EC50 of caffeine in (A) WT, (B) p.D1056H, 
(C) p.D3986E, or (D) p.R2355W. Data points are the mean ± SEM of the normalised peak 
response. P>0.05, two-tailed t-test. n=4-10 transfections, each with 10-25 HEK cells, with the 
transfections performed over 4-7 separate days. 
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3.4.4 Chronic AICAR 
The results of section 3.4.3 revealed that an acute 30 min 1 mM AICAR treatment did 
not significantly affect the caffeine sensitivity of WT or any of the RYR1 variants 
investigated. However, previous experiments using the same RYR1 constructs in our 
laboratory have shown that an overnight treatment with 1 mM AICAR caused a 
significant increase in the caffeine EC50 (Merritt, 2013). Consequently, experiments 
were performed to examine the effects of an overnight (12 hr) treatment with 1 mM 
AICAR on the caffeine-induced calcium release in HEK cells transfected with 
p.D1056H or WT RYR1.  
 
3.4.4.1 AUC Response 
A chronic overnight treatment with 1 mM AICAR did not have a significant effect on 
the EC50 of caffeine in HEK cells transfected with p.D1056H or WT RYR1. The EC50 
in p.D1056H was 3.9 ± 0.9 mM in untreated and 4.9 ± 0.6 mM in AICAR treated cells, 
with a mean difference of 1.0 (-1.6 to 3.6) mM (Figure 3.9A, P=0.414, n=6 and 5). In 
WT the EC50 was 7.5 ± 0.6 mM in untreated cells and 7.5 ± 0.7 mM in treated cells, 
the mean difference was 0.0 (-1.9 to 2.1) mM (Figure 3.9B, P=0.482, n=6 and 5).  
 
3.4.4.2 Peak Response 
Chronic overnight treatment with 1 mM AICAR did not have a significant effect on the 
EC50 of caffeine in HEK cells transfected with either p.D1056H or WT RYR1. The 
EC50 in p.D1056H was 2.8 ± 0.8 mM in untreated cells, and 4.0 ± 0.5 mM after AICAR 
treatment, the mean difference was 1.2 (-1.2 to 3.6) mM (Figure 3.10A, P=0.280, n=6 
and 5). In WT the EC50 was 6.8 ± 0.2 mM in untreated cells, and 7.4 ± 0.9 mM in 
treated cells, with a mean difference of 0.6 (-1.2 to 2.4) mM (Figure 3.10B, P=0.488, 
n=6 and 5). 
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Figure 3.9: The effects of chronic AICAR treatment on the RYR1 AUC and peak 
responses in p.D1056H and WT. Chronic overnight treatment with AICAR had no significant 
effect on the EC50 of caffeine as determined using the AUC in (A) p.D1056H or (B) WT.  
Similarly, chronic AICAR treatment did not have a significant effect on the EC50 of caffeine as 
determined using the peak height of the response in (C) p.D1056H or in (D) WT. Data points 
are the mean ± SEM of the AUC (A and B) or peak (C and D) response to caffeine normalised 
to 20 mM caffeine. P>0.05, two-tailed unpaired t-test, n= 5-6 transfections, each with 10-25 
HEK cells, with the transfections performed over 5-6 days. 
 
 
0.5 1 2 4 6 10 20
0
25
50
75
100
[Caffeine]  (mM)
N
o
rm
a
li
s
e
d
 F
lu
o
re
s
c
e
n
c
e
 
(A
U
C
 %
 o
f 
2
0
 m
M
 C
a
ff
e
in
e
) 
AICAR
No AICAR
EC50 (mM)
4.9
3.9
n
5
6
D1056H
0.5 1 2 4 6 10 20
0
25
50
75
100
[Caffeine]  (mM)
N
o
rm
a
li
s
e
d
 F
lu
o
re
s
c
e
n
c
e
 
(A
U
C
 %
 o
f 
2
0
 m
M
 C
a
ff
e
in
e
) 
EC50 (mM)
7.5
7.5
n
5
5
WT
AICAR
No AICAR
0.5 1 2 4 6 10 20
0
25
50
75
100
[Caffeine]  (mM)
N
o
rm
a
li
s
e
d
 F
lu
o
re
s
c
e
n
c
e
 
(P
e
a
k
 %
 o
f 
2
0
 m
M
 C
a
ff
e
in
e
) 
AICAR
No AICAR
EC50 (mM)
4.0
2.8
n
5
6
D1056H
0.5 1 2 4 6 10 20
0
25
50
75
100
[Caffeine]  (mM)
N
o
rm
a
li
s
e
d
 F
lu
o
re
s
c
e
n
c
e
 
(P
e
a
k
 %
 o
f 
2
0
 m
M
 C
a
ff
e
in
e
) 
EC50 (mM)
7.4
6.8
n
5
5
WT
No AICAR
AICAR
A B 
C D 
 68 
3.5 Discussion  
3.5.1 Perfusion System 
The kinetics of the perfusion system was found be sufficiently rapid for a 2 s at 2 psi 
perfusion of caffeine to generate mean caffeine concentrations that were between 
92 - 95 % of that expected. As the speed of perfusion was 13.3 ml/min at 2 psi, then 
over a 2 s perfusion there would 443 µL of perfusate that would be delivered which is 
approximately 6.5 volume changes in a well that has a residual fluid volume of 68 µL 
(i.e . 443 µL/68 µL). Under these conditions and if the perfusion system followed a 
simple exponential drug wash-in curve, then the expected amount of caffeine after 6 
half-lives would be 98.4 % of that applied. The results for the lower concentrations of 
caffeine applied are consistent with this at 95.0 ± 6.1 % (0.1 mM caffeine) and 
92.2 ± 5.3 % (0.5 mM caffeine). However, for 20 mM caffeine the mean of 93.2 % of 
the expected concentration together with a smaller rate of error (SEM = 1.8 %) meant 
that this was lower than 98.4 %. An explanation for this could be that the system is 
not following a simple drug wash-in kinetics at higher concentrations of the drug which 
thus take longer to reach the concentration applied. Other reasons include the that 
perfusion channel was slightly restricted by a small blockage or kink in its path that 
was not obviously visible, or that this was the result of experimental variability. 
Additional repeats would help clarify this.  
 
The initial experiments with the perfusion system were aimed at studying myotubes 
derived from humans and mice, and these could easily tolerate a perfusion of 2-3 psi. 
However, preliminary live-cell imaging studies with HEK cells revealed that at 2 psi 
the HEK cells peeled off the plate. The perfusion pressure was therefore reduced to 
1 psi and the cells remained adherent to the plate. As each additional psi caused a 
1.23-fold difference in the flow, then the expected flow at 1 psi would be 10.8 ml/min, 
although this was not tested. It is highly likely that there was sufficient total perfusion 
of caffeine to enable the attainment of the desired peak concentration in the HEK cell 
experiments because the cells were perfused for a 2.5-fold longer duration than in 
the preliminary experiments (5 s versus 2 s), and this would compensate for the 
aforementioned 1.23 fold reduction in flow. Nevertheless, it would have been useful 
to actually measure all these parameters fully at the time of the HEK experiments.  
 
The experiments with curcumin revealed that the perfusion of this indicator at 2 psi 
for 2 s caused the fluorescence of the dye (and thus the concentration of the dye) to 
reach 84 % of the maximum, this increased to 92 % and 97 % of the maximum at 5 
and 10 s respectively. These results were lower than what was seen with caffeine. If 
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the curcumin data is more accurate than the caffeine data, this would suggest that 
the time allowed for perfusion at 2 psi or lower was insufficient to allow the drug to 
reach its maximal concentration in the HEK experiments. An additional important 
factor, is the distance from the cell(s) undergoing imaging to the inlet perfusing the 
drug . Cells that are closest to the inlet receive the highest concentrations of drug 
before the rest of the well does, indeed imaging was always performed on cells that 
were closest to the perfusion inlet. Furthermore, the experimental traces of the HEK 
cells show that they had achieved a peak whilst they were still being perfused with 
caffeine, this suggests that the caffeine in the well had sufficient time to reach the 
maximum concentration applied. 
 
3.5.2 Caffeine Responses of RYR1 Variants in HEK Cells 
3.5.2.1 WT RYR1 
The results from the caffeine induced calcium release revealed an EC50 for WT of 
5.1 ± 0.5 mM and 4.4 ± 0.5 mM, respectively. The peak values are consistent to 
those described by Merritt (2013) and Meritt et al., (2017) where it was found to be 
3.8 ± 0.6 mM. As these studies by Merritt did not calculate the EC50 using the AUC, it 
prevented direct comparisons of these data. Other groups have reported a lower peak 
EC50 of 1.4 mM in WT (Tong et al., 1997, Murayama et al., 2016), this lower EC50 
could arise from a normalisation to 10 mM caffeine, as  this would result in a leftward 
shift in the concentration response curves. Other authors have described a lower EC50 
using an AUC analysis (Yang et al., 2003), but this was in myotubes (where the full 
ECC machinery is present). Furthermore, they had also fewer points between 2 and 
20 mM caffeine (3 versus 5 points in ours), and this could also cause a leftward shift 
in the calculated EC50.  
 
3.5.2.2 p.D1056H 
The caffeine induced calcium release data revealed that this variant had a lower EC50 
relative to WT both in the results determined using AUC and peak responses. This 
enhanced sensitivity is consistent with the previous evidence that suggests the 
variant is associated with MH (Merritt, 2013), where the EC50 was 1.8 ± 0.4 mM, this 
value is consistent with my findings of 2.2 ± 0.3 mM. Several lines of evidence 
suggest that p.D1056H meets the EMHG criteria for it to be included as a diagnostic 
variant for MH (Hopkins et al., 2015). These include (a) the functional studies 
presented here as well as by Merritt (2013) that show the variant confers an increase 
sensitivity to caffeine, (b) the variant segregates with MHS on the IVCT in two 
independent families, (c) it is classified as a likely pathogenic variant (Miller et al., 
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2018), and (d) it is located within a domain which is important in channel gating. An 
extension of my functional studies would involve investigating the responses of the 
p.D1056H HEK cells to other RYR1 agonists such as halothane and/or 4-CmC. 
Another option would be to examine the caffeine and halothane responses in 
myotubes from MHS individuals carrying this variant. A more expensive and 
time-consuming approach would be to utilise a modified CRISPR technique called 
prime editing to alter the variant into an MHN human myoblast cell line, followed by 
assessing their response to the aforementioned RYR1 agonists (Anzalone et al., 
2019).  
 
3.5.2.3 p.D3986E 
This variant has previously been shown to not have an effect on the response to 
caffeine (Merritt, 2013, Merritt et al., 2017). However, the results of this study has  
revealed that p.D3986E had the lowest EC50 of all the three variants assessed using 
both AUC (2.2 ± 0.6 mM) and the peak height (1.9 ± 0.6 mM) of the responses. 
Indeed, such an enhanced sensitivity to caffeine would be consistent with the  
‘stronger’ IVCT phenotype reported by Carpenter et al., (2009). A reason for the 
differences between this study and that of Merritt (2013), could be that the transfection 
efficiencies and thus RYR1 expression achieved in my study was greater than that 
obtained by Merritt. In this study LF3000 transfection reagent was used which has 
been reported to be less toxic to cells with a higher transfection efficiency relative to 
LF2000 (ThermoFisher, USA). This would be consistent with Merritt (2013) also 
reporting a lower caffeine EC50 when the expression of p.D3986E was increased.  
The enhanced caffeine sensitivity in p.D3986E is consistent with the predicted 
pathogenicity of the variant and the absence of genotype-phenotype discordance in 
the 6 families that have this variant (Merritt  et al., 2017; Miller et al., 2018). 
Furthermore, Perez et al., (2005) have previously shown that the region containing 
residue 3986 was important in maintaining the resting [Ca2+]i. Such a finding is 
consistent with the elevated resting [Ca2+]i detected both in cells from patients with 
MHS and in animal models of MH (Lopez et al., 1985 and 1987; Eltit.,et al., 2013). 
Further studies looking at protein expression and the response to other RYR1 
agonists would help support the recommendation for p.D3986E to be added to the 
EMHG list of diagnostic mutations.  
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3.5.2.4 p.R2355W 
This study has found that the p.R2355W variant did not to cause a significant change 
in the EC50 relative to WT.  This was an unexpected finding given that the variant has 
been recently added to the EMHG list of diagnostic mutations after several lines of 
evidence have functionally supported its pathogenic effects. These include the 
significantly lower caffeine EC50 of 1.4 (95% CI 0.02 - 2.3) mM relative to WT 
3.8 (95% CI 2.5 -5.4) mM found by Merritt et al., (2017), as well as the data from other 
studies using caffeine, halothane, and/or 4-CmC in either human skeletal myotubes 
or HEK cells (Wehner et al., 2004; Schiemann et al., 2014). The most likely reason 
for the discrepancy in the results from this chapter compared to other studies, is that 
this experiment was underpowered and would benefit from further repeats. Assessing 
for the expression of RYR1 would also help elucidate whether part of the variability 
was due to alterations in the protein expression levels amongst different transient 
transfections. 
 
3.5.3 The Effect of AICAR on RYR1 Channels 
Lanner et al., (2012) discovered that a 10-20 min application of 1 mM AICAR was 
able to prevent heat-induced sudden death in the p.Y524S RYR1 KI mice. This was 
shown to occur through AICAR reducing ROS and RNS production, and by a lowering 
of the RYR1 mediated Ca2+ leak. Given the mechanism and time frames in which 
AICAR has been shown to work in the p.Y524S KI mice (Lanner et al., 2012), it was 
hypothesised that a 30 min AICAR treatment would be sufficient to observe an effect 
on the variant RYR1 channels used in this study.  
 
An acute AICAR treatment did not have a significant effect on the EC50 of caffeine in 
all 3 RYR1 variants and WT. The former result was inconsistent with my hypothesis 
however the latter result with WT was expected. There are several reasons to account 
for this, one is that the acute studies here were in HEK cells versus the mouse fibres 
and myotubes used by Lanner et al., (2012), and HEK cells do not express the full 
range of skeletal muscle proteins. Another reason was that the 30 min treatment was 
an insufficient time in HEK cells to see an effect.  This is supported by the findings of 
Merritt (2013) whereby an overnight treatment of 1 mM AICAR induced a significant 
elevation in the caffeine EC50 in p.D1056H, p.D3986E and p.R2355W, but not WT. 
Thus, a preliminary experiment was performed to assess whether an overnight 
treatment with 1 mM AICAR had any effect on p.D1056H or WT. This chronic AICAR 
treatment also failed to cause any significant changes in the caffeine EC50 in 
p.D1056H or WT.  
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The absence of an effect with both acute and chronic AICAR treatment on the caffeine 
EC50 is most likely due to  the experiments  being underpowered with the variability in 
the data much larger than was anticipated. Performing further repeats would 
overcome the error generated by factors such as using transient transfections and an 
inducible expression system (Dean et al., 2007). A stable transfection overcomes the 
differential protein expression observed with transient transfections, although stable 
transfections are more difficult to achieve, and there is a possibility that the gene of 
interest can integrate into an area that affects the phenotype of the cell.  
 
 
3.6 Conclusion 
In summary: 
1. The perfusion system has been shown to display sufficiently rapid kinetics of 
drug delivery for functional studies.  
2. Both p.D1056H and p.D3986E RYR1 variants confer an enhanced sensitivity 
to caffeine; this provides further functional evidence for their inclusion as a 
diagnostic MH mutation by the EMHG. 
3. p.R2355W did not significantly affect the sensitivity of the RYR1 channel to 
caffeine, however further repeats are required to assess this fully. 
4. Acute and chronic AICAR treatment did not have a significant effect on any of 
the RYR1 variants studied. These experiments also necessitate further 
repeats before a definite conclusion can be reached on the effects of AICAR 
on these variants.  
 
This chapter is a preliminary investigation into the effects of putative RYR1 variants 
on the caffeine induced calcium release, as well as the responses to acute and 
chronic AICAR treatment. The work would benefit from additional studies examining 
the RYR1 protein expression using immunofluorescent cytochemistry or 
quantitatively using western blotting to explore whether the lack of responses 
stemmed from variable expression of these channels.   Furthermore, HEK cells can 
be classified as a reductionist model for studying skeletal muscle disease as they do 
not natively express the key proteins involved in ECC. Accordingly, in the following 
chapters skeletal muscle cells are used for more detailed mechanistic studies as 
these overcome this major disadvantage. 
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Chapter 4. Investigating the p.G2434R and p.R2454H 
Variants in Human MH. 
 
4.1 Introduction 
4.1.1 The p.G2434R Variant 
Variants found in RYR1 account for over 70 % of the UK MHS patients (Miller et al., 
2018), however globally this value varies from 34-86 % depending on the population 
studied (Robinson et al., 2006; Gillies et al., 2008; Kraeva et al., 2011; Brandom et 
al., 2013; Ibarra Moreno et al., 2019). The RYR1 variant p.G2434R (c.7300G>A) is 
the most common variant found in the UK MH population where it is present in 16 % 
of the families (Miller et al., 2018). It is also the most frequent variant found globally, 
although this figure is biased by the fact that over 50 % of the total MH families that 
have undergone detailed genetic studies come from the UK (Lopez et al., 2018). In 
other countries p.G2434R accounts for a much smaller proportion of the MH families. 
For example it was present in only 7 % of the German MH population, whereas 
p.R614C was the commonest variant and contributed to 9 % of the German MH cases 
(Brandt et al., 1999).  
 
p.G2434R was first functionally characterised by Richter et al. (1997), who using high 
affinity [3H]ryanodine binding, identified the variant caused an enhanced sensitivity of 
RYR1 to activating concentrations of Ca2+, caffeine, 4-chloro-m-cresol (4-CMC), and 
a reduction in the sensitivity to inhibiting concentrations of Ca2+. Subsequently, 
Brinkmeir et al. (1999) found this variant caused an increased sensitivity to ryanodine. 
It has since been shown that p.G2434R alters the properties of RYR1 using different 
experimental models including HEK cells, mouse myotubes, human myotubes, 
human fibres and in vivo metabolic tests (Tong et al., 1997; Anetseder et al., 2002; 
Girard et al., 2002; Chen et al., 2018; Cully et al., 2018; Lopez et al., 2018).  
 
 
 
 
 
 
 
 
 74 
4.1.2 The p.R2454H Variant 
The p.R2454H (c.7361G>A) variant is a diagnostic RYR1 mutation as described by 
the EMHG (EMHG diagnostic mutations, 2019).  It was first described by Barone et 
al. (1999) who found it segregated with the MH susceptible phenotype. In RYR1, the 
arginine residue at position 2454 appears to be important as it is conserved across 
all species, furthermore other variants detected at this locus for example p.R2454C, 
are also pathogenic for MH (Brandt et al., 1999). In the UK population p.R2454H 
accounts for nearly 2 % of MH families (Miller et al, 2018), whereas in Germany it 
represented 1 % of MH cases (Brandt et al., 1999). Functionally, p.R2454H causes 
both  a significantly reduced EC50 for caffeine and an elevated resting [Ca2+]i in HEK 
cells (Murayama et al., 2016). 
 
4.1.3 Structure Activity Relation of RYR1 Variants 
Electron microscopy at near atomic resolution has revealed that within the RYR1 
structure residues 2145 to 3613 form a bridging solenoid (BSol) (Zalk et al., 2015; 
des Georges et al., 2016). The residues 2242-2477 within BSol have been found to 
be important in channel gating, as disruption of this area leads to a sensitisation of 
the channel to both Ca2+ and caffeine (Yamamoto et al., 2000). A recent dynamic 
model has further revealed that this region forms an extensive interface with the N-
terminal domain involving residues 1-208 (des Georges et al., 2016), and this may 
explain how other N-terminal domain variants such as p.R163C lead to MH 
susceptibility.  
 
Interestingly, the residues at position 2434 and 2454 within the BSol are conserved 
in all three isoforms of RYR, with the former conserved at the level of mammals, 
whereas the latter is conserved in all species (Carpenter et al., 2009). These findings 
suggest that the latter residue may play a more important role within the channel 
relative to the former. Carpenter et al., (2009) also found that mutations which were 
conserved within all species were affecting the static caffeine tension on the IVCT. 
Consequently, the hypothesis is amino acid changes at the 2454 locus would produce 
a more profound effect, and this effect could be appropriately assessed using 
caffeine. 
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4.1.4 Genotype and Phenotype Correlations 
Genotype-phenotype studies have shown that p.G2434R has a weaker phenotype 
relative to most other MH variants (Robinson et al., 2002; Carpenter et al., 2009). 
When this variant was compared against p.R2454H,  the former had a lower muscle 
tension in the static caffeine, static halothane, and dynamic halothane IVCT tests 
(Carpenter et al., 2009). Furthermore, patients with p.G2434R had relatively lower 
creatine  kinase (CK) concentrations; higher CK concentrations are associated with 
greater skeletal muscle damage (Carpenter et al., 2009).  An earlier study by 
Robinson et al., (2002) similarly found the p.G2434R displayed a less severe 
phenotype on the IVCT when compared with RYR1 variants that are associated with 
CCD or found near the N-terminal of the protein, for example p.R163C (c.487C>T). 
A different group of researchers found that p.G2434R had a higher caffeine threshold 
and lower caffeine tension on the IVCT relative to other variants in particular the 
p.R163C (Manning et al., 1998). Girard et al., (2001) discovered a significant variant 
dependent difference in the caffeine threshold values as well as the tension 
generated by 2 mM caffeine. In that study p.G2434R caused a significantly lower 
caffeine tension at 2 mM caffeine compared with variants such as p.R614C and 
p.V2168M. In HEK cells, p.G2434R caused a significantly higher EC50 for caffeine 
relative to other variants such as p.R163C or p.Y522S (Tong et al., 1997), and this 
provides further evidence to  support the aforementioned IVCT data.   
 
The term MH equivocal (MHE) was found to have a disproportionately high 
association with p.G2434R (Robinson et al., 2002). MHE was classically diagnosed 
when there was a positive IVCT response to either caffeine or halothane but not both 
(Hopkins et al., 2015). This term has become obsolete with all such cases now 
diagnosed as MHSC or MHSh.  Nevertheless, the higher association of p.G2434R with 
MHE suggests the responses with this variant were less severe on the IVCT given 
the response was only seen with one and not both RYR1 agonist. Whether such an 
assumption holds true is not known, particularly as a recent publication by Figueroa 
et al., (2019) found that patients who had only responded to halothane on the CHCT, 
had a more severe response on two novel indices they had created. The first was a 
clinical index encompassing musculoskeletal signs and symptoms, and the second 
was a calcium index that incorporated several intracellular Ca2+ release parameters 
in myotubes.  
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In contrast, these variant-specific effects appear to be less obvious when examining 
the halothane responses. Manning et al., (1998) could not replicate their p.G2434R 
variant specific effects using the halothane responses, and neither could Girard et al., 
(2001). The latter group looked at this in the Swiss MH population, however as 
p.G2434R is less common in the Swiss versus UK MH population, Girard et al., (2001) 
were underpowered to detect a variant dependent response to halothane.  The same 
group went on to further investigate genotype-phenotype correlations by assessing 
the response of myotubes to varying concentrations of halothane (Girard et al., 2002). 
They could not find a variant (including p.G2434R) specific correlation. However, their 
experiments were limited by the low number of patients per genotype, using supra-
normal concentrations of halothane, and sub-optimal ‘myotubes’ as these were not 
polynucleated. Accordingly, these studies reinforce that caffeine would be a more 
suitable agonist when assessing the effects of MH-associated variants on the 
magnitude of cellular responses.  
 
On the other hand, there is some conflicting evidence that suggests p.R2454H does 
not lead to a more severe phenotype. Ibarra Moreno et al. (2019) in a multi-centre 
analysis of human MH RYR1 variants, found probands carrying p.R2454H had a 
more prolonged onset time for their MH reaction relative to p.G2434R. Furthermore, 
the average age of the probands was older at 13 with p.R2454H, versus 6 years old 
in p.G2434R. However, there are several points to note with the Ibarra Moreno et al. 
(2019) study, the first is the combined US and European population was not fully 
representative of the UK MH population. The median age of probands in the UK who 
have had an MH reaction is much older than that found by Ibarra Moreno et al., and 
younger patients tend to have more severe MH reactions (Carpenter et al., 2009a; Ali 
2019). Furthermore, their study was purely based on the CGS and did not include 
results from the IVCT. Solely relying on the former can lead to a reporting bias, as 
patients with a more severe reaction are more likely to be diagnosed with MH as 
discussed in section 1.1.3.1. Barone et al. (1999) also found p.R2454H had a less 
profound response on the IVCT test relative to p.R163C. It maybe that although 
p.R2454H does have a more severe phenotype compared with p.G2434R, this is less 
profound than that observed with p.R163C. Unfortunately no comparisons were made 
with p.G2434R in the study by Barone et al. (1999).  
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Another group did not find a difference in the metabolic response observed in 
p.G2434R and p.R2454H (Anetseder et al., 2002). This study too was limited by the 
small number of patients in each genotype which was further compounded by the 
effects of other confounders such as gender and CK concentrations. Their metabolic 
test consisted of examining the changes in intramuscular PCO2 to an in vivo 
application of caffeine. The fundamentals of this paradigm make it apparent that the 
test is unlikely to be sufficiently sensitive to detect variant specific differences, 
particularly when accounting for the ongoing losses of CO2 to the environment and 
into blood.  
 
It is important to note that one caveat to the Carpenter et al. (2009a) study is the 
immense heterogeneity in the number of probands and families found with each 
variant. The p.G2434R variant had at least 181 individuals over 73 families, yet the 
p.R2454H had 11 individuals over 3 families, and thus such low numbers may bias 
the comparisons as there is a reduced variability in the genetic background. 
 
 
4.1.5 Genotype and Phenotype Discordance 
It became evident during early studies into MH that this condition had a variable 
clinical penetrance (Denborough et al., 1962; Halsall et al., 1979). Such variability 
has additionally been observed between the IVCT phenotype and RYR1 genotype.  
 
Several groups have identified a discordance between the responses on the IVCT 
and the presence of diagnostic RYR1 variants for MH (Keating et al.,1994; Brandt et 
al., 1999; Robinson et al., 2002; Miller et al., 2018). In these studies, genotype-
phenotype discordance was defined as when individuals carrying a familial diagnostic 
variant for MH were found to be MHN on the IVCT, or where individuals from families 
carrying the variants were MHS but did not have the familial RYR1 variant. In their 
study, Robinson et al., (2002) described nearly 10% of mutation-positive families 
exhibited discordance between RYR1 genotype and IVCT phenotype. This 
discordance is not unique to the IVCT, Phillips et al., (1994) have also reported 
individuals with the p.G2434R genotype who were MHN on the CHCT, and those with 
a positive MHS phenotype on the CHCT, but were negative for the familial p.G2434R 
variant. 
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Initial studies reported this discordancy was only observed with the p.G2434R and 
p.G341R variants, however it has since become evident that other variants also 
exhibit such discordance (Miller et al., 2018). Nevertheless, p.G2434R demonstrates 
the greatest degree of genotype-phenotype discordance. In the study by Robinson et 
al. (2003b) of a European MH database, they uncovered that both p.R614C and 
especially p.G2434R had the greatest genotype-phenotype discordance. Similarly 
Miller et al. (2018) using the latest UK data set also found the p.G2434R to have the 
greatest number of discordant individuals.  
 
One reason for this discordance, is the clinical classification of borderline IVCT results 
as MHS to improve the sensitivity of an MHS diagnosis. The primary goal here is to 
mitigate the serious risk to the patient of an exposure to a triggering agent if they had 
been given a misdiagnosis of MHN i.e a false negative. However, Robinson et al., 
(2002) revealed that borderline IVCT results were not deemed to be implicated in 
approximately 50% of discordant families. Furthermore, diagnosing borderline 
patients as MHS instead of MHN would explain the cases where the diagnostic MH 
variants were not present in MHS, but it would not explain those who were MHN but 
carrying the diagnostic variant. 
 
In summary, although there is some conflicting literature regarding genotype-
phenotype correlations some of which may relate to different testing methods (cells, 
temperature of investigations, in vitro vs. in vivo, number of test samples per 
genotype, IVCT vs CHCT protocols for the diagnosis of MHS), it is apparent that 
different MH variants can produce different phenotypes.  
 
 
4.1.6 Extracellular Ca2+ Entry in MH 
Currently, it is not fully understood how at the molecular level the p.G2434R variant 
or other variants commonly related to MH bring about the susceptibility to MH. 
Previous research using non-genotyped human MH samples has shown that skeletal 
muscle fibres from human MHS patients have an elevated [Ca2+]i in the non-triggered 
state (Lopez et al., 1985). There are several different mechanisms that have been 
postulated to initiate, maintain and adapt to the elevated [Ca2+]i found in the resting 
state,  as well as maintain the vastly enhanced [Ca2+]i during an MH reaction. These 
mechanisms can be split into two broad groups, the first is an enhanced SR Ca2+ 
release through a leaky RYR1 protein, the other is altered sarcolemmal membrane 
Ca2+ flux. The later can be further classified according to the processes that are 
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involved in the influx of Ca2+ and includes ECCE, SOCE and RCaE (Cherednichenko 
et al., 2004, Chelu et al., 2006, Yang et al., 2006, Yang et al., 2007, Eltit et al., 2010, 
Esteve et al., 2010., Eltit et al., 2013, Yarotskyy et al., 2013, Altamirano et al., 2014).  
On the other hand, Ca2+ efflux processes are also thought to play an important role 
in maintaining cellular homeostasis in cells susceptible to MH particularly during an 
MH reaction (Cully et al., 2018). The Ca2+ efflux pathways are usually mediated 
through the plasma membrane Ca2+ATPase (PMCA) and NCX (Brini and Carafoli, 
2011). The NCX working in the reverse mode has also been shown to contribute to a 
raised [Ca2+]i (Altamirano et al., 2014). Modifications of the Ca2+ flux across the 
sarcolemmal membrane is believed to be the only way cells can change the [Ca2+]i 
over the long term and thus fulfil the cell boundary theorem. This theorem states that 
the long term steady state of the free [Ca2+]I, must be driven by exchanges with the 
extracellular fluid through fluxes across the sarcolemma (Rios 2009; Eltit et al., 2010). 
Detailed explanation of this theorem are provided by Rios (2009). 
 
The hypothesis in this chapter is that an elevation in [Ca2+]i in the resting state of 
human cells would be maintained over the long-term by an enhanced entry of Ca2+ 
from the extracellular space.  A unidirectional cationic entry into the intact skeletal 
muscle cells can be quantitively assessed using the Mn2+ quench technique (Merritt 
et al., 1989; Eltit et al., 2013). Here, instead of exciting the ratiometric dye Fura2 at 
two different wavelengths, the fluorescence is measured at its isosbestic point of 360 
nm. At this wavelength the fluorescence is independent of the Ca2+ free versus bound 
state and accordingly any changes in [Ca2+]i. Mn2+ is a divalent cation that permeates 
membrane calcium channels and irreversibly binds to Fura2 causing a quench in its 
fluorescence (Bird et al., 2008). In healthy myotubes, Mn2+ entry into the cell initially 
leads to a linear decrease in the dye fluorescence, this then transforms into an 
exponential decline as the dye molecules are saturated (Bird et al., 2008). Using this 
technique, Eltit et al., (2013) revealed and enhanced RCaE in homozygous myotubes 
from the p.R163C RYR1 mouse model. This enhanced RCaE could be attenuated with 
the non-specific cationic channel blocker Gd3+, as well as with the Ca2+ release-
activated Ca2+ current (CRAC) and TRPC channel blocker BTP2 (Zitt et al., 2004; Eltit 
et al., 2013). The results with BTP2 suggest that TRPC channels may mediate the 
process, however, this has not been fully explored. Furthermore, there are no reports 
that have assessed the RCaE in human MHS myotubes. 
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4.2 Aims 
 
The aims of this chapter are to: 
 
I. Characterise and compare the sensitivity of myotubes from human 
p.G2434R and p.R2454H to caffeine. 
a. The primary outcome is to investigate the AUC of the caffeine 
responses. 
b. The secondary outcome is to assess the peak caffeine 
responses. 
 
II. Investigate whether there is an enhanced entry of extracellular calcium 
(i.e. RCaE) in myotubes from patients with the p.G2434R and p.R2454H 
variants, and if these are MH genotype dependent. 
 
III. Pharmacologically assess whether TRPC channels mediate the entry 
of extracellular calcium in the human MH myotubes. 
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4.3 Methods 
The staining of cells, confirmation of variants and caffeine induced calcium release 
imaging was performed by Ms Garima Singh a Master’s student at the University of 
Leeds, who was working directly under my supervision. Ms Singh was blinded to the 
MH status of the patients whilst undertaking these experiments. The rest of the work 
including the data analysis and interpretation of the caffeine-induced Ca2+ release 
was performed by me.  
 
4.3.1 Experimental Cells 
4.3.1.1 Human Myoblasts 
Myoblasts for calcium imaging were isolated from humans heterozygous for the 
p.G2434R or p.R2454H RYR1 variants and diagnosed as MHS. Control myoblasts 
were from their MHN counterparts. The myoblast isolation was performed as 
discussed in section 2.2.1. Myotubes for the calcium imaging and manganese quench 
experiments were differentiated for 10-13 days as described in 2.2.4.1.  To eliminate 
the effects of gender, all samples were from female patients.  
 
4.3.1.2 Confirmation of RYR1 Variants 
A direct PCR (section 2.3.3) was used to confirm the presence of the expected RYR1 
variants in the samples that were used. The PCR products were run on an agarose 
gel to confirm the presence of a unique band as described in 2.3.2, and if so, sent for 
sequencing. The cycling conditions were:  
1 denaturation cycle: 95 ºC for 3 min, 34 amplification cycles: 95 ºC for 30 s, 60 ºC 
for 60 s, 72 ºC for 45 s, 1 completion cycle: 72ºC for 7 min. For p.R2454H the 60 ºC 
amplification and 72 ºC completion were for 30 s and 5 min, respectively.  Primer 
sequences: 
 
p.G2434R   Forward primer- 5’- CCACCTTCCCTGCAGCTTTG -3’ 
Reverse primer- 5’- TTCCCATCCTGCCCTGGCTC -3’ 
 
p.R2454H   Forward primer- 5’- GAGAAAGAGGCCTGCTCTAC -3’ 
Reverse primer- 5’- GGAGGGTGGGTTCGGGGATG -3’ 
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4.3.2 Immunocytochemistry 
Cells from 4.3.3.1 were stained as described in section 2.5, except cells were fixed 
with 100 % ice cold methanol for 1 hour at 4 °C. Non-specific binding was blocked by 
a 10 min incubation with 5% normal goat serum. Imaging was performed on a wide-
field fluorescent inverted microscope (Nikon A1R) using a 20X lens with a 0.75 
numerical aperture, and DAPI or FITC filter sets. 
4.3.2.1 Desmin Staining 
Myoblasts were plated on 96 well plates coated with ECL, allowed to settle overnight 
and stained the next day as per section 2.5. The antibodies used were rabbit anti-
desmin antibody (dilution 1:200; Abcam, UK) and goat anti-rabbit IgG (H+L) 
conjugated to FITC (1:50 dilution; ThermoFisher, UK).  
 
4.3.2.2 Myosin Heavy Chain Staining 
Myoblasts were plated on a 96 well plate coated with either ECL or Matrigel, 
differentiated and stained as per sections 2.2.4.2 and 2.5. Mouse anti-myosin heavy 
chain (MYH) antibody (1:40; MF-20, Developmental Studies Hybridoma Bank, Iowa, 
USA) was used as the primary, and goat anti-mouse IgG2b conjugated to Alexa Fluor 
488 as the secondary (1:200; AB_2535778, ThermoFisher, UK). 
 
4.3.3 Live-Cell Calcium Imaging 
This was performed as described in chapter 2.6 
 
4.3.3.1 Experimental Solutions 
For caffeine, IB was perfused for 10 s then caffeine for 10 s followed by IB for 10 s.  
 
4.3.3.2 Calcium Release 
Myotubes were loaded with 5 PM Fluo4-AM in 10% Pluronic F127 for 15 min. 
 
4.3.3.3 Extracellular Cationic Entry 
Myotubes were loaded with 5 PM Fura-2AM in 10% Pluronic F-127 for 15 min at 37 qC 
and 25 min at room temperature. 
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4.3.4 Statistics 
 
The number of myotubes required for the experiments were determined by similar 
experiments conducted in the laboratories of Professor Paul D Allen using MH mouse 
models (Yang et al., 2006 and 2007; Eltit et al., 2010, 2012 and 2013; Lopez et al., 
2018), and previous studies using human MH myotubes (Brinkmeier et al., 1999; 
Wehner et al., 2004).  
 
4.3.4.1 Calcium Release 
Analysis was as described in section 2.6.3.2.  However, for both the peak and AUC 
fluorescent responses, myotubes with responses that were 20 % greater than the 
maximum response to 20 mM caffeine (the pre-defined maximum), but at 
concentrations lower than 20 mM caffeine, were excluded from further analysis. This 
was done on the basis that these myotubes were unhealthy with aberrant responses.  
 
4.3.4.2 Manganese Quench 
Analysis was as described in section 2.6.3.3. 
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4.4 Results 
 
4.4.1 Human Pedigrees of Human Cell Samples 
The samples used for the calcium imaging studies for the p.R2454H and p.G2434R 
variants were determined by several factors: (1) the patient either had the p.R2454H 
or p.G2434R variant or came from a family containing these variants and were MHN, 
(2) the patient must have undergone an IVCT test to diagnose MHS or MHN, (3) they 
had viable myoblasts that had been stored in the UK MH databank, (4) the myoblasts 
should produce good quality multinucleated myotubes for several passages. 
Myoblast for both MHS and MHN samples were available from a MH family who met 
the above criteria and had the p.G2434R variant (Figure 4.1). Unfortunately, for the 
p.R2454H variant, there were no samples identified that met all the criteria in the 
same family, thus the myoblasts utilised for experiments  were selected from different 
families (Figure 4.2).  
 
 
Figure 4.1: Family pedigree of MHN and MHS samples used with the p.G2434R variant.  
This MH family is known to carry the p.G2434R variant with myoblasts available and able to 
produce  myotubes from both MHS and MHN patients. The proband (black arrow) is the first 
individual within a family who has been referred for investigations at the Leeds MH unit 
following a potential MH reaction. The blue arrows indicate the source of the myoblast samples 
used. 
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 85 
 
 
 
 
Figure 4.2: Family pedigrees of MHN and MHS samples used with the p.R2454H variant.  
(A) The family tree for the MHN sample used. (B) Family tree for one of the MHS samples 
used in the calcium imaging (MHS-I). (C) Family tree for the second MHS sample used (MHS-
II). The family trees shown have been truncated to depict less than 4 generations.  
The probands are shown by the black arrow, with the blue arrows indicating the source of the 
myoblast samples used. 
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4.4.2 Confirmation of Variants in Samples 
To confirm the variants in the samples were as expected, a direct PCR was 
performed using variant specific primers covering exon 45 in RYR1. The p.R2454H 
variant  is encoded in this exon. Agarose gel electrophoresis confirmed the PCR 
had been successful with only one 300-base pair (bp) fragment detected as had 
been predicted from BLAST searching the primer sequences (Figure 4.3A). The 
sequenced PCR product confirmed a heterozygous c.7361G>A change in the two 
MHS samples as would be expected in p.R2454H and the wild-type sequence in 
MHN (Figure 4.3B). A similar method using primers covering the region that 
encodes p.G2434R in exon 44 of RYR1 was used to confirm the presence of 
c.7300G>A in the p.G2434R MHS sample and wild-type sequence in the MHN 
samples (data not shown). 
 
 
 
Figure 4.3: Confirmation of p.R2454H sequence (A) 1 % gel electrophoresis of the PCR 
product showing the 300 bp fragment that was predicted. M contains the 100 bp DNA ladder, 
1,2,3 contain the MHS/MHN samples, ‘+’ is the positive control and ‘–’ the negative control. 
(B) Direct sequencing of the PCR product revealed two samples that were heterozygous for 
c.7361G>A, this is shown by two peaks of equal height corresponding to a guanine plus an 
adenine (MHS), and one sample that was MHN with the wild type sequence c.7361G. 
 
 
 
 
 
 
A B 
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4.4.3 Generation of Myotubes 
These experiments were formally conducted with the p.R2454H MHS and MHN 
samples. The pre-plating technique of Rando and Blau (1994) was used for myoblast 
purification, and this produced a myoblast purity of >60 % in these samples (Figure 
4.4A, top row). The mean ± SEM of desmin positive cells in the samples was 77.0 ± 
5.0 % in MHN, 67.6 ± 11.2 % in MHS (I) and 64.1 ± 4.2 % in MHS (II) (Figure 4.4B), 
the mean values were not significantly different between the three samples (P=0.171, 
one-way ANOVA with Tukey's multiple comparisons, n=3 experiments).  
 
All samples could be differentiated to produce myotubes (Figure 4.5A and 4.5B). The 
human myotubes used for these experiments took at least 5 days to form large 
multinucleated myotubes, and all samples used were able to produce such myotubes 
even at passage 12 (data not shown). Some samples were able to keep producing 
large multi-nucleated myotubes even at passage 20 (data not shown). Although such 
formal assessments were not performed with p.G2434R MHS and MHN samples, my 
previous preliminary work had shown that these samples were also myogenic and 
able to produce polynucleated myotubes.   
 
Several different types of extracellular matrices are available for cell culture, an 
experiment was done to qualitatively identify a superior matrix for the growth and 
differentiation of human myotubes. Growth factor reduced Matrigel (11.3 µg/cm2; 
Sigma, UK) appeared to qualitatively give the best condition for myotube production; 
the myotubes were larger and thicker, overall looked healthier and had a greater 
number of nuclei per myotube (Figure 4.5A). Comparisons were also made for the 
duration that the myotubes should undergo differentiation using the fusion index (FI); 
FI = [number of nuclei within MF20-stained myotubes/total number of nuclei] × 100%. 
FI is a marker of the ability of the myotubes to fuse, a higher percentage indicates 
myoblasts have a greater capacity to fuse and form larger myotubes (Alexander et 
al., 2016). The results revealed that between days 7 and 13 of differentiation, the MH 
status (P=0.739) and duration of differentiation (P=0.098) did not have a significant 
effect on the fusion index (Figure 4.5B; two-way ANOVA with Tukey's multiple 
comparisons, n=3 experiments). However, there was a trend to greater fusion with 
increasing number of days of differentiation in two of the samples (Figure 4.5B).  
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Figure 4.4: The purity of myoblasts in samples from p.R2454H MHS and MHN humans 
(A) Immunofluorescence images showing the presence of myoblasts in the pre-plated 
population using desmin as a marker. Nuclei were stained with DAPI (1A), cells were also 
stained with a rabbit primary anti-desmin antibody (1:200), and then a goat anti rabbit IgG 
FITC secondary antibody (1:50) (1B). The merged images are shown in 1C. The negative 
control omitted the primary anti-desmin antibody (panel 2A-C). Images were taken under DAPI 
or GFP filter sets at 20 x magnification, the scale bar represents 100 µm. (B) The number of 
desmin positive cells were not significantly different between the three human samples, 
P=0.171, (one-way ANOVA with Tukey's multiple comparisons test, n=3 separate 
experiments with 5 fields of view chosen randomly per sample per experiment). 
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Figure 4.5: Effects of extracellular matrix composition and duration of differentiation 
on myotube formation in p.R2454H MHS and MHN samples. (A) Immunofluorescence 
images comparing the growth of myotubes in ECL (top row) and Matrigel (bottom row) 
extracellular matrix over 7, 10 and 13 days. The myotubes qualitatively appeared healthier on 
the Matrigel matrix. Cells were stained with DAPI (nuclei), primary anti-myosin heavy chain 
antibody (1:20), and Alexa Fluor-488 goat anti-mouse secondary antibody (1:200). (B) Time-
course analysis assessing the duration of differentiation on myotube formation in the 
p.R2454H MHS and MHN samples. MHS status (P=0.739) or duration of differentiation 
(P=0.098) did not have significant effect on myotube formation as determined by the fusion 
index (two-way ANOVA n=3 separate experiments with 5 fields of view chosen randomly per 
sample per experiment).  
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4.4.4 p.R2454H Myotubes Have an Enhanced Sensitivity to Caffeine 
Fluo-4AM loaded myotubes from MHN and p.R2454H MHS were exposed to various 
concentrations of caffeine and 60 mM KCl. KCl was used to chemically depolarise 
the myotubes; this induces the activation of the DHPR which via an orthograde 
activation of RYR1 causes SR Ca2+ release, with a subsequent increase in the 
intensity of the Fluo-4 fluorescence (Cherednichenko et al., 2004). The application of 
60 mM KCl did indeed stimulate an increase in the fluorescence (Figure 4.6), and this 
indicated the ECC apparatus was functioning in the myotubes and thus the Cav1.1 
complex and RYR1 proteins were being expressed.  The responses to caffeine were 
only analysed in myotubes with functioning ECC apparatus. Application of caffeine 
produced a reversible increase in the Fluo-4 fluorescence due to the increase in 
intracellular Ca2+ (Figure 4.6). The fluorescence began to return to baseline whilst the 
caffeine was still being perfused. 
 
Myotubes from both MHS and MHN responded to challenges of 0.1 mM to 20 mM 
caffeine (Figure 4.6). Figure 4.7A provides a summary of the responses observed at 
each caffeine concentration in the myotubes as a concentration-response curve on a 
semi-log axis. A non-linear regression using a four parameters variable slope Hill 
equation was used to fit the representative curves for the AUC (Figure 4.7A) and peak 
height (Figure 4.8A) of the responses. The median and IQR of the normalised AUC 
responses at 0.1 mM caffeine were negligible at 0.2 (0.1-1.3) % or 0.6 (0.2-2.1) % for 
MHS and 0.5 (0.1-1.5) % for MHN (Figure 4.7A). The median response increased to 
9.4 (5.4-16.8) % and 8.9 (1.1-12.2) % in MHS upon application of 0.5 mM caffeine, 
whereas in MHN this increase was smaller at 4.7 (1.8-7.5) %.  
 
There was a significantly enhanced sensitivity to caffeine in p.R2454H myotubes from 
two different patients relative to MHN (Figure 4.7; P≤0.005, one-way ANOVA with 
Tukey’s multiple comparison test, n=26-39 myotubes). The mean EC50 for caffeine in 
MHS samples were 2.1 ± 0.1 mM (MHS-I), 1.8 ± 0.2 mM (MHS-II) whereas it was 
2.8 ± 0.8 mM in MHN. There was no significant difference between the two MHS 
samples (P=0.488, one-way ANOVA with Tukey’s multiple comparison test, n=26-36 
myotubes).  The MHS samples also had a significantly enhanced sensitivity to 1 mM 
caffeine relative to MHN with a response of 26.1 ± 2.4 % in MHS(I), and 31.5 ± 3.5 % 
in MHS(II); these were nearly two-fold greater than that observed with MHN myotubes 
where it was 14.8 ± 1.3 % (Figure 4.7C; P≤0.005, one-way ANOVA with Tukey’s 
multiple comparison test).  
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Figure 4.6: The enhanced effect of caffeine on p.R2454H MHS myotubes. Representative 
traces observed in human myotubes from MHN (A) and the p.R2454H MHS (B) individuals 
upon exposure to different concentrations of caffeine (in mM) and KCl. Myotubes were loaded 
with 5 µM Fluo-4AM, and exposed to 10 seconds of the relevant concentration of caffeine 
before it was rapidly washed off. Between each caffeine exposure, there was a 2-minute rest 
period. MHS (top trace) had an EC50 of 2.1 mM, versus 2.8 mM in MHN (bottom). 
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Figure 4.7: Enhanced sensitivity to caffeine in MHS p.R2454H myotubes using AUC.  
(A)Concentration-response curves to caffeine in MHN and RYR1 p.R2454H MHS myotubes. 
Data points are the mean ± SEM normalised AUC response. MHS had a significantly 
enhanced sensitivity to caffeine relative to MHN. (B) The EC50 in the three samples displayed 
as a bar chart. (C) Comparisons of the effects of 1 mM caffeine which was normalised to 
20 mM caffeine; MHS myotubes had the largest response with MHN. In A-C, **P<0.005 and 
***P<0.0005, ****P<0.0001 one-way ANOVA with Tukey’s multiple comparison test. Imaging 
of myotubes was from multiple wells for each genotype, these were assayed over 3-5 days. 
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Comparisons of the peak responses also displayed an enhanced sensitivity to 
caffeine in MHS p.R2454H with a median EC50 of 1.6 (1.2 – 2.6) mM and 
1.4 (1.0 – 2.1) mM respectively relative to MHN 2.7 (1.9 – 3.2) mM  (P≤0.005, 
Kruskal-Wallis test with Dunn’s multiple comparison test, n=26–39 myotubes; Figure 
4.8A). There was no difference in the median EC50 between the two MHS samples 
(P>0.99). Consistent with the AUC data, significantly enhanced peak response to 1 
mM caffeine were observed in MHS relative to MHN myotubes (P≤0.005, Kruskal-
Wallis test with Dunn’s multiple comparison test, n=26-39). The median peak 
response of 37.4 (17.7 – 52.2) % and 28.1 (10.5 – 42.6) % were over three-fold 
greater than that seen in MHN 8.4 (5.6 – 19.7) %, this contrasts with approximate 
two-fold difference seen when assessing the AUC of the (Figure 4.7C and 4.8C). 
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Figure 4.8: An enhanced sensitivity to caffeine in MHS p.R2454H myotubes using peak 
responses. (A) Concentration-response curves to caffeine in RYR1 p.R2454H MHS 
myotubes and MHN. Data points are the mean ± SEM response calculated using the 
normalised peak response. MHS had a significantly enhanced sensitivity to caffeine relative 
to MHN.  (B) The EC50 in the three genotypes displayed as a box-plot showing the median 
and range. (C) Comparisons of the peak normalised response to 1 mM caffeine; MHS(II) had 
the largest response compared with MHS (I) and MHN. In A-C, **P<0.005 and ****P<0.0001, 
Kruskal-Wallis test with Dunn’s multiple comparison test. Imaging of myotubes was from 
multiple wells for each genotype, these were assayed over 3-5 days. 
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4.4.5 p.G2434R Myotubes Have an Enhanced Sensitivity to Caffeine 
As with p.R2454H, myotubes containing the p.G2434R variant had an enhanced 
sensitivity to caffeine as assessed using the primary outcome of a normalised AUC 
(Figure 4.9). In this experiment, the myotubes derived from MHN and MHS individuals 
within a family that is known to carry the p.G2434RH variant. The median EC50 in 
p.G2434R MHS myotubes was 2.2 (1.5 – 3.3) mM, and this was lower than 
3.4 (3.0 – 4.7) mM found in MHN (P<0.005, Mann-Whitney test, n=29 and 21 
respectively, Figure 4.9A and B). Both genotypes had a small response to 0.1 mM 
caffeine; this caused a greater median response of 3.3 (2.1 - 5.8) % in MHS relative 
to MHN 1.7 (0.6-5.1) % (P<0.05, Mann-Whitney test). An enhanced response in MHS 
was also seen at 1 mM caffeine (Figure 4.9C) which was 19.4 (13.2- 28.4) % of the 
maximal normalised AUC response, whereas in MHN it was over two-fold less at 8.3 
(2.9 –  4.7) % (P<0.0005, Mann-Whitney test). The threshold response defined as 
>10% of the maximal response was observed at 1 mM caffeine with MHS, but 3 mM 
caffeine with MHN (Figure 4.9A).  
 
The results for the peak responses to caffeine in p.G2434R were analogous to those 
observed with the AUC (Figure 4.10). In this case the median EC5o in both genotypes 
was 2.4 (1.2 – 3.4) mM and 3.5 (2.9 – 5.4) mM in MHS and MHN respectively. The 
corresponding AUC results were 2.2 and 3.5 mM (Figure 4.9A and 4.10A). 1 mM 
caffeine caused a more muted difference between the two genotypes with 13.2 
(9.0 – 24.6) % observed in MHS and 10.0 (3.3 – 15.0) % in MHN (P<0.05, Mann-
Whitney test). 
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Figure 4.9: Enhanced sensitivity to caffeine in MHS p.G2434R myotubes using AUC. (A) 
Concentration-response curves to caffeine in MHN and RYR1 p.G2434R MHS myotubes. 
p.G2434R MHS had a significantly enhanced sensitivity to caffeine versus MHN (B) The EC50 
displayed as a box plot. (C) The median response to 1 mM caffeine in p.G2434R MHS 
myotubes was greater than that in MHN myotubes, ***P<0.0005, Mann-Whitney test. Imaging 
of myotubes was from multiple wells for each genotype, these were assayed over 3-6 days. 
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Figure 4.10: Enhanced sensitivity to caffeine in MHS p.G2434R myotubes using peak 
responses. (A) Concentration-response curves to caffeine in RYR1 p.G2434R MHS and 
MHN myotubes. Data points are the mean ± SEM peak normalised response. MHS had an 
enhanced sensitivity to caffeine relative to MHN. (B) The EC50 in the two genotypes displayed 
as a box-plot showing the median and range. (C) Comparisons of the peak normalised 
response to 1 mM caffeine; MHS had a larger response compared to MHN. *P<0.05, 
**P<0.005, Mann-Witney test. Imaging of myotubes was from multiple wells for each 
genotype, these were assayed over 3-6 days. 
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4.4.6 Genotype-Phenotype Comparisons with Caffeine 
In order to assess the effect of the different genotypes on the phenotypic responses 
to caffeine, data from the MHN myotubes related to both p.R2454H and p.G2434R 
samples were combined, as were the two p.R2454H samples. Figure 4.11 displays 
the AUC results of the peaks. There was an enhanced sensitivity observed in 
p.R2454H and p.G2434R relative to MHN samples (P<0.05, Kruskal-Wallis test with 
Dunn’s multiple comparison test, n=29-62 myotubes). The median EC50 in p.R2454H 
was 1.8 (1.3 – 2.7) mM, and 2.2 (1.5 – 3.3) mM in p.G2434R, whereas it was 3.0 (2.3 
– 3.5) mM in MHN (Figure 4.11B). There was no significant difference between the 
median EC50 found in p.R2454H and p.G2434R (P=0.21, Kruskal-Wallis test with 
Dunn’s multiple comparison test, n=29-62 myotubes, from 1-2 patients per genotype) 
 
The pattern of results was similar when examining the effect of 1 mM caffeine (Figure 
4.11C). The responses to 1 mM caffeine in p.R2454H of 27.5 (17.2 – 34.9) % of the 
20 mM caffeine response was not significantly different to that observed in it was 
p.G2434R at 19.4 (13.2 - 28.4) % (P=0.17, Kruskal-Wallis test with Dunn’s multiple 
comparison test, n=29-62). In contrast, both these responses were significantly 
greater than the 12.5 (6.9 – 17.9) % observed in MHN (**P≤0.005). 
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Figure 4.11: Enhanced sensitivity to caffeine in MHS p.R2454H and p.G2434R myotubes 
using AUC. (A) Concentration-response curves to caffeine in RYR1 p.R2454H, p.G2434R 
and MHN myotubes. Both p.R2454H and p.G2434R had a significantly enhanced sensitivity 
to caffeine versus MHN. (B) The EC50 displayed as a box plot. (C) The median response to 1 
mM caffeine in p.R2454H and p.G2434R MHS myotubes was significantly greater than in 
MHN myotubes. *P<0.05, **P<0.005, ****P<0.0001, Kruskal-Wallis test with Dunn’s multiple 
comparison test. Myotubes were from multiple wells that were assayed over 3-6 days for each 
genotype. The variation in the number of myotubes is because samples were from two MHS 
patients for p.R2454H, one patient for p.G2434R, and two patients for MHN. 
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4.4.7 Attenuated Peak Responses in MHS Myotubes  
Previous research has found that MH associated RYR1 variants result in a reduced 
SR Ca2+ store due to an enhanced Ca2+ leak (Chelu et al., 2006; Manno et al., 2013). 
Thus the absolute change in fluorescence (F-F0) upon exposure to 20 mM caffeine 
was assessed in p.R2454H and p.G2434R which were then compared to their MHN 
counterparts (Figure 4.12A and B). There was a reduction in the median peak 
response seen in p.R2454H of 62 (37 - 88) AFU relative to MHN 85 (34 – 120) AFU 
(P=0.02, Mann-Whitney test, n=62 and 39 respectively). This contrasts with the 
results observed in p.G2434R MHS myotubes the reduction in the absolute median 
peak response of  68 (33 - 114) AFU was not significant compared with the MHN 
myotubes which had a median response of 88 (47 - 142), (P=0.248, Mann-Whitney 
test, n=28 and 21 respectively).  
 
Given that the previous sections have shown that the AUC response in p.R2454H 
and p.G2343R do not appear to be significantly different, the data was pooled to 
assess the effect of MHS status on the absolute median peak response observed to 
20 mM caffeine (Figure 4.12C). There was a significant reduction in the median 
absolute peak response to 20 mM caffeine in MHS relative to MHN (P=0.009, Mann-
Whitney test, n=90 and 60 respectively). The response was lower in MHS samples 
with a median absolute response of 62 (34 – 91) AFU, whereas in MHN it was 
86 (47 – 124) AFU. These data suggest that although the RYR1 channels containing 
MH variants have an increased sensitivity to activation by caffeine, the reduced SR 
Ca2+ content leads to smaller peak responses in MHS myotubes. 
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Figure 4.12: Reduced SR calcium release in MHS myotubes. (A) Absolute changes in the 
peak fluorescence response from baseline (F-F0) in p.R2454H and MHN myotubes in 
response to 20 mM caffeine. p.R2454H had a significantly lower median peak response 
relative to MHN (P = 0.02, Mann-Whitney test, n=62 and 39 respectively). (B) The absolute 
change in the peak response in p.G2434R was not lower than in MHN (P=0.248, Mann-
Whitney test, n=28 and 21 respectively). (C) The combined median absolute response in 
p.G2434R and p.R2454H myotubes to 20 mM caffeine was significantly lower than observed 
in MHN myotubes (P=0.009, Mann-Whitney test, n=90 and 60 respectively). Imaging of 
myotubes was from multiple wells for each genotype, these were assayed over 3-6 days. 
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4.4.8 Human MHS Myotubes Exhibit an Enhanced RCaE 
The Mn2+ quench of Fura-2 fluorescence was used to quantify the divalent cation 
influx and thus RCaE from the extracellular space into intact skeletal myotubes (Figure 
4.13A-D). Fura-2 was excited at its isosbestic wavelength of 360 ± 5 nm using a 
narrow band-pass filter (Figure 4.13B).  The fluorescence signal being examined for 
the RCaE is extremely small compared to that observed with SOCE where the 
extracellular cationic entry is much larger (Pan et al., 2014). This small signal renders 
the system very sensitive to minor changes in the fluorescence as observed by the 
deviations seen in Figure 4.13C. Upon changing from the Ca2+ containing IB to Mn2+ 
containing buffer MnB, there was a linear decrease in the fluorescence signal i.e. the 
dye was becoming quenched (Figure 4.13C). This decrease was also observed in the 
baseline of some of the myotubes during IB perfusion, however it was at a much lower 
rate (Figure 4.13D).  The decrease at baseline is likely to be due to several factors 
which include the extrusion of the Fura-2 dye from the cell, as well as excitation-light 
dependent dye degradation. 
 
The increased quench upon changing to MnB was observed in all MHS and MHN 
genotypes examined (Figure 4.14A).  The median Mn2+ entry was greater in 
p.G2434R MHS myotubes at -0.21 (-0.12 to -0.33) AFU/s relative to their MHN 
counterparts -0.15 (-0.05 to  -0.29) AFU/s (P=0.02, Mann-Whitney test, n=67 and 44 
respectively). The p.R2454H MHS myotubes also had an enhanced Mn2+ entry at  
-0.19 (-0.12 to -0.33) AFU/s, and this was greater that in MHN -0.12 (-0.07 to -0.17) 
AFU/s (P<0.0001, Mann-Whitney test, n=84 and 80 respectively). 
 
There was no statistically significant difference in the median Mn2+ entry between the 
two groups of MHN samples (P = 0.24, Mann-Whitney test). Thus, the data for the 
MHN samples were pooled, and these used to examine whether there was a variant 
dependent effect on the rate of Mn2+ entry seen in MHS myotubes (Figure 4.14B). 
The median Mn2+ entry in the pooled MHN samples was -0.12 (-0.01 to -0.21) AFU/s, 
this was lower than that seen in p.G2434R and p.R2454H (P<0.0001, Kruskal-Wallis 
test with Dunn’s multiple comparison test, n=67-124). The median Mn2+ entry 
observed in myotubes containing p.G2434R was not significantly different to 
p.R2454H (P>0.99). 
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Figure 4.13: Sarcolemmal cationic permeability in MHS and MHN myotubes. (A) 40 x 
magnified image of Fura-2AM loaded myotubes from a MHS patient with the p.G2434R 
variant, the nuclei are whiter and oval shaped. Myotubes were classed as cells containing ≥ 2 
nuclei highlighted by blue arrows. Red arrows show myotubes that did meet this criterion, 
although not all the nuclei were visible in the frame shown. (B) Fluorescence excitation spectra 
of Fura-2 at different calcium concentrations with the emissions measured at 510 nm. Asterix 
indicates the independence of the spectra at the 360 nm isosbestic point (image adapted from 
Invitrogen). (C) Representative trace from an MHN myotube showing the change in the slope 
of the fura-2 fluorescence upon switching the imaging buffer containing 2 mM Ca2+ (orange 
broken line) to a 0.5 mM Mn2+ containing buffer (light-green broken line). The rate at which 
the external Mn2+ quenches cytoplasmic Fura-2 fluorescence is used to estimate the 
sarcolemmal permeability to Ca2+. A greater slope indicates a larger resting sarcolemmal 
permeability. (D) Representative trace from an MHS p.G2434R and MHN myotubes displaying 
the change in the slope of the fura-2 fluorescence upon perfusion of 0.5 mM Mn2+. Note the 
greater gradient of the slope in MHS p.G2434R versus MHN.   
*
D 
A B 
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Figure 4.14: Enhanced RCaE in MHS myotubes is independent of the RYR1 variant. (A) 
Box-plots showing the Mn2+ mediated rate of change in the Fura-2 fluorescence in myotubes 
from patients carrying the p.G2434R and p.R2454H RYR1 variants as well as in their MHN 
counterparts. The individual rates of decrease in fluorescence in each myotube are presented, 
the box-plots represent the median and IQR, with the whiskers showing the range. A greater 
rate of quench is signified by a more negative number and this indicates a greater extracellular 
cationic entry across the sarcolemma (i.e. increased RCaE). p.G2434R and p.R2454H 
myotubes had a significant enhancement in the extracellular cationic entry relative to MHN 
(*P=0.02, ****P<0.0001, Mann-Whitney test). (B) Data from (A) with the results of MHN 
pooled. Both MHS samples had a significant enhanced extracellular cationic entry relative to 
MHN (****P<0.0001, Kruskal-Wallis test with Dunn's multiple comparisons test). n= 67-124 
myotubes from multiple wells for each genotype, that were assayed over 6-9 days. 
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4.4.9 RCaE is Mediated by Non-Specific Cationic Channels 
In order to determine which channels were mediating the RCaE, the non-specific 
cationic channel blocker gadolinium (Gd3+) was used. 25 µM Gd3+ produced a 
relatively rapid reduction in the quench of the fluorescence (Figure 4.15A). The effect 
of Gd3+ is particularly apparent when comparisons are made between the slopes in 
each genotype before and after the application of Gd3+; slope A and D (p.R2454H 
MHS), slope B and E (MHN), and slope C and F (p.G2434R MHS). Here A-C 
represent the period pre-Gd3+ and D-F post treatment with this cationic channel 
blocker.  25 µM Gd3+ profoundly blocked the Mn2+ entry to near baseline levels in all 
three genotypes (P<0.0001, Kruskal-Wallis test with Dunn’s multiple comparison test, 
n=30-51, Figure 4.15B). The median slope of the quench in MHN post Gd3+ treatment 
decreased by 91.7 % from -0.12 (-0.07 to -0.19) AFU/s to -0.01 (0 to -0.08) AFU/s, 
whereas the block was even more profound in MHS (decreased by 100%). In 
p.R2454H median slope decreased from  -0.19 (-0.01 to -0.37) AFU/s to 0 (0 to -0.01) 
AFU/s and in p.G2434R from -0.17 (-0.11  o -0.29) AFU/s to 0 (0 to -0.06) AFU/s.   
 
The difference in the Fura-2 quench pre- and post- Gd3+ was compared between the 
two genotypes (Figure 4.15C), the results were found to be normally distributed and 
thus compared using a t-test. Myotubes containing the p.R2454H variant had a much 
greater sensitivity to 25 µM Gd3+ with a mean (± SEM) change in the gradient 
of -0.25 ± 0.03 AFU/s compared with -0.17 ± 0.02 AFU/s in p.G2434R (P=0.038, 
unpaired two-tailed t-test, n=30-39). 
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Figure 4.15: The cationic entry is mediated by non-specific cationic channels. (A) 
Representative traces showing the effect on the Fura-2 fluorescence seen in MHN, p.G2434R 
and p.R2454H MHS myotubes upon the addition of MnB followed by 25 µM Gd3+ in MnB. The 
non-specific cationic channel blocker Gd3+ induced a rapid and profound decrease in the 
cationic entry as evidenced by change in the gradient of the lines A-C versus D-F. Lines A-C 
represent the slope of the quench when MnB was perfused onto p.R2454H, MHN and 
p.G2434R myotubes respectively, and lines C-D the slope in these  genotypes following the 
addition of 25 µM Gd3+. (B) Application of 25 µM Gd3+ to each of the three genotypes caused 
a significant decrease in the rate of Mn2+ quench; this suggests that cationic channels are 
mediating the observed RCaE. (****P<0.0001, Kruskal-Wallis with Dunn’s multiple comparisons 
test). (C) Bar chart showing an enhanced sensitivity to Gd3+ in p.R2454H myotubes relative 
to p.G2434R. In each myotube the change in the slope pre-and post Gd3+ was calculated, the 
mean of this change was compared in the two MHS genotypes (*P=0.038, unpaired two-tailed 
t-test).  n=30-51 myotubes from multiple wells for each genotype, that were assayed over 4-5 
days. 
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4.4.10 RCaE is Mediated by TRPC Channels 
Next, in order to test the hypothesis that TRPC channels were mediating the 
enhanced RCaE, the TRPC3, 6 and 7 blocker SAR7334 was used. The perfusion of 
myotubes with MnB containing 250 nM SAR7334 caused a relatively rapid decrease 
in the Mn2+ entry in MHS (both p.R2454H and p.G2434R) but not MHN myotubes 
(Figure 4.16A and B). In MHS myotubes the median slope decreased from a pre-
SAR7334 of -0.31 (-0.21 to -0.47) AFU/s, to -0.21 (-0.10 to -0.36) AFU/s post- 
SAR7334 (Figure 4.16B; P=0.046, Kruskal-Wallis test with Dunn’s multiple 
comparison, n=25). In MHN myotubes SAR7334 treatment caused a decrease in the 
slope from -0.19 (-0.12 to -0.30) AFU/s to -0.16 (-0.07 to -0.24) AFU/s, but this was 
not statistically significant (P=0.480, Kruskal-Wallis test with Dunn’s multiple 
comparison, n=19).  
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Figure 4.16: MHS myotubes have an enhanced sensitivity to SAR7334.   
(A)Representative traces indicating the effects of applying 250 nM SAR7334 on the 
fluorescence quench rate in the MHN (green) and MHS (red). In each genotype, line A and B 
represent the slope pre- and post-SAR7334 treatment. (B) Box-plots showing the effects of 
250 nM SAR7334 in MHS and MHN myotubes. SAR7334 triggered a significant reduction in 
the Mn2+ quench rate in MHS p.G2434R and p.R2454H myotubes, but not MHN myotubes. 
**P<0.01, Kruskal-Wallis with Dunn’s multiple comparisons test. n=19-25 myotubes from 
multiple wells for each genotype, that were assayed over 3 days. 
B 
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4.5 Discussion  
The aim was to investigate whether the weaker phenotype observed with p.G2434R 
was based on differences in sensitivity to caffeine and sarcolemmal calcium handling 
in myotubes containing this and the p.R2454H variants.   Myotubes heterozygous for 
these variants were found to have and enhanced sensitivity to caffeine a direct 
agonist of RYR1. Human myotubes were then used to show the presence of 
differential handling of divalent cations (i.e. Ca2+) in the MHS myotubes relative to 
MHN. This enhancement in the entry of extracellular Ca2+ i.e.  RCaE was shown to be 
mediated by cationic channels with some preliminary data suggesting human TRPC3 
and 6 channels were involved. 
 
4.5.1 Sensitivity to Caffeine in Human MHS Myotubes 
4.5.1.1 Culture and Production of Myotubes 
In order to identify appropriate samples to be used for this study, the UK MH database 
was screened for the availability of myoblasts from patients that would allow 
comparisons to be made between individuals carrying a certain variant and close 
family members who did not carry the variant of interest. This was achieved for 
p.G2434R, but not p.R2454H where such comparisons were limited by the availability 
of such patient samples, as well as the quality of myoblasts and myotubes that could 
be produced from the samples available. The non-relatedness in the MHN and MHS 
samples used for the studies with p.R2454H may have meant that there was a greater 
genetic heterogeneity in the responses which lowered the differences in the response 
to caffeine between the two samples. However, it is difficult to estimate the effect of 
the non-relatedness in these p.R2454H MHS and MHN samples as detailed genetic 
analysis were not perform to identity the % of alleles in common. Although, when 
comparisons were made for the sensitivity to caffeine between the MHN samples 
from families with p.R2454H and p.G2434R, no significant difference was found in 
the EC50.  
 
All the samples used had myoblasts of a sufficient purity to produce myotubes, this 
was demonstrated by both the presence of a high proportion of desmin positive cells 
(i.e myoblasts), as well as the production of multinucleated myotubes that express 
MYH. The purities of the cells used were comparable between MHN and MHS groups. 
Matrigel was found to to produce higher quality myotubes with the human myoblasts 
used in this study relative to the ECL matrix.  Both Matrigel and ECL are reconstituted 
basement membrane preparations that are extracted from Engelbreth-Holm-Swarm 
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mouse sarcoma. Matrigel is rich in extracellular matrix proteins with the 
predominance of laminin (60%), type IV collagen (30%) and entactin (8%) (BD 
Lifesciences). Matrigel also contains growth factors such as epidermal growth factor 
and insulin like growth factors, the latter play an important role in myoblast 
differentiation and muscle hypertrophy (Tollefsen et al., 1989; Vandenburgh et al., 
1991). A growth factor reduced version was used in this study as this has been shown 
to result in an increased polymerisation of the matrix. Enhanced polymerisation leads 
to an ECM with a larger Young’s modulus. A modulus in the range that is present in 
native tissue is associated with a more developed cell morphology (Engler et al., 
2004). Technical information regarding the concentrations of growth factors or 
alterations to the preparations extracted from the sarcoma are not available from 
Merck who produce the ECL matrix, therefore direct detailed comparisons cannot be 
made. The higher concentration of Matrigel (11.3 µg/cm2) used relative to ECL (1.3 
µg/cm2) is the most likely explanation for the higher quality of myotubes produced 
using this matrix. Studies have shown that higher concentrations of proteins in 
particular laminin are essential for migration as well as proliferation of mouse and 
human myoblasts (Ocalan et al., 1988; Chowdhury et al., 2015; Soriano-Arroquia et 
al., 2017). A higher concentration of proteins would create an extracellular matrix with 
a larger Young’s modulus.  
 
The experiments investigating the differentiation of human myotubes, found that there 
was no significant difference in the fusion index between 7, 10 and 13 days. This was 
consistent with the results of some who have found that after 4 days of differentiation, 
myotubes were mature with the expression of contractile proteins and actin cross-
striations (Van der Ven et al., 1992). However, others report an increase in contractile 
protein expression with peak levels between day 10-12 (Stern-Straeter et al., 2011). 
As a result of this, calcium imaging studies were performed on myotubes that had 
been differentiated for 10-13 days. 
 
4.5.1.2 Enhanced Sensitivity to Caffeine 
Myotubes are a validated method to study the physiology of skeletal muscle cells, 
however, a limitation of their use is the lack of the well-developed T-tubular system 
found in skeletal muscle fibres (Mendell et al., 1972). Nevertheless, the presence of 
functioning ECC was confirmed through the use of myotubes that had an increased 
fluorescence in response to the 60 mM KCl challenge. Caffeine exposure caused an 
increase in Fluo-4 fluorescence which then started to return to baseline whilst caffeine 
was still being perfused (Figure 4.6); one mechanism explaining this is the inhibition 
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of further Ca2+ release by the increasing [Ca2+]i. RYR1 is known to have a biphasic 
response to Ca2+, at low µM cytosolic Ca2+concetrations RYR1 is activated through a 
high affinity Ca2+ site (Laver et al., 1997a; Lamb, 2000; Laver et al., 2004), but 
becomes inactivated at high mM cytosolic Ca2+ concentrations acting at a low affinity 
site (Melzer et al., 1995; Laver et al., 1997a; Lamb, 2000; Laver et al., 2004). Other 
sources for this decrease in fluorescence during caffeine perfusion is the active 
transport of Ca2+ back into the SR via the SERCA pumps and/or Ca2+ extrusion out of 
the cell by PMCA and NCX pumps (Brini and Carafoli, 2011).  
 
The data were normalised to 20 mM caffeine to overcome known limitations of non-
ratiometric dyes such as Fluo-4AM, these include changes in the raw fluorescence 
signal due to subtle differences in cellular dye-loading, the focal plane of the 
microscope, the efficiency of dye de-esterification and dye extrusion 
(Helmchen, 2011).  
 
This is the first time that human MH myotubes containing the p.G2434R and 
p.R2454H variants found within the central part of RYR1 have been assessed for 
their concentration-response to caffeine. Previous publications that have examined 
both of these variants have utilised HEK cells (Tong et al., 1997; Murayama et al., 
2016).  On the other hand, human studies have either investigated other RYR1 
variants, only examined responses to halothane, used a single caffeine 
concentration, not used both variants nor stratified the responses according to the 
variants (Censier et al., 1998; Girard et al., 2001; Girard et al., 2002; Kobayashi et 
al., 2011). In the current study, there was an enhanced sensitivity to caffeine in MHS 
myotubes with an EC50 1.8 – 2.2 mM relative to MHN which had EC50 of 3 mM. The 
primary outcomes used to assess the sensitivity of the myotubes to caffeine in this 
chapter were the AUC data. AUC integrates various process involved in the Ca2+ flux 
over a set time period which provides a more dynamic output that includes the effect 
of the SERCA pumps, retrograde regulation of the DHPR, and the inhibition of the 
RYR1 by the raised [Ca2+]i. In contrast, the peak response provides a snapshot of the 
maximum release of Ca2+, which is useful when attempting to determine the highest 
[Ca2+]i during a response. Nevertheless, both the AUC or peak data revealed a similar 
caffeine EC50. This enhanced sensitivity to caffeine is consistent with what was 
expected from previous IVCT results for the patients from whom the samples were 
isolated, as well as with the previous published literature on these variants, and 
reinforces these variants being listed as a diagnostic variant for MHS (Richter et al., 
1997; EMHG diagnostic mutations, 2019).  
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The EC50 of around 3 mM caffeine found in MHN myotubes determined using the 
AUC is consistent with that seen in mouse myotubes containing wildtype RYR1 as 
reported by other authors (Weiss et al., 2004; Yang et al., 2003). However, some 
have reported higher values in wildtype mouse RYR1 (Eltit et al., 2012; Lopez et al., 
2018). Part of these variations are likely to be a result of the methods used to 
determine the EC50, and particularly how the data were normalised. Although the EC50 
values for human MHS and MHN are greater than that seen in some HEK studies 
(Murayama et al., 2016; Tong et al., 1997). A major reason for these differences is 
that relative to HEK cells, skeletal myotubes express a greater number of proteins 
that are important in muscle ECC thus affecting the overall cellular response. An 
example of this is seen in studies by Tong et al., (1999) who discovered that when 
HEK cells were transfected with both SERCA and wildtype RYR, this increased the 
EC50 of caffeine from 1.5 mM to 3 mM. The latter value is consistent with the EC50 I 
found in MHN myotubes where both SERCA and RYR1 are present. Furthermore, 
they also revealed that the addition of SERCA increased the caffeine EC50 in the 
p.Y522S MH variant from 0.7 mM to 1.4 mM, the later was significantly lower than 3 
mM  observed in HEK cells co-expressing wild type RYR1 with SERCA (Tong et 
al.,1999). This revised HEK model produced results that were consistent with my 
findings in the human myotubes.  
 
In this study two different patient samples were used for p.R2454H, and as there was 
no statistical difference in their caffeine EC50 the data was pooled. It would be 
interesting to explore further if the caffeine sensitivity in myotubes from different 
individuals carrying the same variant is consistent. Assessing more samples for each 
variant would also allow detailed comparisons on the effects of the different RYR1 
MH variants have on the sensitivity of the channel to agonists. It would be fascinating 
to examine other variants that are known to produce a stronger phenotype which also 
have an animal model, for example p.R163C (Yang et al., 2006). The p.R163C mice 
have been shown to have a high resting [Ca2+]i, and humans carrying this variant 
have been shown to have a stronger response on the IVCT (Yang et al., 2006; 
Carpenter et al., 2009). Correlating animal models with the findings in human samples 
would help identify perturbed Ca2+ mechanisms that are preserved across species.  
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As mentioned earlier, although there was a genotype dependent trend in sensitivity 
to caffeine with p.R2454H having the greatest sensitivity, this was not statistically 
significant. These data are consistent with those found in studies using HEK models 
(Murayama et al., 2016), or those assessing the metabolic response to an in vivo test 
of caffeine (Anetseder et al., 2002). Murayama et al., (2016) undertook a major study 
to examine the genotype-phenotype correlations using HEK cells with variants that 
included p.G2434R and p.R2454H. In their experiments both these variants had a 
similar EC50 of caffeine (approximately 0.6 mM) which was significantly lower than 
that found with wildtype RYR1 (1.5 mM). On the other hand, my findings contrast the 
UK IVCT differences found with these variants using human skeletal muscle fibres 
(Carpenter et al., 2009). It is plausible that there were an insufficient number of 
p.G2434R myotubes investigated resulting in an underpowered statistically analyses. 
Consequently, further repeats with this variant would help clarify this. On the other 
hand, it may be that the differences seen in the IVCT are not translatable to myotubes 
particularly when using caffeine as the RYR1 agonist. Experiments using the potent 
RYR1 agonist 4-chloro-m-cresol (4-CMC) and halothane would be helpful in 
confirming or refuting the results of this study.  
 
Another possible reason for the difference in Ca2+ handling seen between myotubes 
and the skeletal muscle fibres used in the IVCT, is that the former are developmentally 
more immature. This would also explain the lack of difference observed in the HEK 
study (Muruyama et al., 2016). In addition, the caffeine sensitivity may also be too 
crude a marker for the genotype-phenotype differences observed between these two 
variants. Indeed a highly valuable experiment would be to use microelectrodes to 
directly measure the [Ca2+]i found in both human p.G2434R and p.R2454H myotubes 
as well as fibres. One would hypothesise if the variant dependent differences on the 
IVCT hold true, then the p.G2434R would have a lower [Ca2+]i relative to p.R2454H. 
Indeed mouse studies using a novel knock-in mouse model that has the equivalent 
RYR1 variant (p.G2435R) was found to have a lower [Ca2+]i in both heterozygous and 
homozygous mice, as well as a weaker phenotype relative to mice carrying p.R163C 
(Yang et al., 2006, Lopez et al., 2018). Consistent with this hypothesis, Muruyama et 
al., (2016) have explored the [Ca2+]i in HEK cells containing p.R2454H and p.G2434R 
using Fura-2, and found only the former had a significantly elevated [Ca2+]i relative to 
wildtype. However the measurement of absolute [Ca2+]i using a dye that is derived 
from a Ca2+ buffer 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid 
(BAPTA), can affect the measured [Ca2+]i, and thus makes this data less robust 
(Rudolf et al, 2003). Instead Lopez et al., (1985) have directly measured the [Ca2+]i in 
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human skeletal muscle fibres using microelectrodes and discovered a much higher 
[Ca2+]i in MHS over MHN fibres. These results have also been consistently found in 
mouse MH models (Yang et al.,2006; Yuen et al., 2012; Lopez et al., 2018). 
Unfortunately, Lopez et al., (1985) did not investigate the effect of human MH variants 
on the [Ca2+]i. 
 
4.5.1.3 Lower Peak SR Ca2+ Release 
In order to grossly examine whether MHS myotubes have reduced SR Ca2+ stores, 
the absolute SR Ca2+ was determined by looking at the change in fluorescence from 
baseline on exposure to 20 mM caffeine. The results revealed that MHS myotubes 
had a significantly reduced peak fluorescence compared to MHN myotubes. The 
reduced fluorescence suggests that less Ca2+ was released from the SR which is 
consistent with the SR stores being smaller in MHS myotubes, in line with the findings 
of others groups (Tong et al., 1999; Chelu et al., 2005; Manno et al., 2013; Murayama 
et al., 2016). A smaller SR store is consistent with a variant mediated leakier RYR1 
protein. However, this conclusion is tentative as there are many confounders that 
would affect the results including the amount of dye loaded. A more objective 
assessment of SR stores could be made using ratiometric fluorescent dyes or more 
SR specific/genetically encoded fluorescent probes.  
 
 
4.5.2 RCaE in Human MHS Myotubes 
The key findings of the experiments investigating the RCaE in p.G2434R myotubes 
are: 
1. RCaE was present in both human MHS and MHN myotubes. 
2. The RCaE was significantly elevated in both p.R2454H and p.G2434R MHS 
myotubes, and this was variant independent.  
3. Gd3+ profoundly abolished the RCaE in both human MHS and MHN myotubes 
with p.R2454H having a greater sensitivity.  
4. There was a genotype dependent effect of known TRPC3/6 antagonists. 
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4.5.2.1 Enhanced RCaE in Human MHS 
The importance of extracellular Ca2+ entry in skeletal muscle cells in physiological 
and pathological states in humans is being increasingly recognised (Duke et al.,2010; 
Cully et al., 2018). In the current study the Mn2+ quench assay demonstrated that 
there was a cationic influx from the extracellular space occurring in both MHN and 
MHS. The most likely cation to mediate this is Ca2+ (Merrit et al., 1989; Hofmann et 
al., 1999; Kurebayashi and Ogawa, 2001).  This entry was present in the resting state 
of the cells and is thus classed as RCaE instead of the traditional SOCE, as in the 
latter, severe SR store depletion is required to trigger the extracellular Ca2+ entry 
(Kurebayashi and Ogawa, 2001). Human MHS myotubes had an enhanced RCaE 
relative to MHN, with the RYR1 MH variant not found to affect the magnitude of the 
RCaE. The MH RYR1 variant independence in the enhanced RCaE is consistent with 
the aforementioned results examining the differences in caffeine sensitivity. The 
existence of a RCaE that is elevated in human MH is a novel finding which provides a 
potential mechanism that explains how human MH cells are able to maintain an 
elevated [Ca2+]i and thus fulfil the cell boundary theorem. Other groups who have 
reported the presence of extracellular Ca2+ influx in human MHS cells, have done so 
in stimulated, store depleted skeletal muscle fibres, and not in the non-triggered state 
(Duke et al.,2010; Cully et al., 2018).  
 
4.5.2.2 TRPC Channels Mediate the Enhanced RCaE  
Gadolinium is a trivalent ion which has a high charge density and a similar ionic radius 
to Ca2+. It is known to block cationic channels that allow the permeation of Ca2+, and 
has previously been shown to inhibit the influx extracellular cations in MHS and non-
MHS cells in a concentration dependent manner (Vandebroucka et al., 2002; Eltit et 
al., 2013). I sought to use this at the higher concentration of 25 µM to help determine 
whether there was a decrease in the RCaE as measured by the Mn2+ quench assay. 
The profound block observed with Gd3+ suggested that non-specific cationic channels 
were indeed mediating the RCaE as has been observed in mice (Eltit et al., 2013). The 
largest effect of Gd3+ was observed in MHS myotubes, particularly with the p.R2454H 
which had a much larger change in the median quench upon application of Gd3+. The 
enhanced sensitivity to Gd3+ in MHS particularly p.R42454H suggests that MHS 
myotubes may have an altered expression and/or function of the cationic channels 
that are mediating the extracellular cationic entry. However, this MHS variant specific 
difference was not observed in the baseline RCaE. It maybe that the MHS variant 
specific differences were too small to detect on the RCaE due to the known variability 
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in Mn2+ quench experiments, or that the MHS variant dependent sensitivity to Gd3+ 
was the result of a type 2 error.  
 
As it was hypothesised that TRPC3 and 6 channels mediate an enhanced RCaE, 
SAR7334 a TRPC3 and 6 antagonist was applied to the myotubes (Maier et al., 
2015). A concentration of 250 nM was used as this would affect TRPC6 channels 
preferentially given that these channels exhibit an IC50 of 9.5 nM compared to 282 nM 
for TRPC3. (Maier et al., 2015). Consistent with my hypothesis, there was a genotype 
dependent difference in the SAR7334 inhibition, with MHS having a significant 
decrease in the quench.  In contrast, there was no significant effects of SAR7334 on 
the quench in MHN. This supports a differential activity/expression of TRPC3 and 6 
channels in human MHS myotubes, and this is consistent with the data observed with 
Gd3+. There were insufficient myotubes per MHS group to allow assessment of the 
MHS RYR1 variant specific difference. Further repeats would help address these 
limitations, as would investigating the effects of other compounds active at TRPC3/6 
channels such as the novel and more selective antagonists GSK417651A or 
GSK2293017A, as well as GSK1702934A a recently discovered agonist (Xu et al., 
2013). Western blot studies would help elucidate whether there is a difference in 
TRPC3/6 protein expression, or whether the differences are due to changes in activity 
of these channels. It would be interesting to examine what is mediating the enhanced 
RCaE observed in MHS tissue, the most likely cause is the postulated increased RYR1 
leak that has been reported in other studies into MHS RYR1 variants (Yang et al., 
2006b; Andersson and Marks 2011). This leak would result in an elevated [Ca2+]i 
which according to the cell boundary theorem would need to involve changes in the 
sarcolemmal Ca2+ handling. Indeed, Eltit et al. (2011) have published evidence using 
dyspedic (lack expression of RYR1) skeletal myotubes that indicates the basal 
sarcolemmal Ca2+ influx contributes to the regulation of the resting [Ca2+]i, and is itself 
is governed by RYR1 expression. 
 
The work investigating the RCaE in human MHS myotubes should be seen as 
preliminary results that point to future avenues of research. However, the scope of 
future mechanistic studies that can be performed using these human primary 
myoblasts, is restricted by the limited proliferative potential seen in primary human 
myoblasts. Two potential solutions that can overcome these limitations are the 
immortalisation of human myoblasts, or the use of animal models. The former has 
been reported before and will be explored in the next chapter (Mamchoui et al., 2011), 
with the later approach utilised in the chapter 6. 
 117 
4.6 Conclusion 
In summary, the results above demonstrate that human myotubes containing the 
diagnostic MH RYR1 variants p.G2434R and p.R2454H have an both an enhanced 
sensitivity to caffeine as well as elevated influx of extracellular Ca2+. The magnitude 
of this caffeine sensitivity or Ca2+ influx was not dependent on the type of variant. This 
enhanced Ca2+ entry appears to be mediated by TRPC3 and 6 channels, however 
further studies are required to investigate this in detail, and to see whether this 
perturbed Ca2+ handling is also observed in other species. 
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Chapter 5. The Immortalisation of Human Skeletal 
Myoblasts  
 
5.1 Introduction 
5.1.1 Skeletal Muscle Stem Cells 
Skeletal muscle has an incredible capacity to regenerate in vivo in response to injury 
through the activation of the quiescent satellite cells which reside under the basal 
lamina of the muscle fibres (Mauro, 1961; Shafiq et al., 1967). These adult skeletal 
muscle stem cells are known to be the main myogenic progenitors, and when they 
expand into committed progenitors they are known as myoblasts (Snow, 1978, 
Bischoff 1986, Yin et al., 2013). Myoblasts can participate in the regenerative process 
by fusing with either pre-existing myofibers or other myoblasts, and in the latter case 
differentiate to form skeletal muscle myotubes (Kuang et al., 2008). This fusion is cell-
type specific, with myoblasts only fusing with myogenic cells (Wakelam, 1985). The 
myotubes then undergo further maturation to form skeletal muscle fibres that have an 
intact T-tubular system. As human satellite cells commit and differentiate into the 
myogenic line, they express different factors such as Pax7, myf5, and MyoD (Seale 
et al., 2000; Buckingham, 2007; Lecourt et al., 2010). Many of these proteins have 
been used to identify, characterise and purify skeletal muscle cells, as well as to 
transform cells from a non-myogenic fibroblast lineage into a skeletal muscle lineage 
(Rovina et al., 2019).  
 
The isolation of myoblasts is often impeded by the presence of other skeletal muscle 
cells particularly fibroblasts which can outgrow the myoblasts (Boldrin et al., 2010). 
Different techniques have been proposed to help improve the myogenic purity of 
isolated cells. The simplest technique that is independent of any specialist equipment 
is to preplate the cells (Rando and Blau, 1994).  This process involves plating the cell 
slurry that has been isolated from skeletal muscle onto uncoated plastic plates, the 
cells are allowed to settle for 30 min or longer, after which the media is moved to 
another plate, with the process repeated several times. This exploits an enhanced 
binding observed with fibroblasts, and can produce a 95 % pure myoblast population 
(Rando and Blau, 1994; Springer and Blau, 1997). Another approach is to use 
magnetic activated cell sorting (MACS); here an antibody specific to an antigen of 
interest is conjugated to a magnetic bead, the antibody binds to the antigen and a 
magnet helps purify the bead:cell complex. An alternative method is fluorescent 
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activated cell sorting (FACS); this also exploits antibody labelling, but combines this 
with interrogating the light scattering characteristics of individual cells and thus allows 
for diverse cell sorting strategies. Although FACS requires more specialist equipment 
relative to MACS, the latter does not directly allow single cell sorting for the generation 
of monoclonal populations. 
 
The proteins CD56 and melanoma cell adhesion molecule (MCAM, also known as 
CD146) are antigens that have been used to isolate and purify myogenic cells 
(Schubert et al., 1989; Mechtersheimer et al., 1992; Cerletti et al., 2006; Lecourt et 
al., 2010; Mamchaoui et al., 2011; Snijders et al., 2015; Alexander et al., 2016). CD56 
which is also known as neuronal cell adhesion molecule (N-CAM) or Leu-19, is a 
glycoprotein found within the immunoglobulin like cell adhesion molecule family 
(Fidziańska and Kamińska, 1995). It is expressed on the surface of myoblasts, 
neurons, glia plus natural killer cells of the haemopoietic system (Rutishauser et al., 
1988; Ziegler et al., 2017), and has a role in cell-cell adhesion during development as 
well as regulating interactions between neurons and skeletal muscle (Schubert et al., 
1989; Rutishauser et al., 1988). CD56 is the most common antigen used in the 
isolation of mice and human myoblasts (Boldrin et al., 2010; Mamchaoui et al., 2011), 
however within these isolates, there are different subpopulations which have varying 
abilities to differentiate into myotubes (Lecourt et al., 2010, Alexander et al., 2016).  
 
5.1.2 The Regenerative Potential of Myoblasts 
Primary human satellite cells have a significant regenerative potential in vivo, 
however this proliferative capacity is limited in vitro by cellular senescence (Di Donna 
et al., 2003). Two major mechanisms underlie this senescence, one involves the p16-
mediated cellular stress pathway, the other is a shortening of the telomeres (Wright 
and Shay, 2002; d’Adda et al. 2003; Stadler et al., 2011). In the former pathway, the 
binding of p16 to cyclin dependent kinase 4 (CDK4) inhibits the ability of the latter to 
facilitate the progression from the gap 1 (G1) to the synthesis (S) phase of the cell 
cycle and thus stops the cell cycle (Wright and Shay, 2002). In the second major 
pathway, the shortening of telomeres during the cell cycle leads to critically short 
telomeres, this causes enhanced cellular stress and DNA damage which 
subsequently leads to an irreversible arrest in cell proliferation (d’Adda et al. 2003). 
However, it has been shown that this replicative senescence can be overcome 
through viral mediated gene delivery of two genes. The first gene (CDK4 R24C) 
encodes a mutated form of the CDK4 protein rendering it insensitive to p16, the other 
(hTERT) encodes the human telomerase reverse transcriptase catalytic subunit 
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which is known to facilitate telomere elongation (Di Donna et al., 2003; Zhu et al., 
2007; Mamchaoui et al., 2011; Stadler et al., 2011; Robin et al., 2015). This system 
has allowed an increase in the population doublings from 20 in primary myoblasts to 
over 200 in their immortalised counterparts (Mamchaoui et al., 2011; Stadler et al., 
2011). 
 
5.1.3 Retroviral Gene Delivery 
Gene delivery has now become a highly useful technology in basic life science 
research as well as in regenerative medicine.  The ability to deliver genes that result 
in the suppression of aberrant proteins, or enhancement/replacement of insufficient 
proteins has enormous utility in different diseases. Viruses are a common method 
used for gene delivery, with several different viral systems in existence. The 
γ-retroviral system uses an adapted RNA virus, the murine leukaemia virus (MLV) to 
deliver the gene(s) of interest. This virus uses a reverse transcriptase to generate a 
DNA provirus which with the assistance of an encoded integrase protein, becomes 
randomly integrated into the genome of the host cell (Maetzig et al., 2011). This 
system can be used to package large amounts of DNA (up to 8 kilobyte), which when 
incorporated into the host cell, confer long-term expression of the trans-gene. To 
ensure biological safety, the retroviral system has been adapted to only function when 
several different retroviral components are combined in trans (Maetzig et al., 2011). 
The key components are a cell line or plasmid that contains the viral packaging genes, 
a plasmid that contains the envelope gene and a transfer plasmid that encodes the 
transgene of interest (Cooray et al., 2012). In this chapter, the two genes are CDK4 
R24C and hTERT, each of these is packaged with a different antibiotic selection 
maker. The envelope gene allows the control of viral tropism with vesicular stomatitis 
virus glycoprotein (VSV-G) providing the widest cellular tropism, and this includes 
infecting skeletal muscle cells (Burns et al., 1993). Replication incompetent viruses 
are then produced by the packaging cells and used to infect the target cells (Springer 
and Blau, 1997).  Employing a cell line that stably expresses the viral packaging 
genes helps reduce the number of plasmids required; this simplifies the generation 
of viral particles, increases transfection efficiency and enhances viral titres (Cooray 
et al., 2012).  
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5.1.4 Models of MH 
Previous studies examining the molecular mechanisms underlying the MH reaction 
have been restricted in their scope due to the use of either primary human muscle 
cells and tissue, mouse models, or HEK cells.  Each of these systems has certain 
limitations.  Certain MH mouse models have shown a different phenotype to that seen 
in humans, for example the RYR1 channel in cells from the R163C mouse model of 
MH did not have an altered sensitivity to the inhibitory effects of magnesium or high 
calcium concentrations, whereas it did in human MH (Feng et al., 2011).  
 
The porcine stress syndrome (PSS) in pigs also provides another animal model of 
MH, however this too has some differences (Fujii et al., 1991). The first is that this is 
an autosomal recessive condition in pigs, versus the autosomal dominant found in 
humans (Fujii et al., 1991; Denborough, 1998). Other differences include the ability 
of stress to trigger a hypermetabolic response in PSS, but this is not observed in MH 
(Hopkins, 2011). Furthermore, only one RyR1 mutation (R615C) accounts for all PSS 
cases, yet over 48 RYR1 variants are diagnostic for MH, and these have a greater 
phenotypic diversity (Fujii et al., 1991; Miler et al., 2018; EMHG diagnostic mutations, 
2019). Furthermore, the reaction observed in pigs appears to be different to that seen 
in MH, muscle rigidity is an early feature in the porcine model, but late in human MH 
(Jungbluth et al., 2016). Nevertheless, there are some advantages of using animal 
models, this includes a greater tissue availability, homogeneity in the genetic 
background in the knock-in models, and the potential to produce heterozygous and 
homozygous animals which permits the study of the effects of gene-dose. 
 
HEK cells are also commonly used in functional investigations into MH. Their utility 
prevents any harm to animals, they are very easily available, cheap and more 
amenable to genome editing. However, as these cells are derived from embryonic 
kidney cells and not muscle, they do not natively express the full complement of 
skeletal muscle proteins that play an important role in skeletal muscle physiology 
and/or the regulation of RyR1 (Thomas and Smart, 2005; Jiang et al., 2010). Use of 
the chemically immortalised C2C12 skeletal muscle cells overcomes some of the 
problems associated with HEK cells, such as their ability to differentiate into functional 
myotubes (Blau et al., 1985; Burattini et al., 2004). However, C2C12 are sub-optimal 
as they are derived from mice, are aneuploid, and the widespread use over 30 years 
with repeated passages has facilitated the  accumulation of numerous mutations of 
unknown significance (Blau et al., 1985). 
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Primary muscle cells are advantageous as they provide cells that are a true sample 
of the organism affected by the disease, contain the relevant genetic background and 
the full machinery to produce the native proteome. Such a model is particularly 
important when trying to investigate the molecular mechanisms that underlie the 
genotype and phenotype interactions that exist in human samples. However, the 
traditional limitation with these primary cells has been cellular senescence (Springer 
and Blau, 1997; Wright and Shay, 2002). This limits the number of functional assays 
possible, including restricting the ability to utilise technologies such as CRISPR-Cas9 
genome editing which require multiple cell replication events. The immortalisation of 
human myoblasts can overcome these limits, however to date there are no reports 
on the successful immortalisation of human MH cells. 
 
 
5.2 Aim 
 
To immortalise myoblasts isolated from MHS patients with the p.G2434R and 
p.R2454H RyR1 variants, as well as their MHN relatives using a J-retroviral system. 
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5.3 Methods 
5.3.1 Isolation of Human Skeletal Muscle Myoblasts  
This was performed as described in section 2.2.1. Primary skeletal muscle cells had 
previously been isolated from seven patients; three were MHS (two p.G2434R and 
one p.R2454H) and four MHN. Three of the four MHN samples were from members 
within the same family as those who were MHS.  
 
5.3.2 Fluorescence Activated Cell Sorting of Myoblasts 
Cells for FACS analysis were rapidly thawed from liquid nitrogen storage, spun at 300 
x g for 6 min, resuspended in proliferation media and grown in cell culture flasks up 
to a confluence of 60%. They were then trypsinised (TrpLE, Gibco, UK), rinsed in 
proliferation media, centrifuged at 300 x g for 5 min, washed twice with PBS, and 
blocked with 10% mouse serum plus 1 % human IgG (Sigma-Aldrich, USA) for 25 min 
at 4 qC. After further PBS washes, each sample was then split with an aliquot of 1 
x105 cells used as an unstained negative control. This was incubated in PBS with 
10 % FBS and 200 U/ml of pen/strep (FACS buffer). The remaining cells were 
incubated for 30 min at 4qC in the dark with the same solution plus 2.5µL per 106 cells 
of mouse anti-human CD56 antibody conjugated to allophycocyanin (APC; clone 
HCD56, Biolegend, USA). Cells underwent further PBS washes before being 
resuspended in FACS buffer at a density of 5 x 106 cells/mL. These were then filtered 
through a 70 Pm filter and stored on ice in the dark until analysis. The FACS staining 
was performed by me. 
 
The FACS sorting was performed by Dr Adam Davison and Liz Straszynski at St 
James’s Hospital, University of Leeds as part of the institutional FACS service. 
Unstained negative controls and CD56 stained samples were run on a BD InfluxTM 
cell sorter (BD Biosciences, USA) in the absence and presence of 7-
aminoactinomycin D (7-AAD, Biolegend, USA). Sorted cells were collected into 
proliferation media in several different formats including as a population of cells, or 
through an index sort as either a single cell or multiple cells (5, 20, 50 100) per well 
within a 96-well plate format.  Monoclonal and polyclonal colonies were then 
expanded until 60% confluence in a T75 flask, after which they were stored in liquid 
nitrogen as mentioned above. This CD56 based FACS sorting was performed either 
before or after viral immortalisation of the primary human skeletal muscle cells.  
In a further FACS purification experiment, immortalised cells were sorted based on 
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the presence of CD56 and CD82. The protocol for this was similar to above, except 
cells were stained with both 2.5µL/106 cells anti-CD56-APC and 20uL/106 cells anti-
CD82-phycoerythrin (PE; clone ACL-24, Biolegend, USA) antibodies. Fluorescence 
compensation beads (CompBead, BD Biosciences, USA) were used to 
mathematically compensate for spectral overlap between the APC and PE 
conjugated antibodies, and this was done as per the manufacturer’s 
recommendations.  
 
 
5.3.3 The Immortalisation of Myoblasts  
5.3.3.1 Plasmid Maxi-Preparation 
The J-retroviral plasmids containing pCMV-VSV-G, pBABE-hygro CDK4 R24C, 
pBABE-puro hTERT (plasmid # 8454, 11254, and 1771) and pBABE green 
fluorescent Protein (GFP, plasmid # 10668) were obtained in DH5D competent E.coli 
cells  from the Addgene repository (Addgene, USA). The former three were a gift from 
Bob Weinberg, and the pBABE-GFP was a gift from William Hahn. Plasmids were 
isolated as described in 2.4.2. 
 
5.3.3.2 Antibiotic Selection Assays 
Skeletal muscle cells were plated in replicates of two or three wells at a density of 
4 x 104 cells per well on a 24 well plate. After reaching 40-50 % confluence, the 
relevant antibiotic containing proliferation media was added to the solution, and 
refreshed every 2-3 days. The antibiotics tested were hygromycin (0-500 Pg/ml; 
ThermoFisher, USA) and puromycin (0-2 Pg/ml, Gibco, USA). Furthermore, the 
cytotoxic effects of a 24 hr continuous treatment with the transduction agents 
diethylaminoethyl dextran (DEAE-D, 0-50 Pg/ml; Sigma-Aldrich, USA) and protamine 
(0-20 Pg/ml; Sigma-Aldrich, USA) were also assessed. The media was changed 
regularly every 2-3 days.  
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5.3.3.3 Generation of Viral Particles 
HEK-GP2 cells (Clontech, USA), were freshly plated (2 – 20 x 104 cells per well) on 
ECL coated 24-well plates in DMEM containing 10% FCS and 2 x pen/strep on the 
day prior to transfection. The GP2 cells were then transfected with the 
aforementioned plasmids using the Turbofect transfection reagent (ThermoFisher, 
USA) as per the recommendations of the manufacturer. The media was changed at 
24, 48, 72, and 96 hr. The media from the latter three time points was collected for 
the transduction of myoblasts. This was filtered through a 0.45 Pm filter, mixed with 
RetroX concentrator (Clontech, USA) and incubated overnight at 4 °C. On the 
following day, the solution was centrifuged at 1500 x g for 45 min at 4 qC, finally the 
pellet was re-suspended in 1 – 1/10 the original volume of proliferation media. This 
was then briefly spun at 500 x g for 10 min at 4 qC, and then used to transduce the 
myoblasts. 
 
5.3.3.4 Transduction of Myoblasts 
Myoblasts were plated on the day prior to transduction at a density of 2 x 104 cells per 
well on a 12-well plate, and left overnight in the incubator. Myoblasts were then 
incubated with the concentrated viral solution containing hTERT and/or CDK4 R24C 
in the presence of either DEAE-D (5 Pg/ml) or protamine (10 Pg/ml). Following 
transduction, fresh proliferation media was added and cells allowed to recover for at 
least 48 hr before commencing antibiotic selection using either puromycin (0.3 Pg/ml) 
and/or hygromycin (50 Pg/ml). Selection continued for a minimum of 14 days, 
however during this period the cells were trypsinised and moved to a larger plate/flask 
as necessary to ensure the confluence did not exceed 60 %. Cells were visualised 
with a Zeiss Axiovert 135 microscope using phase-contrast light microscopy or 
fluorescent microscopy with GFP filter sets.  
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5.3.4 Immunocytochemistry 
Non-immortalised cells (from section 5.3.1) and immortalised cells were differentiated 
on ECL coated slides (section 2.2.4.2), these were then stained as described in 
section 2.5.  Non-specific binding was blocked through a 10 min incubation with 5 % 
normal donkey serum (Sigma-Aldrich, USA).  
 
5.3.4.1 Desmin Staining 
The antibodies used were mouse anti-human desmin primary antibody (dilution 1:25 
- 1:50; clone D33, DAKO, UK), and donkey anti-mouse secondary antibody 
conjugated to Texas Red (1:500; ThermoFisher, UK). AB1167C2 cells were used as 
a positive control.  These monoclonal cells were generated following the 
immortalisation of human skeletal myoblasts from a healthy individual by the team of 
Dr V Mouly (Centre for research In Myology, INSERM) who kindly gifted them 
(Mamchaoui et al., 2011). These cells had been phenotyped by the host laboratory 
who had demonstrated the ability of the cells to still differentiate into myotubes despite 
undergoing 43 population doublings. 
 
5.3.4.2 Myosin Heavy Chain Staining 
Mouse anti-myosin heavy chain (MYH) antibody (1:20; MF-20, Developmental 
Studies Hybridoma Bank, Iowa, USA) was used as the primary, and goat anti-mouse-
AlexaFluor 488 as the secondary (5 µg/ml; AB_2535778, ThermoFisher, UK). 
 
5.3.5 RT-PCR for RyR1 
5.3.5.1 RNA Extraction 
Immortalised cells were plated and differentiated for 14 days as per 2.2. After 14 
days, the differentiation media was removed and 1 ml of TRIzol (ThermoFisher, USA) 
was added for 5 min at room temperature. The homogenate was removed and mixed 
with 0.2ml of chloroform for 3 min, then centrifuged at 15700 x g for 15 min at 4 ºC. 
The aqueous phase was extracted and mixed with 0.1 volumes of 3 M sodium acetate 
(pH 5.2) and 3 volumes of ice cold 100 % ethanol, then stored at -80 ºC overnight. 
The next day, the sample was centrifuged at 15700 x g for 30 min at 4 ºC, washed 
with ice cold 75% ethanol and centrifuged at 15700 x g for 10 min at 4 ºC. The ethanol 
was removed and the pellet resuspended in RNase free molecular biology grade 
water (ThermoFisher, UK). The purity and content of RNA was analysed using an 
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Agilent 2100 TapeStation System (Agilent, USA) as per the manufacturer’s 
recommendations. Samples with a RINe ≥ 8.5 were used for reverse-transcriptase 
(RT) PCR. DNase treatment (DNA-free, ThermoFisher, USA) was used to remove 
DNA contamination of the samples as per the manufacturer’s recommendations. 
 
 
5.3.5.2 RT-PCR 
Reverse transcriptase-PCR was performed on the samples using a high-capacity 
cDNA reverse transcription kit (4368814, Applied biosystems, ThermoFisher, UK) as 
per the manufacturers recommendations with the cDNA stored at -20ºC. 
 
5.3.5.3 PCR and Agarose Gel Electrophoresis 
The RYR1 cDNA was amplified by PCR using primers for exon 91 with a predicted 
fragment size of 257 base pairs. 40 ng of DNA was added to a 25 µL mix containing 
13.65 µL nuclease free, 2.5 uL 10 x buffer, 100 µM dNTPs, 2.5 µL DMSO, 2 µL 
Betaine, 0.5 Units Taq polymerase (DreamTaq, ThermoFisher, UK) and 20 pg each 
of forward and reverse primers with the sequence: 
 
Forward primer- 5’-GCCGGGCCCTGCGAGGCCTCA-3’ 
Reverse primer- 5’-GGTGGGGTCGGGCATGCCTGCC-3’ 
 
The thermocycler settings were: 
1 denaturation cycle: 94 ºC for 5 min, 30 amplification cycles: 94 ºC for 30 s, 62.2 ºC 
for 20 s, 72 ºC for 30 s, 1 completion cycle: 72 ºC for 5 min. The PCR product was 
run on an agarose gel as described in 2.3.2. 
 
5.3.6 Statistics 
All bar charts present the data as the mean ± SEM. Statistical analysis was performed 
using GraphPad Prism 7, a two-tailed unpaired t-test was used to determine 
significance which was accepted as P < 0.05. 
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5.4 Results 
5.4.1 The Immortalisation Process 
An overall summary of the workflow used in the subsequent sections during the 
immortalisation of human skeletal muscle cells is shown in Figure 5.1. All human 
skeletal muscle samples had been preplated prior to immortalisation. The majority of 
the MHS and MHN samples underwent both a FACS sort before and after 
immortalisation. However, an MHN sample that was used in the preliminary 
optimisation phase of the experiments, only underwent a FACS sort after 
immortalisation, whereas. In case the FACS sort was damaging to the myoblasts, a 
batch of non-FACS sorted cells were stored for each sample that had undergone the 
immortalisation process. 
 
 
Figure 5.1 : Schematic for the process of immortalising human skeletal myoblasts. This 
is a summary of the process used to immortalise human MHS and MHN cells. All samples 
were preplated initially, the majority also underwent FACS sorting pre- and post-
immortalisation, whereas some were only sorted after immortalisation, and others did not 
undergo any FACS sorting.  
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5.4.2 FACS Isolation of Human Myoblasts  
CD56 was used to identify myogenic precursor cells from the mixed skeletal muscle 
cell population. Figure 5.2 displays the data from a FACS purification for one MHS 
patient sample. 7-AAD was used to identify viable cells as which have a lower 
fluorescence as a consequence of the impermeability of 7-AAD across intact cell 
membranes. 91 % of the counts were found to be from live cells (Figure 5.2A). The 
background fluorescence in control samples not stained with the anti-CD56 antibody 
was negligible at 0.05 % of the total events (Figure 5.2B). The anti-CD56 stained 
sample contained two distinct cell populations that had an approximately 100-fold 
difference in their fluorescence intensities (Figure 5.2D), with CD56+ cells (i.e. 
myoblasts) accounting for 80 % of the live cells (Figure 5.2C, D and F).  
 
Figure 5.2: CD56 based FACS analysis of MHS skeletal muscle cells. Skeletal muscle 
cells from a patient susceptible to MH were stained with 7-AAD to identify the gating strategy 
for live cells (A). The negative control was not stained with anti-CD56 antibody and this was 
used to determine the background fluorescence (B). Live gated cells were sorted against the 
presence or absence of the CD56 antigen (C and D). Summary tables with the cell count 
results from unstained (E) and CD56 stained cells (F).  
A B
DC
E F
B 
C 
FSC 
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A summary of the data obtained from several FACS sorts of MHS plus MHN patient 
samples that subsequently underwent immortalisation are shown in Figure 5.3A. 
Overall there was a variation in the percentage of CD56+ cells obtained from each 
sample (Figure 5.3B-D). MHS samples had a greater proportion of CD56+ cells with 
a mean of 68 % relative to 44 % in MHN patients, although this was not statistically 
significant (P=0.13, n=3 and 4, respectively). In some samples the distribution of 
CD56 expressing cells identified two distinct populations (Figure 5.2D), however in 
other samples the expression was more evenly spread (Figure 5.3C and D). A lack 
of distinct populations was also observed after the immortalisation of previously 
unsorted cells (Figure 5.3E and F), and this was associated with a reduction in the 
proportion of CD56+ cells, however the sample numbers were insufficient to allow 
statistical comparisons.  
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Figure 5.3: The expression of CD56 in different MHS and MHN patient samples. (A)Table 
showing the % of live, CD56 positive and negative cells relative to the parent populations 
found during FACS purifications of human skeletal muscle cells. (B) The proportion of CD56+ 
cells purified in MHS and MHN samples were not significantly different, P = 0.13, unpaired 
two-tailed t-test, n=3-4 samples. Histograms show the CD56 antigen expression on primary 
non-immortalised skeletal muscle cells in different human samples (C, D), and in immortalised 
human skeletal muscle cells (E, F). 
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5.4.3 Purity of Myoblasts 
In this experiment, I investigated the capability of a CD56 based FACS purification 
technique in enhancing the myogenic fraction of human skeletal muscle cells. 
Immunocytochemistry (ICC) revealed that FACS sorting increased the proportion of 
desmin positive cells from 13% to 28% (Figure 5.4A-C and 5.5A). The cells shown in 
Figure 5.4A are the same as those in Figure 5.2, but after a few further passages. It 
was hypothesised that the majority (if not all) of the FACS sorted CD56+ cells would 
be desmin positive. The fact that only 28 % were desmin positive, suggests that either 
not all the CD56+ cells isolated under the gating strategy were myogenic, or that the 
staining and/or sorting was not sufficiently specific to only purify myogenic cells. The 
staining protocol appears to be appropriate since nearly all of the positive control cells 
clearly stained for desmin (Figure 5.5B). Interestingly, AB1167C2 cells also appeared 
to have a more rounded shape (Figure 5.5B); this feature is consistent with the 
appearances of undifferentiated myoblasts (Cerletti et al., 2006, Alexander et al., 
2016).  
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Figure 5.4: ICC staining for desmin in preplated primary human skeletal muscle cells.  
(A) Desmin staining using a mouse anti-desmin antibody), together with the isotype negative 
control in the presence (B) and absence (C) of the donkey anti-mouse secondary antibody. In 
each panel, the top row corresponds to DAPI staining of nuclei, the middle for desmin, and 
the lower panel is the merged picture. Preplated samples had a predominance of desmin 
negative cells, with only 13% of the cells desmin positive (A). Minimal Texas Red background 
staining was observed in the negative control (B). 
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Figure 5.5: ICC staining for desmin in preplated and CD56+ FACS sorted primary human 
skeletal muscle cells. (A) FACS sorted MHS sample. (B) Externally immortalised clone 
AB1167C2. (C) Negative control in the absence of mouse anti-desmin antibody, or (D) 
absence of both primary and donkey anti-mouse secondary antibodies. the top row 
corresponds to DAPI staining of nuclei, the middle for desmin using a filter for Texas Red, and 
the lower panel is the merged picture. Approximately 28% of the FACS sorted cells stained 
positive for desmin (A), in contrast the majority of the externally immortalised AB1167C2 cells 
stained positive for desmin (B). There was minimal background staining with the secondary 
antibody (C, D).  
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5.4.4 Skeletal Muscle Cell Toxicity Assays 
Antibiotic toxicity assays were performed in order to identify the appropriate antibiotic 
concentrations to use when selecting for cells that had incorporated the gene(s) of 
interest. The CDK4 R24C containing vector also included a gene for hygromycin 
resistance, whereas the hTERT containing plasmid encoded for puromycin 
resistance. An ideal antibiotic concentration is one that kills all the control cells 
between days three-seven. Puromycin at 0.3 Pg/ml and hygromycin at 50 Pg/ml were 
found to induce appreciable cell death by day three, with all the skeletal muscle cells 
dead by day seven (Figure 5.6A).  
 
At higher concentrations, the transduction agents DEAE-D and protamine are known 
to have toxic effects on primary cells and this depends on the cell type.  Thus, I sought 
to assess the cytotoxic effects of a 24 hr treatment of these transduction agents on 
the cultured skeletal muscle cells. Concentrations of up to 5 Pg/ml DEAE-D and 20 
Pg/ml of protamine did not attenuate the rate of proliferation, or exhibit an increased 
cytotoxic effect (Figure 5.6C). 
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 Figure 5.6: The effects of antibiotics and transduction agents on human myoblast 
growth. (A) Antibiotic selection assay showing the % confluence of cultured human skeletal 
muscle cells over a seven-day treatment with puromycin. The effects of the transduction 
agents DEAE-dextran (B) and protamine (C) on the growth of human skeletal muscle cells 
over 7 days. n=2-3 wells per data point. 
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5.4.5 J-Retroviral Immortalisation 
 
5.4.5.1 GFP Transduction 
The pBABE-GFP plasmid was used as a reporter to assess the optimal conditions for 
the transfection of GP2 cells and the transduction of myoblasts. GP2 cells transfected 
with the pBABE GFP and pVSV plasmids emitted a green fluorescence within 24 hr, 
with the proportion of fluorescent cells increasing by 72 hr. The optimised conditions 
per well for the production of viral particles in GP2 cells using a 24 well plate was 
found to be 15 x 104 GP2 cells, 2 Pg DNA, 1:1 Turbofect, and plating on ECL. The 
ideal transduction conditions were observed with either 1 x 18 hr or 2 x 9 hr 
transductions, as well as concentrating the virus by 5-fold (Figure 5.7). Vehicle treated 
cells did not result in any GFP fluorescence. 
 
Figure 5.7: Muscle cells transduced with the pBABE-GFP plasmid. Muscle cells were 
transduced for 2 x 9 hr with a 5-fold concentrated J–retroviral supernatant in the presence of 
5 Pg/ml DEAE-D; (A) phase-contrast light microscope image (B) epifluorescence image taken 
under a GFP filter set. The transduction efficiency here was 7 %. 
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5.4.5.2 hTERT and CDK4 Transduction  
The above conditions were then used to optimise the immortalisation of human 
skeletal muscle cells with the hTERT and CDK4 R24C containing plasmids. The ideal 
conditions were found to be 2 x 9 hr incubations with the virus, furthermore both 
DEAE-D and protamine could facilitate the transduction of muscle cells. Figure 5.8 
displays an example of this process whereby cells survived a four-week extended 
selection period using puromycin 0.3 Pg/ml and/or hygromycin 50 Pg/ml, whereas the 
control cells all died early during selection.  
 
Figure 5.8: Antibiotic selection of immortalised human skeletal muscle cells. Phase-
contrast images assessing the same samples during four weeks of antibiotic selection. The 
muscle cells were transduced for 2 x 9 hr using a 5-fold virus concentrate containing hTERT 
and/or CDK4 R24C in the presence of 10 Pg/ml of protamine. Antibiotic selection was with 50 
Pg/ml hygromycin and 0.3 Pg/ml puromycin, all control cells (protamine vehicle or deionised 
water) were dead within two weeks of dual antibiotic selection. 
This optimised protocol was used to immortalise skeletal muscle cells from other 
patients. 83% of patient samples (n=6) survived three weeks of double antibiotic 
selection, whereas all the control cells died by week two (Figure 5.9). The polyclonal 
cells were then expanded and FACS sorted to produce monoclonal and polyclonal 
immortalised cell lines. To examine the ability of immortalised cells to form myotubes, 
cells were differentiated as described in section 2.2.4. The majority of the 
immortalised cell colonies did not differentiate into myotubes (images not shown). 
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Figure 5.9: The immortalisation of MHS and MHN human skeletal muscle cells. Phase-
contrast images showing the antibiotic selection process of CD56 positive (sample MHS1, 
MHN-1, MHN-2, MHN-4) and unsorted muscle cells (MHS-3, MHN-3). Cells were transduced 
using 2 x 9hr treatments with CDK4 R24C and hTERT containing J-retrovirus, in the presence 
of 10 Pg/ml protamine. Dual antibiotic selection with 50 Pg/ml hygromycin and 0.3 Pg/ml 
puromycin was started 3-4 days post-infection. The first column shows cells during the first 
week of dual antibiotic selection, the second column is at the end of antibiotic selection (2-3 
weeks), and finally the cells after 4-6 weeks in the proliferation media. 
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5.4.6 Additional Purification of Immortalised Cells 
It had become evident during the course of this study that CD82 was a potentially 
useful marker of myogenic cells that have an enhanced ability to differentiate into 
myotubes (Alexander et al., 2016, Uezumi et al., 2016). Furthermore, many of the 
preliminary immortalised CD56+ samples were not differentiating into myotubes, 
therefore the FACS purification of immortalised cells was adapted to isolate both 
CD56+ and CD82+ cells. Figure 5.10A and B show the gating strategy used for MHN 
and MHS immortalised cells. Comparisons were made between the proportion of live 
cells that were isolated in MHS and MHN samples. The mean ± SEM % of 
CD56+CD82+ cells isolated in MHN samples was 35.1 ± 14.3 %, whereas it was lower 
in MHS at 16.5 ± 13.1 % (Figure 5.10C), but this difference was not statistically 
significant (P=0.46, n=4 and 2 respectively samples per group, each with 
5000-100000 live cells).  Similarly, there was no significant difference between the 
mean % of CD56+ cells isolated from MHN (18.4 ± 9.3 %) and MHS (59.8 ± 19.0 %) 
samples (Figure 5.10D), P=0.08, n=4 and 2. In order to compare all potentially 
myogenic cells, the results for the isolation of CD56+ alone and CD56+CD82+ cells 
were pooled, with comparisons made between the two MH groups. There was no 
significant difference between MHN and MHS samples (P=0.32, n=2-4), MHN had a 
mean of 53.5 ± 13.2 % and MHS 76.2 ± 5.9 % (Figure 5.10E). Furthermore, the 
mean % of CD56-CD82- was not significantly different between MHN versus MHS at 
47.6 ± 11.9 % and 4.0 ± 0.05 %, respectively (P=0.07, n=4 and 2, Figure 5.10F). 
Taken together these results suggest the MH status did not affect the proportion of 
cells expressing of CD56+ and/or CD82+ antigens. The immortalisation process itself 
also did not significantly affect the proportion of CD56+ cells purified by FACS pre- 
and post-immortalisation (P=0.77, paired t-test, n=5, data not shown). 
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Figure 5.10: The isolation of CD56+ and CD82+ immortalised cells. Representative FACS 
plots for the isolation of CD82+CD56+ immortalised cells in an MHN (A) and MHS sample (B). 
The left panels show the population density plot and right panels the individual cells. 
(C-E) Comparisons between all MHN and MHS immortalised samples for (C) the proportion 
of CD56+CD82+ cells, (D) CD56+ only cells, (E) both CD56+ plus CD56+CD82+ cells and (F) 
CD56-CD82- double negative cells. There was no significant difference between MHN and 
MHS samples in any of these comparisons, P>0.05, two-tailed unpaired t-test, n=2 (MHS) n=4 
(MHN) samples per group, each sample contained 4000-100000 cells. The bar charts show 
the mean ± SEM. 
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5.4.7 Characterisation of Immortalised Cells 
In order to further characterise the immortalised human skeletal muscle cells, the 
FACS unsorted plus sorted samples underwent assessment for their ability to 
differentiate into myotubes, express RYR1 mRNA and myosin heavy chain (MYH) 
protein. Overall, there was a great deal of variability in the ability of samples to 
accomplish this, certain samples produced large multinucleated myotubes with many 
nuclei visible (Figure 5.11A and B), whilst others produced smaller myotubes with two 
nuclei (Figure 5.11C; MHS-1, MHS-2, MHN-2, MHN-4). In many cases, cells would 
not differentiate into myotubes (Figure 5.11C, MHN-1), and this was evident even 
after the FACS purification of cells expressing myogenic markers. 
 
 
Figure 5.11: Immortalised cells variably differentiate into multinucleated myotubes. 
Phase-contrast images of cells that have undergone seven days of differentiation. (A) An 
immortalised polyclonal MHN sample following differentiation seen at 10 x and (B) 32 x 
magnification. (C) Images showing other differentiated immortalised samples at 32 x 
magnification (the sample number indicated to the left/top of the images). The blue arrows 
indicate myotubes and the red arrow heads the nuclei. 
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RT-PCR was used to assess the expression of RYR1 mRNA within differentiated 
myotubes (Figure 5.12). Differentiated cells were able to express RYR1 mRNA 
(Figure 5.12, sample B-F), however this was not seen with all samples. For example, 
there was no and minimal bands visible for RyR1 cDNA in sample A and B, 
respectively (Figure 5.12).  
 
 
Figure 5.12: Immortalised cells express RYR1 mRNA and myosin heavy chain. Agarose 
gel electrophoresis showing a clone dependent expression of RYR1 mRNA in different 
immortalised cells containing polyclonal (B, D, E) or monoclonal (A, C, F) cell lines. Primers 
used were specific for cDNA for exon 91 with a predicted fragment size of 257 base pairs. The 
positive controls are an externally immortalised human myoblast cell line (A) and genomic 
DNA (B), the negative control had water only instead of cDNA. 
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To functionally assess the presence of protein markers detected when myoblasts 
differentiate into myotubes, ICC was performed using the MF-20 antibody that is 
known to bind to all MYH isoforms. MYH proteins are expressed in differentiated 
muscle cells. As mentioned earlier, although many samples including the 
CD56+CD82+ cells did not differentiate into myotubes, of those that did, MYH proteins 
were expressed in only one of the samples. However, the experiment was only 
performed once with five different cell lines. This MYH expression was found in a 
polyclonal immortalised MHN sample that had not undergone a second round of 
FACS sorting (Figure 5.13A), and is the same sample as in Figure 5.11A. The quality 
of the myotubes seen in the immortalised cells were not as good as those seen in the 
externally immortalised cell line; the latter had larger myotubes that contained larger 
numbers of nuclei (Figure 5.13B).  
 
 
 
 
Figure 5.13: The expression of myosin heavy chain in immortalised cell lines. Upper row 
of images shows the DAPI stained nuclei, bottom row shows cells stained with mouse MF20 
anti-myosin heavy chain primary antibody (1:20 dilution) with goat anti-mouse AlexaFluor 488 
secondary (5 µg/ml), plus DAPI nuclei staining. (A) Immortalised polyclonal human MHN cell 
line. (B) Externally immortalised human skeletal muscle cell line AB1167C2 cells. (C) Negative 
control using vehicle instead of the primary antibody. 
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5.5 Discussion 
5.5.1 A Regenerative Pool of Human MH Cells  
The basis of this chapter was a need to develop a sufficient regenerative pool of cells 
derived from MHS and MHN patients that could facilitate detailed mechanistic studies 
into the altered Ca2+ handling found in human MH (Chapter 4), This chapter has 
investigated the feasibility of immortalising human myoblasts derived from MHS and 
MHN skeletal muscle. Although I have shown some success in the process, there is 
little utility for the majority of these cells as they were not able to differentiate into 
multinucleated myotubes. Thus, these results should be regarded as preliminary data 
that can be used to help improve the quality and efficiency of the immortalisation 
technique in future studies.  
 
5.5.2 Purification of Myoblasts 
The early part of these experiments focussed on isolating and enriching for myoblasts 
that could then be immortalised. Initially, the preplating technique alone was used to 
enrich for myoblasts as this together with the use of media such as Ham’s F10 are 
simple, do not require specialist equipment, involve less mechanical stress to cells 
compared with FACS, and have been reported to produce a 95% pure myoblast 
population  (Rando and Blau, 1994; Springer and Blau, 1997). However, the results 
from the FACS sort of CD56+ cells (42-80 % of cells were CD56+, Figure 5.3), as well 
as the ICC staining for desmin (Figure 5.5), suggested my preplating technique did 
not appear to enrich to the same degree as reported by others. Several reasons may 
account for this, one could be the species being studied, my investigations used 
human cells which are known to be more difficult to isolate and purify relative to the 
mouse cells used by the Blau group (Boldrin et al., 2010).  Another reason is that I 
performed an insufficient number and/or time of preplatings relative to others, for 
example some groups preplate their cells up to six times to minimise the number of 
fibroblasts (Paul D Allen, personal communication), although Yaffe (1968) had 
success with only a single preplate of their mouse cells. Consequently, in future it 
would be beneficial to use more than the 2 x 60 min preplates used in this study.   
 
Another unexpected finding was that not all the CD56+ cells stained positive for 
desmin. This could be explained by a deficiency in the stringency of the FACS sorting 
criteria, however there is evidence for and against this. The ability of the FACS sort 
to identify two clearly distinct populations (Figure 5.2D) would suggest the gating 
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criteria was appropriate, however the counter evidence is that the majority of this 
batch of cells, stained negative for desmin (Figure 5.5A). This implies that the FACS 
gating criteria used in this study for CD56+ cells did not isolate pure myogenic cells. 
It is conceivable that very small numbers of fibroblasts were purified together with the 
CD56+ fraction and due to their shorter doubling time (Rando and Blau, 1994), these 
outgrew the myoblasts. This is feasible as FACS has been shown to not produce pure 
cell populations particularly as enzymatic treatment with agents such as trypsin can 
alter the cell surface markers leading to a reduced sort quality (Boldrin et al., 2010). 
A suboptimal CD56 staining protocol would also lower the quality of the FACS 
purification. Consequently, future FACS sorts would benefit from further 
improvements in the staining technique together with employing more stringent gating 
criteria. Further enhancements to the gating criteria would be the addition of  an 
antibody that detects the TE7 epitope which is specific to fibroblasts, and use this as 
a negative marker for myogenic cells (Stewart et al., 2003; Agley et al., 2013).  
 
An alternative approach would be to positively select out the fibroblasts, and then 
immortalise the remaining cells because some myogenic cells are CD56- (Stadler et 
al., 2011). On the other hand, it may be the FACS sort was appropriate as during my 
initial immortalisation experiments, evidence emerged that not all CD56+ muscle cells 
are myogenic Alexander et al., (2016). Alexander et al., (2016) found CD56+ cells 
contained subpopulations which exhibited different capacities to differentiate into 
myotubes, and those that did expressed tetraspanin (CD82) had an enhanced 
capacity to differentiate. They also found that the CD82+CD56- population were not 
myogenic. Others have also shown the importance of CD82 in the early establishment 
of proliferation and differentiation (Risinger et al., 2014). These studies would 
potentially explain the incongruity between desmin staining and CD56+ expression 
seen in Figures 5.2-5.4. Consequently, I incorporated using CD82 into the FACS 
sorting protocol, however the majority of the CD56+CD82+ colonies did not 
differentiate into myotubes. It could be that CD56 and CD82 are not great markers of 
myogenic cells, or more likely that the FACS and/or immortalisation methods were 
not sufficiently gentle for the myoblasts, and thus rendered them unable to 
differentiate.  
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5.5.3 Myoblast Immortalisation  
The experiments to immortalise human myoblasts used a retroviral system for 
numerous reasons; the first was that successful reports of myoblast immortalisation 
used J-retroviruses (Di Donna et al., 2003; Hashimoto et al., 2006; Mamchaoui et al., 
2011; Stadler et al., 2011), next was the availability of CDK4 R24C and hTERT 
containing retroviral plasmids, and finally the host laboratory had already begun early 
experiments with this. In this study the optimal conditions were identified and then 
used to produce many monoclonal and polyclonal colonies from a total of 7 samples 
from MHS and MHN patients. One of the variables investigated was the type of 
transduction agent. I found that both protamine and DEAE-D were suitable for this in 
myoblasts, however the former had a more favourable cellular toxicity profile as even 
at the maximal concentration of 20 µg/ml the rate of myoblast proliferation was 
unaffected. Consistent with this, other groups have also found protamine to be a safe 
transduction agent at similar or lower concentrations (Cornetta and Anderson, 1988; 
Jackson et al., 2012).  
 
The transduction of skeletal muscle cells appeared to be effective with 83 % of patient 
samples surviving dual antibiotic selection; this indicates they had incorporated the 
antibiotic selection genes and it would be anticipated that they also integrated the 
genes encoding hTERT and CDK4 R24C. Although due to the lack of time detailed 
studies to prove this were not performed. There is some evidence to suggest that the 
cells were immortalised as primary myoblasts tend to senesce after 20 passages 
(Motohashi et al. 2014). However, in my study the putatively immortalised monoclonal 
cells had undergone more than 20 doublings as they proliferated from a single cell 
into over 1 000 000 cells (number of doublings = {log final number of cells – log initially 
seeded}, in addition to the number of doublings that would have taken place pre- and 
post-immortalisation and single-cell sorting.  
 
Transduction efficiency of my J-retroviral system was approximately 7%, although this 
is low, such values are not uncommon with human primary myoblasts which are 
known to be resistant to viral transduction (Springer and Blau, 1997). Accordingly, 
further work is required to improve the process of immortalisation, this includes 
enhancing both transfection and transduction, for the latter it would be advantageous 
to utilise a lentiviral system. Lentiviruses also belong to the retrovirus family, however 
in contrast to the J-retroviruses they are known to infect both dividing and non-dividing 
cells, and have an improved transduction efficiency (Cooray et al., 2012). 
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Interestingly, one group working on immortalising myoblasts reported they found no 
difference between the two viral transduction systems in infecting human myoblasts 
(Stadler et al., 2011).  In contrast, others have found the lentiviral system to be more 
effective and moved solely to this (V. Mouly, personal communication).  
 
A minority of the immortalised cells differentiated into multinucleated myotubes 
expressing RyR1 mRNA and MYH proteins, but the majority did not. This was 
observed particularly in cultures that had undergone post-immortalisation FACS 
sorting. Possible reasons for these findings include the FACS sort was too damaging 
to the myoblasts, the majority of the sorted cells were not myoblasts, or I had selected 
for a population of non-differentiating myoblasts. The lack of differentiation could also 
result from the fact that J-retroviruses are known to randomly integrate into the host 
genome (Buchholz et al., 2015), and if this integration occurs within genes that are 
important for differentiation this would prevent the production of myotubes. 
 
Another factor could be the media used during the immortalisation process did not 
contain all the growth factors necessary to allow successful immortalisation of good 
quality myoblasts that are able to then differentiate. The presence of hepatocyte 
growth factor (HGF), epidermal growth factor, insulin and dexamethasone have all 
been found to enhance myoblast proliferation (Tatsumi et al., 1998; Sheehan and 
Allen, 1999; Jarocha et al., 2014). It would be worth examining whether 
supplementing the proliferation media with these factors does indeed enhance the 
quality of the immortalised myoblasts as well as their capacity to differentiate.  
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5.6 Future Directions 
As mentioned earlier, the work in this chapter should be seen as exploratory and will 
require further development by pursuing several avenues of research. The first would 
be to utilise another system of purifying human myoblasts such as using MACS, as 
this is believed to cause less mechanical stress on cells compared with FACS 
(Motohashi et al., 2014). An alternative approach is to use an explant model for the 
generation of myoblasts, here small samples of human skeletal muscle tissue are 
placed in proliferation media, the satellite cells within the tissue then produce 
myoblasts that grow on the culture vessel (Conboy and Rando, 2002; Shahini et al., 
2018). The isolated cells would still not be purely myogenic and MACS could be 
utilised both before and after immortalisation to help improve the myogenic purity of 
these polyclonal populations. Using MACS does not preclude the production of 
monoclonal colonies from a single cell, as this can be achieved using a serial dilution 
method although this is more time consuming than single-cell FACS sorting. 
 
The second will be to use a lentiviral system of immortalisation.  As both the hTERT 
and CDK4 R24C genes are not currently available in such a system, Gibson cloning 
would be suitable to clone both hTERT and CDK4 R24C genes from the J-retroviral 
plasmids into lentiviral vectors (Gibson et al., 2009). A more targeted approach would 
be to use a receptor-specific lentiviral system directed at cells expressing CD34+; this 
is another marker of myogenic skeletal muscle cells (Beauchamp et al., 2005), a 
CD34+ targeted lentivirus is already available (Liang et al., 2009).  
  
In addition, more rigorous validation is required of the clones that have survived 
antibiotic selection and were able to produce myotubes. Experiments should aim to 
assess the proliferative capacity of the cells, the presence of increased hTERT 
activity using a telomeric repeat amplification protocol (TRAP) assay (Mamchaoui 
et al., 2011), and the expression of CDK4 R24C mRNA. Calcium imaging would also 
be used to assess the responses of these cells to caffeine, KCl depolarisation and 
halothane; the former two could then be compared with the results obtained with the 
non-immortalised cells in chapter 4. This would help validate whether the responses 
are still consistent with an MHS phenotype.  
 
Finally, the use of induced pluripotent stem cells derived from the fibroblasts isolated 
from MHS and MHN patients is an alternative approach to immortalisation (Lovino et 
al., 2015; Sun et al., 2019). These could then be differentiated into a myogenic lineage 
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by the introduction of muscle specific transcription factors (Chal et al., 2015, Rovina 
et al., 2019). The production of high quality human skeletal muscle myoblasts through 
an immortalisation process or those derived from pluripotent stem cells will allow 
detailed functional experiments to be performed on human myotubes. The addition 
of specific mutations introduced though prime-editing would greatly expand the utility 
of these experiments (Anzalone et al., 2019). This would allow detailed studies into 
the cellular Ca2+ handling mechanisms that mediate the susceptibility to MH as well 
as others related disorders such as central core disease and exertional heat illness. 
 
In summary, the process of immortalising human skeletal myoblasts has proven to 
not be trivial and still needs further research before a robust platform of 
immortalisation is established in the MH unit in Leeds. Consequently, detailed 
functional studies utilising immortalised human myotubes could not be performed at 
present. However, in the next chapter a novel knock-in mouse model of the human 
p.G2434R RyR1 variant will be used to investigate whether the perturbed calcium 
handling that has been observed with this variant in chapter 4, is conserved between 
species. These studies will then provide an insight into the molecular mechanisms 
that result in cells which are primed for the MH reaction. 
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Chapter 6. Investigating p.G2434R RYR1 in a Mouse 
Model 
 
6.1 Introduction 
6.1.1 The p.G2434R Variant 
This RYR1 variant has already been described in detail in the previous chapters.  
Furthermore, the problems associated with the use of HEK cells, primary human cells, 
and the difficulties in immortalising human cells for MH research, have been 
highlighted in earlier chapters. Accordingly, in order to fully understand the molecular 
mechanisms that underlie the perturbed Ca2+ handling in MH, as well as the 
phenotypic variability observed with this condition, there is significant value in 
developing a knock-in (KI) mouse model that is equivalent to human p.G2434R.  
 
6.1.2 MH models 
Several animal models have been reported which contain RYR1 variants that are 
equivalent to those found in human MH. The original animal model that was used was 
the porcine p.R615C which underlies the porcine stress syndrome (Fuji et al., 1991). 
Since then, three knock-in mouse models have been created to encompass human 
MH variants found at different loci within RYR1; these are the p.R163C (Yang et al., 
2006), p.Y522S (Chelu et al., 2006), and p.T4826I (Yuen et al., 2012). The former 
two variants are found on the N-terminus of RYR1 within a region that was classically 
referred to as MH region 1 (aa 35-614), whereas the latter is on the C-terminus also 
known as MH region 3 (aa 3916-4942). The human equivalence of these MH variants 
are less commonly found in the UK MH population, for example p.R163C is found in 
21 families,  p.T4826I in 10 families, and p.Y522S is not found in any of the UK 
families (Miller et al., 2018). There have been no reports of animal models that have 
variants within the middle of the RYR1 protein which was previously referred to as 
MH region 2 (aa 2129-2458) (Manning et al., 1990).  
 
In all four animal models of MH (p.R163C, p.Y522S, p.R615C, and p.T4826I), 
exposure to MH triggers causes a fulminant MH-like episode (Chelu et al., 2006; Yang 
et al., 2006; Yuen et al., 2012). A consistent finding in these RYR1-MH models as 
well as in human RYR1-MHS fibres is an enhanced [Ca2+]i that is thought to emanate 
from a leaky RYR1 channel (Lopez et al., 1985; Lopez et al., 1986; Yang et al., 2006; 
Durham et al., 2008; Eltit et al., 2010; Feng et al., 2011; Yuen et al., 2012; Altamirano 
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et al., 2014). This view has been challenged by investigators who found a normal 
[Ca2+]i based on measurements made using the Ca2+ indicator dye (Fura-2) (Iaizzo et 
al., 1988). However, Fura-2 itself is not an ideal dye for such measurements as it is 
based on the Ca2+ chelator BAPTA, and thus it can affect the measured [Ca2+]i (Rudolf 
et al, 2003). Nevertheless, it is universally accepted that the detailed molecular 
mechanisms by which RYR1 variants result in MH susceptibility still remain elusive.  
 
Consequently, developing an animal model that contains the most common MH 
genetic variant and is unique in that it is in the middle of the RYR1 sequence (MH 
regions 2), has significant value in investigating the calcium handling mechanisms in 
MH. Thus, a knock-in mouse model with p.G2435R an equivalent variant to 
p.G2434R was successfully created by the MRC Harwell Institute (UK). This mouse 
model can be used to corroborate findings observed in human MH cells such as those 
described in chapter 4, and assess whether the mechanisms mediating the perturbed 
Ca2+ handling in MH are conserved between species. 
 
6.1.3 Enhanced Extracellular Ca2+ Entry 
As discussed in detail in the preceding chapters, there are several different 
mechanisms in RYR1 dependent MH that have been postulated to initiate, maintain 
and cause an adaptation to the elevated [Ca2+]i found in the resting state. 
Furthermore, chapter 4 revealed there was a significant elevation in RCaE in human 
MHS myotubes, this was mediated by non-specific cationic channels, and suggested 
TRPC3/6 proteins were likely candidates. 
 
The focus of this chapter will be to examine whether such enhanced extracellular Ca2+ 
entry also occurs in p.G2435R MHS heterozygous (MHS-Het) and homozygous 
(MHS-Hom) and wild-type (MHN) myotubes in the resting state, and if it is enhanced 
in p.G2435R MHS mice myotubes. As previously mentioned (section 4.1.6), Eltit et 
al., (2013) discovered that in the p.R163C mouse model, homozygous myotubes had 
an elevation in their RCaE and [Ca2+]i. These were more effectively attenuated with 
Gd3+ and GsMTx-4 a mechanosensitive and stretch-activated ion channel inhibitor, 
than BTP2 or the dominant-negative ORAI1 variant E190Q. Furthermore, TRPC3 and 
TRPC6 proteins were overexpressed in p.R163C homozygous myotubes. Therefore, 
they concluded that a non-STIM1/ORAI1 pathway was involved in mediating the 
enhanced RCaE in MH, and suggested it was dependent on TRPC3/6 channels. This 
enhanced RCaE observed in the R163C MH mouse model provided a potentially new 
paradigm to explain how cells carrying the RYR1-associated MH variants, may 
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maintain their intracellular Ca2+ homeostasis under the condition where a raised 
[Ca2+]i is the new set-point. However, it is not known if the enhanced RCaE observed 
in p.R163C is specific to this variant or is conserved in other mouse models of MH. 
Furthermore, Eltit et al., (2013) did not explore in detail which channels mediated this 
enhanced RCaE, neither did they examine a gene-dose effect by investigating the RCaE 
in heterozygous p.R163C myotubes. 
 
 
 
6.2 Hypothesis and Aims 
 
6.2.1 Hypothesis 
I. The p.G2435R variant leads to an RYR1 channel that has an enhanced 
sensitivity to RYR1 agonists and a greater SR Ca2+ leak. This leak drives an 
enhanced entry of extracellular Ca2+ in the non-triggered state, which 
consequently causes an elevated sarcoplasmic Ca2+, together these result in 
skeletal muscle cells that are primed to initiate an MH reaction when exposed 
to triggering anaesthetic agents. 
 
 
6.2.2 Aims 
I. Characterise the sensitivity of myotubes from the p.G2435R mouse model of 
MH to caffeine, halothane and potassium chloride: 
a. Examine if there is a gene-dose dependent effect on the 
response to these RYR1 agonists. 
b. The primary outcome will be to assess the AUC of the 
responses, and secondary outcome the peak height of the 
responses. 
II. Investigate whether there is an enhanced RCaE in myotubes from the 
p.G2435R mouse model at rest. 
III. Pharmacologically evaluate the channels mediating the RCaE in the p.G2435R 
mouse model. 
 
 
 
 154 
6.3 Methods 
6.3.1 Experimental Cells and Solutions 
Myoblasts for the calcium imaging were isolated from wild type (MHN), MHS-Het and 
MHS-Hom p.G2435R RYR1 mice as described in 2.2.2. Solutions were made as 
described in detail in section 2.6.2.1.  
 
6.3.2 Epifluorescence Imaging 
6.3.2.1 Calcium Release 
Myotubes were loaded for 12 min with 5 PM Fluo-4AM at 37 qC then washed and 
imaged as mentioned in section 2.6. In the experiments investigating the effects of 
caffeine and halothane, IB was perfused at 3 psi for 10 s then the agonist for 10 s 
followed by IB for 10 s. The responses to halothane were normalised to the maximum 
response observed in that cell to 60 mM KCl. In the experiments investigating the 
concentration-dependent effects of KCl, this agonist was perfused for 5 s at 3 psi. 
 
6.3.2.2 Extracellular Cationic Entry 
Myotubes were loaded with 5 PM Fura-2AM for either 30 min at 37 qC, or 5 PM 
Fura-2AM in 10 % Pluronic F-127 for 15 min at 37 qC and then 25 min at room 
temperature. The difference in the loading conditions did not cause statistically 
significant difference to the RCaE (data not shown). Imaging was as described in 
section 2.6. 
 
6.3.2.3 Statistics 
All n numbers represent the number of myotubes analysed, unless stated otherwise. 
The number of myotubes required for the experiments were determined by similar 
experiments conducted in MH mouse models in the laboratories of Professor Paul D 
Allen (Yang et al., 2006 and 2007; Eltit et al., 2010, 2012 and 2013), and from studies 
in human myotubes (chapter 4). I was not blinded to any of the experimental groups. 
 
6.3.2.3.1 Calcium Release 
Parametric data are presented as mean ± 95 % CI. The EC50 values were compared 
between the three groups using one-way ANOVA with Tukey’s multiple comparisons 
test to determine significance. 
 
6.3.2.3.2 Manganese Quench 
As discussed in section 2.6.3.4.2 
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6.4 Results 
6.4.1 Myoblasts Isolation 
Myoblast were isolated and enriched for using the preplating technique. Qualitatively 
this produced a high myoblast purity as demonstrated by the universal production of 
myotubes upon cell differentiation. 
 
6.4.2 Enhanced Sensitivity to Caffeine 
As previously mentioned, the human p.G2434R variant causes an enhanced 
sensitivity to caffeine and halothane in skeletal muscle fibre on the IVCT (Robinson 
et al., 2002 and 2009). In addition, human myotubes containing this variant also have 
a significantly enhanced sensitivity to caffeine (section 4.4.6). Myotubes from MHN, 
MHS-Het and MHS-Hom loaded with Fluo-4 were exposed to various concentrations 
of caffeine and 60 mM KCl (Figure 6.1). Caffeine produced a reversible increase in 
the Fluo-4 fluorescence, as observed in human myotubes (section 4.4.4). 
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Figure 6.1: The enhanced effect of caffeine in MHS myotubes.  
Representative traces showing the caffeine induce Ca2+-release in myotubes from MHN and 
p.G2435R MHS-Het and MHS-Hom mice. Myotubes were loaded with 5 µM Fluo-4AM, and 
exposed to 10 seconds of the relevant concentration of caffeine (mM) before it was rapidly 
washed off (* and ** highlight similar caffeine concentrations applied across the three 
genotypes to aid in their comparisons). Myotubes were also exposed to 60 mM KCl. Between 
each caffeine exposure, there was a 2 min rest period. MHN (top trace) had an EC50 of 5.7 mM, 
MHS-Het (middle) 4.5 mM and MHS-Hom 1.8 mM (bottom). 
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6.4.2.1 Responses Measured Using AUC 
The concentration-response curves identified an enhanced sensitivity to caffeine as 
shown by a leftward shift from the MHN to MHS-Het and MHS-Hom (Figure 6.2A). 
Myotubes from all three genotypes responded to the 20 mM caffeine challenge 
(Figure 6.2A), however only those from MHS-Het and MHS-Hom animals had a 
response to 0.5 mM caffeine. The normalised AUC response in MHN was 0.17 % 
(-0.03 - 0.38 %), MHS-Het 6.36 % (3.18 - 9.54 %) and MHS-Hom 13.69 % 
(9.77 - 17.61 %). At the lower concentration of 0.1 mM caffeine, both MHS-Het and 
MHS-Hom myotubes had a negligible response with 0.04 % (-0.03 - 0.11 %) in the 
former, and 1.61 % (0.97 - 2.26 %) in the latter (Figure 6.1 and 6.2A). 
 
There was a significant difference in the EC50 of the intracellular Ca2+ response 
(defined by the AUC) to increasing concentrations of caffeine, and this was gene-
dose dependent (P<0.001, one-way ANOVA with Tukey’s multiple comparison test, 
n=38-53 myotubes; Figure 6.2A).  The mean EC50 values for caffeine were 
5.7 (95 % CI 5.0 - 6.3), 4.5 (3.9 - 5.0), and 1.8 (1.5 - 2.1) mM (Figure 6.2B) for MHN, 
MHS-Het, and MHS-Hom, respectively. The threshold response, defined as the 
concentration where ≥ 10 % of the maximal response was observed, was 3.0, 1.0 
and 0.5 mM caffeine for MHN, MHS-Het and MHS-Hom, respectively (Figure 6.2A). 
Comparisons of the normalised AUC at 1 mM caffeine showed a gene-dose 
dependent enhancement in sensitivity (Figure 6.2C), MHS-Hom having the greatest 
response at 30.2 (24.1 - 26.3) %, compared with MHS-Het 13.1 (8.0 - 18.2) %, and 
MHN 1.5 (0.9 - 2.0) % (P<0.001-0.0001, one-way ANOVA with Tukey’s multiple 
comparison test, n=38–53).  
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Figure 6.2: The enhanced sensitivity MHS myotubes to caffeine using AUC.  
(A) Concentration-response curves to caffeine in MHN, RYR1 p.G2435R MHS-Het and 
MHS-Hom myotubes. Data points are the mean ± 95 % CI response calculated using the AUC 
which was normalised to 20 mM caffeine. MHS-Hom and MHS-Het had an enhanced 
sensitivity to caffeine relative to MHN mM. (B) The EC50 in the three genotypes displayed as 
a bar chart. (C) Comparisons of the effects of 1 mM caffeine which was normalised to 20 mM 
caffeine; MHS-Hom had the largest response compared with MHS-Het and MHN. In A-C, 
**P<0.01, ***P<0.001 and ****P<0.0001, one-way ANOVA with Tukey’s multiple comparison 
test, n=38-53 myotubes from 12-15 different wells in 3-4 plates cultured on 3 separate days. 
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6.4.2.1 Responses Measured Using the Peak Height 
Comparisons of the peak responses also displayed an enhanced sensitivity to 
caffeine in MHS-Hom with a mean EC50 of 1.5 (1.2 - 1.8) mM, compared with MHS-
Het 3.9 (3.3 - 4.6) and MHN 4.4 (3.7 - 5.1) mM (P<0.0001, one-way ANOVA with 
Tukey’s multiple comparison test, n=38–53 myotubes; Figure 6.3B). However, the 
post-hoc Tukey’s analysis did not reveal a significant difference between the EC50 of 
the peak responses to caffeine in MHS-Het and MHN myotubes (P=0.24). However, 
an effect of gene-dose on the peak response to caffeine was noted whilst using a test 
for linear trend (slope= -1.42, P<0.0001, one-way ANOVA with post-test for linear 
trend); these discrepancies suggests the data may be underpowered to look for a 
difference between the peak responses in MHS-Het and MHN mice. There does 
appear to be an enhanced sensitivity in the MHS-Het relative to MHN at lower 
concentrations of caffeine which is then lost at higher concentrations (Figure 6.3A 
and C).  Consistent with this, further analysis revealed a genotype dependent 
significant enhancement peak response to 1 mM caffeine (Figure 6.3C), with MHS-
Hom myotubes displaying a mean peak response of 34.9 (27.2 – 42.6) % compared 
with MHS-Het of 14.7 (9.0 - 20.4) % and MHN of 1.6 (0.9 - 2.4) % (P<0.001, one-way 
ANOVA with Tukey’s multiple comparison test, n=38–53). 
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Figure 6.3: The enhanced sensitivity MHS myotubes to caffeine using peak responses. 
(A) Concentration-response curves to caffeine in MHN, RYR1 p.G2435R MHS-Het and MHS-
Hom myotubes. Data points are the mean ± 95 % CI response calculated using the peak 
response which was normalised to 20 mM caffeine. MHS-Hom myotubes had an enhanced 
sensitivity relative to MHS-Het and MHN. (B) The EC50 in the three genotypes revealed there 
was a gene-dose dependent effect on the peak response to caffeine when utilising a test for 
linear trend (slope= -1.42, P<0.0001, one-way ANOVA with post-test for linear trend) (C) 
Comparisons of the peak normalised response to 1 mM caffeine; MHS-Hom had the largest 
response compared with MHS-Het and MHN. In A-C, **P<0.01 and ****P<0.0001, one-way 
ANOVA with Tukey’s multiple comparison test, n=38-53 myotubes from 12-15 different wells 
in 3-4 plates cultured on 3 separate days. 
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6.4.3 Enhanced Sensitivity to Halothane 
MHN, MHS-Het and MHS-Hom p.G2435R myotubes loaded with Fluo-4 were 
exposed to 0.04 mM or 0.1 mM halothane and 60 mM KCl. The latter was used for 
the normalisation of the halothane responses within each myotube. 0.11 mM 
halothane is equivalent to 0.5 % halothane as used in the IVCT protocol of the EMHG 
(Hopkins et al., 2015.).  To confirm the concentrations of halothane, a robust method 
was designed where 2 % halothane was bubbled through 40 ml of imaging buffer 
using a halothane vaporiser as discussed in section 2.6.2.2.3.  
 
Application of halothane caused a temporary but reversible increase in the Fluo-4 
fluorescence in MHS-Hom and Het myotubes indicating a reversible increase in 
intracellular Ca2+ (Figure 6.4A). The effects of halothane in MHN was negligible 
(Figure 6.4A and B). The response observed during exposure to 0.04 mM halothane 
in MHN cells was 2.3 (95 % CI 1.2 - 3.3) %, and this  was not different to that observed 
in MHS-Het at 5.0 (3.5 - 6.4) % (P = 0.28, one-way ANOVA with Tukey’s multiple 
comparison test, n=33-44 myotubes; Figure 6.4B). However, there was a greater 
response in MHS-Hom of 12.7 (7.6 - 17.9) % relative to MHS-Het and MHN (P<0.01 
and P<0.0001, respectively, one-way ANOVA with Tukey’s multiple comparison test, 
n=33-45; Figure 6.4B).  
 
The response observed during exposure to 0.1 mM halothane in MHN myotubes was 
3.2 (2.0 - 4.4) %, this was not different to that observed at 0.04 mM (P=0.22, two-
tailed unpaired t-test, n=44-46 myotubes). Both MHS-Het and MHS-Hom had a 
greater sensitivity to 0.1 mM halothane relative to MHN, with the response in MHS-
Het of 19.1 (12.4 - 25.7) % and MHS-Hom 63.1 (48.1 - 78.1) %, respectively (P<0.03 
and P<0.0001, respectively, one-way ANOVA with Tukey’s multiple comparison test, 
n=38-48). 
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Figure 6.4: The enhanced sensitivity of MHS myotubes to halothane.  
(A) Representative traces demonstrating the effect of 0.1 mM halothane and 60 mM KCl on 
MHN, RYR1 p.G2435R MHS-Het and MHS-Hom myotubes loaded with 5 µM Fluo-4AM. (B) 
Bar chart indicating the mean ± 95 % CI response to 0.04 mM and 0.1 mM Halothane, data 
are AUC normalised to 60 mM KCl. At 0.04 mM Halothane, MHS-Hom had an enhanced 
response relative to MHS-Het and MHN (**P<0.001, ****P<0.0001, one-way ANOVA with 
Tukey’s multiple comparison, n=33–44 myotubes), however at 0.1 mM Halothane, both 
MHS-Het and MHS-Hom myotubes had a greater response relative to MHN, as well as 
MHS-Hom compared to MHS-Het (*P<0.05, ****P<0.0001, one-way ANOVA with Tukey’s 
multiple comparison). n=33-45 myotubes from 5-6 different wells in 3-6 plates cultured on 2-
5 separate days. 
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6.4.4 Enhanced Sensitivity to KCl 
Application of KCl induced a reversible increase in fluorescence in the myotubes from 
all three genotypes (Figure 6.5-6.7). In MHN and MHS-Het myotubes the mean AUC 
response to 7 mM KCl was nominal at 2.2 (95% CI 0.7 – 3.8) % and 3.4 (2.7 - 4.1) % 
respectively, whereas the response was more robust in MHS-Hom at 13.6 (10.5 - 
16.7) % (Figure 6.5 and 6.6). 
 
There was a gene-dose dependent difference in the EC50 of KCl as defined by the 
AUC (P<0.0001, one-way ANOVA with Tukey’s multiple comparison test, n=30-37 
myotubes; Figure 6.6B).  The mean EC50 values for KCl were 21.4 (19.8 - 23.1), 16.2 
(15.2 - 17.2), and 11.2 (10.2 - 12.2) mM (Figure 6.6B) for MHN, MHS-Het, and MHS-
Hom, respectively. The threshold response, defined as the concentration where 10% 
or more of the maximal response was observed, was 15, 10 and 7 mM KCl caffeine 
for MHN, MHS-Het, Het and Hom, respectively (Figure 6.6A). 
 
Comparisons of the peak responses also revealed an enhanced sensitivity to caffeine 
in MHS-Hom with a mean EC50 of 10.6 (9.8 - 11.4) mM, compared with MHS-Het 14.6 
(13.6 - 15.6) and MHN 17.1 (14.7 - 19.5) mM (P<0.0001, one-way ANOVA with 
Tukey’s multiple comparison test, n=30-37 myotubes; Figure 6.7). As observed with 
caffeine, the post-hoc Tukey’s analysis did not reveal a difference between the EC50 
of the peak responses to KCl in MHS-Het and MHN myotubes (P=0.06). However, 
there was an effect of gene-dose on the peak response to caffeine when utilising a 
test for linear trend (slope= -3.27, P<0.0001, one-way ANOVA with post-test for linear 
trend).  
 
 
 
 164 
 
Figure 6.5: The response of myotubes from the three genotypes to potassium chloride.  
Representative traces of myotubes from the wild type (MHN) and the p.G2435R KI MH mouse 
model releasing Ca2+ when exposed to different concentrations of KCl. Myotubes were loaded 
with 5 µM Fluo-4AM, then exposed for 5 seconds to the relevant concentration of KCl before 
it was rapidly washed off. Between each KCl exposure, there was a 2 min rest period. MHN 
(top trace) had an EC50 of 21.4 mM, MHS-Het (middle) 16.2 mM and MHS-Hom 11.2 mM 
(bottom). Note the y-axis is different between the three genotypes as different cells in each 
genotype will display variations in the absolute changes in fluorescence in their responses. 
Consequently, comparisons are made between the responses normalised to the 60 mM KCl. 
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Figure 6.6: Gene-dose dependent enhanced sensitivity of MHS myotubes to KCl.  
(A) Concentration-response curves to KCl in MHN, RYR1 p.G2435R MHS-Het and MHS-Hom 
myotubes. Data points are the mean ± 95 % CI response calculated using the AUC response 
which was normalised to 60 mM KCl. MHS-Hom and MHS-Het had an enhanced sensitivity 
to KCl relative and MHN (***P<0.001, one-way ANOVA with Tukey’s multiple comparison test, 
n=30-37 myotubes, from 5-6 different wells in 4-5 plates cultured on 2-3 separate days). (B) 
The EC50 in the three genotypes displayed as a bar chart. 
 
5 7 10 15 20 40 60
0
20
40
60
80
100
KCl  (mM)
N
o
rm
al
is
ed
 F
lu
o
re
sc
en
ce
 
(A
U
C
 %
 o
f 6
0 
m
M
 K
C
l)
 
MHN:
MHS-Hom: 
MHS-Het:
EC50 (mM)
11.2 ***
16.2 ***
21.4
n
37
30
33
MHS
Hom
MHS
Het
MHN
0
10
20
30
A
U
C
 K
C
l E
C
50
 (m
M
)
***
******
A 
B 
 166 
 
 
Figure 6.7: Sensitivity of MHS myotubes to the KCl using peak response.  
Concentration-response curves to KCl in MHN, RYR1 p.G2435R MHS-Het and MHS-Hom 
myotubes. Data points are the mean ± 95 % CI response calculated using the peak response 
which was normalised to the peak in 60 mM KCl. MHS-Hom myotubes had an enhanced 
sensitivity to KCl relative to MHS-Het and MHN (***P<0.001, ****P<0.0001, one-way ANOVA 
with Tukey’s multiple comparison test, n=30-37 myotubes from 5-6 different wells in 4-5 plates 
cultured on 2-3 separate days). (B) The peak EC50 in the three genotypes displayed as a bar 
chart; here gene-dose had an effect on the peak response to KCl (slope= -3.27, P<0.0001, 
one-way ANOVA with post-test for linear trend. 
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6.4.5 p.G2435R-Hom Myotubes Have an Elevated RCaE 
The Mn2+ quench of Fura-2 fluorescence was used to examine the RCaE (Figure 6.8). 
Changing the perfusion from the Ca2+ containing IB to Mn2+ containing MnB caused 
a noticeable increase in the slope of the quench, this was similar to the previous 
observation in human myotubes (section 4.4.8).   
 
 
 
Figure 6.8: The presence of a RCaE in MHS and MHN myotubes. 
(A) 40 x image of multi-nucleated myotubes from p.G2435R MHS-Het loaded with Fura-2AM; 
the nuclei are whiter and oval shaped. (B) Representative trace from an MHN myotube 
showing the change in the slope of the Fura-2 fluorescence when changing from the imaging 
buffer containing 2 mM Ca2+ (dark-green broken line) to a 0.5 mM Mn2+ containing buffer (light-
green broken line). The rate at which the external Mn2+ quenches cytoplasmic Fura-2 
fluorescence is used to estimate the sarcolemmal permeability to Ca2+. A greater slope 
indicates a larger resting sarcolemmal permeability. Acquisition rate was 5 fps with cells 
excited at 360 +/- 5 nm and emission measured at 510 +/- 40 nm with 40x 1.3 NA objective, 
and 2x2 binning. (C) Representative trace from an MHS-Hom myotube and MHN myotube 
displaying the change in the slope of the Fura-2 fluorescence upon perfusion of 0.5 mM Mn2+. 
Note the greater gradient of the slope in MHS-Hom versus MHN myotubes.   
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This increased quench was observed in all three genotypes, however the median 
Mn2+ quench was greater in MHS-Hom at -0.229 (IQR -0.129 to -0.378) AFU/s versus 
MHS-Het at -0.184 (IQR -0.105 to -0.32) AFU/s, and MHN at -0.191 (-0.117 to -0.319) 
AFU/s (Figure 6.9). Kruskall-Wallis test revealed that there was a significant 
difference between genotypes (P=0.013), Dunn's multiple comparisons test indicating 
MHS-Hom myotubes had an elevated median Mn2+ quench relative to MHS-Het 
(P=0.015, n=300-311) and MHN myotubes (P=0.034, n=294-311). 
 
 
 
 
Figure 6.9: MHS-Hom myotubes exhibit an enhanced RCaE.  
Data showing the quench rate per second of the Fura-2 fluorescence by Mn2+ in MHN, 
MHS-Het and Hom myotubes from the RYR1 p.G2435R MH mouse model. Data displayed 
are the individual quench rates with a box-plot showing the median ± IQR. Increased quench 
is represented by a more negative number and this indicates a greater membrane cationic 
entry from the extracellular space. There was a significant enhancement in the RCaE in 
MHS-Hom relative to MHS-Het (P=0.015) and MHN (P=0.034, Kruskal-Wallis test with Dunn's 
multiple comparisons test). n=294-311 myotubes in multiple wells assayed over 10-15 days. 
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6.4.6 RCaE is Mediated by Non-Specific Cationic Channels 
 
To determine which channels were mediating the RCaE, 25 µM Gd3+ was used, and 
this concentration was chosen because it had previously been shown to be effective 
in earlier studies of other MH-RYR1 cells (Eltit et al. 2013). Exposure to Gd3+ 
produced a relatively rapid reduction in the quench (Figure 6.10A). This is particularly 
apparent when comparing slope A with C (MHN) or slope B with D (MHS-Hom); these 
represent the rate of quench in the absence and presence of Gd3+ (Figure 6.10A).  
25 µM Gd3+ profoundly blocked the Mn2+ quench to near baseline levels in all three 
genotypes (P<0.0001, Wilcoxon two-tailed matched-pairs test, n=65-96, 
Figure 6.10B). This reduction in the median quench was 88 % in MHN (n=65), 100 % 
in MHS-Het (n=72) and 96 % in MHS-Hom (n=96) (Figure 6.10B). Interestingly 
post-Gd3+ treatment, the median slope of the quench in MHN myotubes (-0.017 (0 to 
-0.086 AFU/s)) was over two-fold greater than that in MHS-Het (0 (IQR 0 to -0.037 
AFU/s)) and MHS-Hom (-0.008 (IQR 0 to -0.061)), suggesting that MHN cells are 
slightly less sensitive to 25 µM Gd3+ than the MHS cells. My results are consistent 
with those seen by Eltit et al. (2013) with the p.R163C cells, they reported a 74% and 
94% reduction in MHN and MHS-Hom cells respectively. 
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Figure 6.10: The RCaE is mediated by non-specific cationic channels.  
Representative traces from MHN and MHS-Hom myotubes that were initially perfused with 
MnB, followed by MnB containing 25 µM Gd3+. There was a rapid and profound decrease in 
the RCaE on application of the non-specific cationic channel blocker Gd3+, this is evident from 
the change in the gradient of the lines A and B versus C and D respectively. Lines A and B 
indicate the slope of the quench when MnB was perfused onto MHN and MHS-Hom myotubes 
respectively, and lines C and D the slope in the two respective genotypes following the 
addition of 25 µM Gd3+. (B) Application of 25 µM Gd3+ to each of the three genotypes produced 
a significant decrease in the rate of Mn2+ quench, with the greatest reduction observed in 
MHS-Hom and Het myotubes, compared to MHN myotubes. Individual data points shown and 
the median ± IQR. ****P<0.0001, Wilcoxon two-tailed matched-pairs test. n=65-96 myotubes 
from multiple wells for each genotype, these were assayed on 3 separate days. 
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6.4.7 RCaE in p.G2435R MHS is Mediated by TRPC Channels 
Next, in order to further identify the putative channels that mediate the RCaE several 
more specific sarcolemmal cationic channel blockers were used.  
 
6.4.7.1 BTP2 
In the first set of experiments, the CRAC and TRPC channel blocker BTP2 was used 
to ascertain if this was able to attenuate the RCaE. 5 µM BTP2 was used as previous 
studies have reported an IC50 for TRPC3 of 4.2 µM (Schleifer et al., 2012), and this 
concentration caused a reduction in the RCaE in the p.R163C mouse model (Eltit et 
al., 2013). Cells were pre-treated with BTP2 for 20 min and then continuously 
perfused with IB or MnB. BTP2 did not result in a reduction in the Mn2+ quench in 
MHN cells (Figure 6.11), in untreated cells the median slope was -0.191 (IQR -0.117 
to -0.319) AFU/s, and in treated it was -0.165 (-0.081 to -0.295) AFU/s (P=0.423, 
Kruskal-Wallis test with Dunn’s multiple comparison, n=294 and 60). In contrast, 
BTP2 caused a reduction in the Mn2+ quench in the MHS-Het cells from -0.184 (-0.32 
to -0.105)  AFU/s to -0.109 (-0.082 to -0.153) AFU/s (P<0.0001, Kruskal-Wallis test 
with Dunn’s multiple comparison, n=300 and 50), and a reduction in Mn2+ quench in 
MHS-Hom cells from -0.229 (-0.129 to -0.378) AFU/s to -0.086 (-0.052 to -0.127) 
AFU/s (P<0.0001, Kruskal-Wallis test with Dunn’s multiple comparison, n=311 and 
57). The median Mn2+ quench in BTP2 treated MHS-Het (-0.184 AFU/s) and Hom (-
0.109 AFU/s) cells was also lower than that seen in non-BTP2 treated MHN cells (-
0.191 AFU/s) (P<0.0001, Kruskal-Wallis test with Dunn’s multiple comparison, n=50-
294).  
 
There was no difference between the Mn2+ quench seen in BTP2 treated MHS-Het 
(-0.109) and MHS-Hom (-0.086) myotubes (P>0.999, Kruskal-Wallis test with Dunn’s 
multiple comparison, n=50-294). Furthermore, MHS-Het and MHN myotubes did not 
have a difference in their rates of quench (P=0.14, Kruskal-Wallis test with Dunn’s 
multiple comparison, n=50 and 60, respectively). In contrast, BTP2 caused a 
reduction in the quench in MHS-Hom relative to MHN myotubes treated with BTP2 
(P=0.001, Kruskal-Wallis test with Dunn’s multiple comparison, n=57 and 60).  
 
 
 
 
 172 
 
 
Figure 6.11: MHS myotubes have an enhanced sensitivity to BTP2. Chart showing the 
effects of a 20 min pre-treatment with 5 µM BTP2 on the fluorescence quench rate in the three 
genotypes. BTP2 caused a reduction in the Mn2+ quench rate in MHS-Het and MHS-Hom 
myotubes. There was no significant difference between MHN myotubes treated with and 
without 5 μM BTP2, or between BTP2 treated MHS-Het and MHS-Hom myotubes. Individual 
data points shown and the median ± IQR. ****P<0.0001, Kruskal-Wallis test with Dunn’s 
multiple comparison. n=50-311 myotubes from multiple wells for each genotype, these were 
assayed over 6-15 separate days. 
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6.4.7.2 SAR7334 
 
The TRPC3, 6 and 7 blocker SAR7334 was used to separate the role of the TRPC3/6 
pathway from CRAC channels in the enhanced Mn2+ quench observed in MHS-Hom 
cells (Maier et al., 2015). SAR7334 was also used to further assess whether there 
was a potential difference in the resting sarcolemmal cation permeability between 
MHS-Het and MHN cells. A 250 nM concentration of SAR7334 was used as previous 
studies have shown an IC50 of 9.5, 282 and 225 nM for TRPC6, 3 and 7, respectively 
(Maier et al., 2015). 
 
The perfusion of myotubes with MnB containing 250 nM SAR7334 caused a relatively 
rapid decrease in the Mn2+ quench in MHS-Het and MHS-Hom, but not in MHN 
myotubes (Figure 6.12A and B). SAR7334 did not affect the median slope in MHN 
myotubes which was -0.196 (IQR -0.143 to -0.284) AFU/s pre-SAR7334, and 0.182 
(-0.1239 to -0.2791) AFU/s post-SAR7334 (P>0.999, Kruskal-Wallis test with Dunn’s 
multiple comparison, n=49). In MHS-Het, SAR7334 decreased the median Mn2+ 
quench from -0.204 (-0.144 to -0.270) AFU/s to -0.113 (-0.066 to -0.181) AFU/s 
(P<0.005, Kruskal-Wallis test with Dunn’s multiple comparison, n=53), and in MHS-
Hom it decreased the median Mn2+ quench from -0.256 (-0.101 to -0.312) AFU/s 
to -0.081 (-0.047 to -0.178) AFU/s (P<0.001, Kruskal-Wallis test with Dunn’s multiple 
comparison, n=35). Furthermore, 250 nM SAR7334 treatment caused a decrease in 
the Mn2+ quench observed in MHS-Het and MHS-Hom compared to untreated MHN 
cells (P=0.006 and P=0.001 respectively, Kruskal-Wallis test with Dunn’s multiple 
comparison, n=35-53).  However, comparisons between Mn2+ quench observed in 
SAR7334 treated MHS-Hom myotubes versus SAR7334-treated MHN myotubes 
revealed a decrease in the quench in in the MHS-Hom (P=0.018, Kruskal-Wallis test 
with Dunn’s multiple comparison, n=35-49). This difference was not observed 
between SAR7334 treated MHS-Het cells and SAR7334-treated MHN cells (P=0.088, 
Kruskal-Wallis test with Dunn’s multiple comparison, n=49-53). 
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Figure 6.12: MHS myotubes have an enhanced sensitivity to SAR7334.  (A) 
Representative traces indicating the effects of applying 250 nM SAR7334 on the fluorescence 
quench rate in the three genotypes. In each genotype, line A and B represent the slope pre- 
and post-SAR7334 treatment. In MHS-Het and Hom, there was a relatively rapid change in 
the quench rate when SAR7334 was applied. (B) The responses to 250 nM SAR7334 in the 
three genotypes. SAR7334 triggered a reduction in the Mn2+ quench rate in MHS-Het and 
MHS-Hom myotubes, but not MHN myotubes. Individual data points shown and the median ± 
IQR. **P<0.01, ***P<0.001, Kruskal-Wallis test with Dunn’s multiple comparison. n=50-311 
myotubes from multiple wells for each genotype, and assayed over 6-15 separate days. 
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6.4.7.3 OAG 
 
The preceding Mn2+ quench experiments have investigated the response to cationic 
channel antagonists, in the next set of experiments, the effects of direct and indirect 
TRPC3 and 6 channel agonists are explored. Diacylglyceride (DAG) is known to 
indirectly activate the TRPC3 and 6 channels through a receptor operated pathway 
that is independent of protein kinase C (PKC) (Hoffman et al., 1999; Venkatachalam 
et al., 2003). A membrane permeable DAG analogue 1-oleoyl-2-acetyl-sn-glycerol 
(OAG), was used to investigate the effects of a TRPC3/6 channel agonist on the Mn2+ 
quench (Tu et al., 2009; Ikeda et al., 2013).  
 
Pre-treatment with 100 µM OAG for 5 min induced an enhanced Mn2+ quench in all 
three genotypes (Figure 6.13). The median Mn2+ quench increased in MHN 
from -0.191 (IQR -0.117 to -0.319) to -0.383 (-0.237 to -0.494) AFU/s, (P<0.0001, 
Kruskal-Wallis with Dunn’s multiple comparisons test, n=52 - 294). In MHS-Het 
100 µM OAG increased Mn2+ quench by 104 % from -0.184 (-0.105 to -0.320) 
to -0.374 (-0.188 to -0.719) AFU/s, (P<0.0001, Kruskal-Wallis with Dunn’s multiple 
comparisons test, n=35-300), and in MHS-Hom OAG increased the quench 
from -0.229 (-0.128 to -0.3784) to -0.397 (-0.212 to -0.596) AFU/s, (P<0.0001, 
Kruskal-Wallis with Dunn’s multiple comparisons test, n=54-311). There was no 
significant difference in the increase induced by 100 µM OAG among treated MHN, 
MHS-Het and MHS-Hom myotubes (P>0.999, Kruskal-Wallis with Dunn’s multiple 
comparisons test). 
 
In order to examine whether SAR7334 was able to antagonise the OAG mediated 
increase, myotubes were treated with 250 nM SAR7334 following the OAG exposure 
in a paired treatment paradigm (Figure 6.13). In each genotype, SAR7334 
antagonised the OAG induced enhanced Mn2+ quench by restoring it to baseline 
levels (P<0.0001, Wilcoxon matched-pairs signed rank test, n=35-54). In MHS-Hom 
SAR7334 decreased the median quench from -0.397 (-0.212 to -0.596) AFU/s 
to -0.190 (-0.129 to -0.345) AFU/s, in MHS-Het the reduction was from -0.374 (-0.188 
to -0.719) AFU/s to -0.227 (-0.076 to -0.477) AFU/s, and in MHN from -0.383 (-0.237 
to -0.494) AFU/s to -0.216 (-0.154 to -0.316) AFU/s. 
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Figure 6.13: TRPC3/6 channels mediate the RCaE.   
Chart showing the effects of 100 µM OAG in the absence and presence of 250 nM SAR7334 
in the three genotypes. Treatment with OAG a membrane permeable analogue of the 
secondary messenger DAG caused a significant increase in the Mn2+ quench rate in all three 
genotypes. DAG is known to activates TRPC3/6 channels, this stimulatory effect of 100 µM 
OAG was abolished with the application of 250 nM SAR7334 in all three genotypes. Individual 
data points shown and the box-plots are the median ± IQR. ****P<0.0001, Kruskal-Wallis test 
with Dunn’s multiple comparison for OAG versus the untreated myotubes.  ****P<0.0001, 
Wilcoxon matched-pairs signed rank test for OAG versus OAG + SAR7334. n=35-311 
myotubes from multiple wells for each genotype, these were assayed over 4-15 separate 
days. 
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6.4.7.4 Hyperforin 
 
DAG is a major secondary messenger that activates multiple proteins involved in a 
variety of signalling cascades. In contrast, hyperforin is a TRPC6 agonist that is 
thought to have no effect on TRPC3, TRPC4 or TRPC5 (Leuner et al., FASEB 2007). 
The latter was used to assess the effects of increasing the activity of TRPC6 in the 
three genotypes. 5 µM hyperforin caused a significant increase in the Mn2+ quench in 
all three genotypes (P<0.0001 n=37-54, Wilcoxon matched-pairs signed rank test for 
each genotype, Figure 6.14A and B). However, the response was not rapid when 
compared to Gd3+ or SAR7334, in those experiments within 20 s of perfusing the 
drugs there was a visible change in the slope of the quench (Figure 6.10A and 12A), 
however with hyperforin the response took at least 30 s (Figure 6.14A). 
Consequently, the slope of the quench in the fluorescence was only examined 60 s 
after starting the application of hyperforin (Figure 6.14A). In MHN myotubes, there 
was an increase in the median Mn2+ quench from -0.204 (IQR -0.204 to -0.262) AFU/s 
to -0.306 (-0.180 to - 0.462) AFU/s, in MHS-Het the increase was even more profound 
at from -0.160 (-0.109 to -0.264) AFU/s to -0.279 (-0.200 to -0.471) AFU/s, but in 
MHS-Hom the increase although significant, was less drastic from -0.167 (-0.118 
to -0.274) to -0.239 (-0.148 to -0.462) AFU/s. The differences observed within each 
genotype were still significant when analysed using a Kruskal-Wallis with Dunn’s 
multiple comparisons test where P=0.023, <0.0001 and 0.024 for MHN, MHS-Het, 
and MHS-Hom, respectively, n=37-54. There was no significant difference between 
the three genotypes in the Mn2+ quench following 5 µM hyperforin treatment 
(P=0.433-0.999, n=37-54, Kruskal-Wallis with Dunn’s multiple comparisons test). 
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Figure 6.14: TRPC6 partly mediate the RCaE.  (A) Representative traces indicating the 
effects of applying 5 µM hyperforin (HYPERF) on the fluorescence quench rate in the three 
genotypes. In each genotype, line A and B represent the slope pre- and post-hyperforin 
treatment. In all three genotypes hyperforin increased the quench rate. (B) The summary of 
the effects of 5 µM hyperforin on the three genotypes. Hyperforin induced a significant 
elevation in the Mn2+ quench rate in all three genotypes. All data points are shown with the 
box-plots representing the median ± IQR. ****P<0.0001, Wilcoxon matched-pairs signed rank 
test. n=37-54 myotubes from multiple wells for each genotype, these were assayed over 3 
separate days. 
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6.4.8 RYR1 Leak Contributes to the Enhanced RCaE 
 
It has been reported by several groups that MHS myotubes have an enhanced 
release of SR Ca2+ mediated by a MH-variant related RYR1 leak (Tong et al., 1999; 
Brini et al., 2005; Yang et al., 2007; Eltit et al., 2013; Cully et al., 2018). To investigate 
whether the leak was responsible for the enhanced Mn2+ quench observed in 
unstimulated MHS cells versus MHN cells, the RyR1 inhibitor tetracaine was used 
(Pickering et al. 2009; Cully et al. 2018). 1 mM tetracaine caused a rapid reduction in 
the Mn2+ quench observed in MHS-Het and MHS-Hom myotubes (Figure 6.15A and 
B). In MHN cells, tetracaine reduced the rate of quench from -0.203 (IQR -0.107 
to -0.353) AFU/s to -0.147 (-0.056 to -0.338) AFU/s, but this was not statistically 
significant (P>0.999, n=41, Kruskal-Wallis with Dunn’s multiple comparisons test). In 
MHS-Het, 1 mM tetracaine reduced the rate of Mn2+ quench from -0.288 (-0.159 to -
0.447) AFU/s to -0.159 (IQR -0.062 to -0.282) AFU/s (P=0.022, n=33, Kruskal-Wallis 
with Dunn’s multiple comparisons test). Tetracaine also reduced the rate of Mn2+ 
quench in MHS-Hom from -0.320 (-0.255 to -0.403) AFU/s to -0.167 (-0.104 to -0.235) 
AFU/s (P=0.0004, n=31, Kruskal-Wallis with Dunn’s multiple comparisons test). The 
rate of Mn2+ quench was not different between tetracaine treated MHN, MHS-Het and 
MHS-Hom myotubes (P>0.999 for both, n=31-41, Kruskal-Wallis with Dunn’s multiple 
comparisons test). Similarly, there was no difference in the Mn2+ quench between 
tetracaine treated MHS-Het and MHS-Hom myotubes, compared with non-tetracaine 
treated MHN myotubes (P=0.539 and P=0.578 respectively, n=31-41, Kruskal-Wallis 
with Dunn’s multiple comparisons test).  
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Figure 6.15: The RYR1 leak mediates an enhanced RCaE.  (A) Representative traces 
indicating the effects of the RYR1 blocker tetracaine (1 mM) on the fluorescence quench rate 
in the three genotypes. In each genotype, line A and B represent the slope pre- and post-
tetracaine (TET) treatment. (B) The summary of the responses to 1 mM tetracaine in the three 
genotypes. Blocking the RYR1 leak using tetracaine caused a significant decrease in the Mn2+ 
quench rate in MHS-Het and MHS-Hom myotubes, but not in MHN. Individual data points are 
shown with the box-plots representing the median ± IQR. *P<0.05, ***P<0.001, Kruskal-Wallis 
test with Dunn’s multiple comparison. n=31-41 myotubes from multiple wells for each 
genotype, these were assayed over 3 separate days. 
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6.5 Discussion  
RYR1 p.G2434R is the most common human MH variant found in the UK and is a 
diagnostic variant for MH (EMHG diagnostic mutations, 2019). It is also the most 
common variant to be associated with genotype-phenotype discordance (Robinson 
et al., 2003; Carpenter et al., 2009; Miller et al., 2019). It is not comprehensively 
understood how the p.G2434R variant or other MH-associated variants induce 
susceptibility to MH at the molecular level. It is generally accepted  that the RYR1 
variants result in a leaky RYR1 channel that releases the SR Ca2+, and there is an 
overall perturbation in the Ca2+ handling observed in these cells. Furthermore, there 
is growing evidence to suggest that the entry of extracellular Ca2+ plays an important 
role in skeletal muscle during physiological and pathophysiological states such as in 
MH (Duke et al., 2010, Edwards et al., 2010, Eltit et al., 2013, Cully et al., 2018). By 
understanding the detailed molecular events that mediate the perturbed Ca2+ 
handling will facilitate a better insight into MH and help clarify the genotype-phenotype 
differences.  
 
In order to study the molecular mechanisms underlying the susceptibility conferred 
by this variant, a novel KI mouse model expressing the isogeneic p.G2435R RyR1 
variant was created. In this chapter evidence was presented to add to the mechanistic 
understanding of this model, and develops on the data published by Lopez et al. 
(2018).  Myotubes from the RyR1 p.G2435R KI mouse model were shown to have a 
genotype dependent enhanced sensitivity to the direct agonists and/or indirect 
activators of RyR1 (caffeine, halothane and KCl). Cells from this novel KI MH mouse 
model were used to demonstrate the differences in the way divalent cations (i.e. Ca2+) 
are handled by sarcolemmal cation channels in the MHS cells, particularly those from 
MHS-Hom animals. I demonstrated that the enhancement in the entry of extracellular 
Ca2+ termed the RCaE was mediated by TRPC3 and 6 channels and driven by the 
enhanced leak from SR stores from the p.G2435R RyR1 channel. 
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6.5.1 The Validation of the Novel p.G2435R KI Mouse Model of MH 
Myotubes provide one method of studying the physiology of skeletal muscle cells. 
They have the advantages of utilising a renewable source of cells (myoblasts) and so 
assist in reducing the number of animals required for experiments in support of the 
National Centre for Replacement Refinement, and Reduction of animals in Research 
(NC3R) strategy (https://www.nc3rs.org.uk). However, one limitation of myotubes is 
their lack of a well-developed T-tubular system. Nevertheless, ECC can be studied in 
these cells and has been shown to be present in myotubes that have undergone 3 
days or more of differentiation (Barientos et al., 2012; Bannister et al., 2013; Eltit et 
al., 2013; Altamirano et al., 2014; Perez et al., 2018). In my experiments, the ECC 
apparatus was confirmed to be functioning as myotubes responded to a 60 mM KCl 
challenge.  
 
When the myotubes were challenged with different concentrations of KCl, there was 
a gene-dose dependent enhanced sensitivity, with the lowest EC50 determined in 
MHS-Hom (Table 6.1). These results were consistent with those from the p.R163C 
MH mouse model by Yang et al., (2006), and as I have done in this chapter for my 
primary outcomes, they also  focussed on the AUC component of the responses. As 
discussed in section 4.5.1.2 AUC integrates various process involved in the Ca2+ flux 
over a set time period, whereas the peak response provides a snapshot of the 
maximum Ca2+ release. When the peak responses to KCl were examined, the EC50 
in MHS-Het was not significantly different from MHN; this may be due to the data 
being underpowered to examine this, as the number of myotubes were comparatively 
less than that used in the caffeine experiments.  Although, if this was a real effect it 
would suggest that the immediate Ca2+ release from the RYR1 proteins is similar to 
MHN. In contrast, the more dynamic results seen using the AUC results, indicate that 
the KCl depolarisation of p.G2435R-Het myotubes significantly affects the overall SR 
Ca2+ handling relative to the native wild-type channel.  
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 EC50 KCl (µM) EC50 Caffeine (µM) 
 p.G2435R p.R163C p.G2435R p.R163C 
MHS-Hom 11.2 12.1 1.8 2.5 
MHS-Het 16.2 16.4 4.5 3.3 
MHN 21.4 21.3 5.7 6.5 
Table 6.1: Summary of EC50 for KCl and caffeine in myotubes from the p.G2435R and 
p.R163C mouse models. The p.R163C data from Yang et al., (2006). 
 
The AUC EC50 for caffeine found in p.G2435R were consistent with the p.R163C 
model (Table 6.1). However, in contrast to the AUC KCl results, the caffeine sensitivity 
of p.G2435R MHS-Het myotubes was closer to that of MHN myotubes, particularly 
with the peak responses. This similarity may be result of experimental variability, 
although it could be a true pharmacological effect as studies with fibres from the 
p.G2435R mouse model have shown only a marginally elevated [Ca2+]i in MHS-Het 
(156 nM) compared with MHN fibres (123 nM) (Lopez et al., 2018). Table 6.2 
summarises the [Ca2+]i in skeletal muscle fibres from different mouse models of MH 
which were measured using microelectrodes (Yang et al., 2006; Yuen et al., 2012; 
Lopez et al., 2018). The principal finding is that p.G2435R fibres have a more modest 
elevation in [Ca2+]i relative to the other KI MH models, for instance the MHS-Het in 
this model have a 33 nM increase in the fibre [Ca2+]i versus wild-type, whereas it is 
208 nM and 175 nM higher  in fibres from p.R163C and p.T4826I heterozygous mice 
respectively. Similarly the increase in [Ca2+]i in fibres from mice homozygous for the 
p.G2435R,  p.R163C, p.T4826I  is 132 nM, 214 nM and 228 nM  greater than in wild-
type fibres.  
 
Table 6.2: Intracellular [Ca2+] measured using direct microelectrodes in different mouse model 
of MH. Values are in nM and from skeletal muscle fibres except in the p.R163C-Hom where 
the values are from myotubes as these animals are not viable post-partum. Data from Yang 
et al., 2006, Yuen et al., 2012, Lopez et al., 2018. It is important to note that the [Ca2+]i found 
in myotubes from these KI mouse models are within 20 % to that found in their skeletal muscle 
fibres (Yuen et al., 2012, Eltit et al., 2013). Yang et al., Anesthesiology, 2006.
Yuen et al., FASEB, 2012.
Lopez et al., BJA 2018.
[Ca2+}i (nM) R163C T4826I G2435R
WT 120 ± 0.3 117 ± 5 123 ± 3 
Het 328 ± 1.2  292 ± 14 156 ± 16
Hom (334 ± 2) 345 ± 19 265 ± 32 
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Comparisons made between the measured [Ca2+]i and the concentration-response 
curves to RYR1 agonists have revealed that the results with caffeine (using AUC 
data) appear to provide a better reflection of the [Ca2+]i found in these KI MH mouse 
models. For example the p.R163C MHS-Het have a concentration-response curve 
that is closer to MHS-Hom and these have a similar [Ca2+]i (Yang et al., 2006). In 
contrast, the response to caffeine in p.G2435R MHS-Het myotubes have a closer 
relation to MHN where the [Ca2+]i is comparable (Lopez et al., 2018). A mechanism 
to explain this could be that the higher [Ca2+]i in the low µM range results in RYR1 
channels that are more sensitive to the effects of caffeine. As discussed earlier, low 
µM cytosolic Ca2+ concentrations have been shown to activate RYR1 and at higher 
mM concentration inactivate the channel (Melzer et al., 1995; Laver et al., 1997a; 
Lamb, 2000; Laver et al., 2004). The latter feature also explains the reduction in the 
fluorescence that preceded the cessation of caffeine perfusion (section 6.4.2).  
 
Experiments to further investigate a correlation between [Ca2+]i and concentration -
response curves in MHS models would be very useful in helping understand this. This 
could be accomplished by utilising myotubes or fibres from the different MH mouse 
models. An alternative method is using skinned MH fibres with the [Ca2+]i manipulated 
by applying the methods of either the Steele (Duke et al., 2010) or Launokonis 
laboratories (Choi et al., 2017; Cully et al., 2018). However, it is likely that the true 
mechanism for the enhanced sensitivity to caffeine in MH is a lot more complex than 
this, as for example at higher concentrations of caffeine (>3 mM) the membrane 
potential is affected due to an increased [Ca2+]i, which then causes a depolarisation 
and uncoupling of ECC  (Herrmann-Frank et al., 1999).  
 
The response of the p.G2435R myotubes to halothane also exhibited a gene-dose 
dependent effect, with MHS-Hom the most sensitive (Lopez et al., 2018). This is 
consistent with the initial hypothesis. Both MHS-Het and Hom myotubes had a greater 
response than MHN to 0.1 mM halothane. A concentration of 0.11 mM halothane is 
equivalent to 0.5 % halothane according to the EMHG protocol (Hopkins et al.,2015).  
 
Direct comparisons of my data with the wider literature is hampered by the absence 
of publications utilising halothane with myotubes from other MH mouse models. 
Nevertheless, in human myotubes halothane concentrations ≧3.9 mM were used to 
detect a difference between MHS and MHN patients (Censier et al., 1998; Girard et 
al., 2002). However, 3.9 mM halothane is supranormal in clinical practice, furthermore 
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the EMHG IVCT guidelines state that the diagnosis of susceptibility to MH using 
halothane (MHSh) requires a contracture of at least 2 mN using ≦0.44 mM halothane 
(Hopkins et al., 2015). It is important to note that changes in [Ca2+]i as measured using 
fluorescent microscopy may not directly relate to contractures in fibres, furthermore, 
there may be species-dependent variations in the sensitivity to halothane. Indeed, 
previous experiments by Feng et al., (2015) have shown a clear difference in the 
response of MHN and p.R163C MHS-Het mouse skeletal muscle fibres to 0.1 % 
volume/volume halothane.  
 
Although there is a paucity of literature on the effects of halothane on Ca2+-dependent 
fluorescence in myotubes, there is sufficient evidence from skeletal muscle fibres. 
Lopez et al., (2018) reported that upon exposure to halothane there was a significant 
increase in [Ca2+]i and [Na+]i in both p.G2435R MHS-Het and Hom fibres compared 
with MHN fibres. Interestingly, the magnitude of the increase was attenuated relative 
to those witnessed in the p.R163C and p.T4826I models (Yang et al., 2006; Feng et 
al., 2011; Barientos et al., 2012; Altamirano et al., 2014; Lopez et al., 2018). This 
diminished response is coherent with the p.G2435R expressing a weaker phenotype 
and lower resting [Ca2+]i; the former mirrors observations in humans with p.G2434R 
(Carpenter et al., 2009). Consistent with this concept, Diaz-Sylvester et al., (2008) 
have reported an enhanced RYR1 response to halothane with increasing [Ca2+]i in 
single-channel experiments using native rabbit RYR1. These observations are likely 
to also explain why there was no significant difference in the response to 0.04 mM 
halothane between MHN and p.G2435R MHS-Het myotubes given the 33 nM 
difference in their resting [Ca2+]i (Table 6.2). Thus, as mentioned for KCl and caffeine 
above, it would be interesting to assess the effects of altering the [Ca2+]i on the 
halothane responses.  
 
Collectively these results together with other data published by Lopez et al., (2018) 
suggest that p.G2435R is a model that has utility in studying the molecular 
mechanisms underlying the human p.G2434R MH response and to help elucidate the 
aforementioned genotype-phenotype discordance. However, additional experiments 
that would provide even further evidence for the utility of this model include 
investigating whether the effect of dantrolene in this model parallels that seen in 
human MH and other KI mouse models of MH. It would also be interesting to explore 
the consequences of decreasing the extracellular [Ca2+] on the response of p.G2435R 
myotubes to caffeine, KCl and halothane, particularly as there is growing evidence 
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for the role of extracellular Ca2+ influx on maintaining the altered Ca2+  homeostasis 
seen in MH susceptible cells (Altamirano et al., 2014; Cully et al., 2018). These 
experiments would also assist in assessing the importance of extracellular [Ca2+] in 
perpetuating the triggered MH response in MHS individuals (Duke et al., 2010; Eltit 
et al., 2013).  
 
 
6.5.2 Increased RYR1 Leak Drives an Enhanced Entry of Extracellular 
Ca2+ in p.G2435R. 
The major findings of the experiments investigating the RCaE in p.G2435R myotubes 
are: 
1. Extracellular Ca2+ entry termed RCaE was present in all three genotypes. 
2. The RCaE was significantly elevated in MHS-Hom myotubes. 
3. Gd3+ profoundly abolished the RCaE in all three genotypes. 
4. There was a genotype dependent effect of known agonists and antagonists of 
TRPC3/6. 
5. The RYR1 leak appeared to mediate an enhanced RCaE. 
 
6.5.2.1 Extracellular Ca2+ Entry is Enhanced in MHS-Hom. 
There is growing evidence for the importance of extracellular Ca2+ entry in skeletal 
muscle cells in physiological and pathological states (Eltit et al., 2013; Wei-Lapierre 
et al., 2013; Cully et al., 2018). Here I have shown using the Mn2+ quench assay that 
there is a cationic influx in all three genotypes with the most likely cation being Ca2+ 
(Merrit et al., 1989; Hofmann et al., 1999; Kurebayashi and Ogawa, 2001).  This entry 
was present in the resting state of the cells and thus is classed as RCaE instead of the 
traditional SOCE where severe SR store depletion is required to trigger the 
extracellular Ca2+ influx (Kurebayashi and Ogawa, 2001). The presence of a RCaE in 
MHN as well as MHS myotubes is consistent with the results of Eltit et al., (2010, 
2013); they reported the presence of a Mn2+ quench in wild-type RYR1 and p.R163C 
myotubes. In my results, a significant elevation in the RCaE was only detected in 
p.G2435R MHS-Hom myotubes, and this satisfies the aforementioned cell boundary 
theorem (Rios 2009). However, the difference between the RCaE in MHS-Hom and 
MHN were not as distinct as has previously been observed in p.R163C (Eltit et al., 
2013). Furthermore, in contrast to my hypothesis, p.G2435R MHS-Het myotubes did 
not have an elevated RCaE despite having a raised [Ca2+]i.  
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Both of the above maybe explained by the measured [Ca2+]i (table 6.2) which is  not 
as drastically elevated in p.G2435R MHS-Het and Hom mice compared with previous 
KI mouse models of MH. If my working hypothesis is correct, then a lower [Ca2+]i 
would necessitate a smaller influx of extracellular Ca2+ to maintain the intracellular 
Ca2+ homeostasis in these models. In p.G2435R MHS-Het this influx maybe too small 
to resolve with the Mn2+ quench assay because the [Ca2+]i is only 33 nM greater than 
that found in MHN. Furthermore, in p.G2435R MHS-Hom the increase in [Ca2+]i at 
rest is  132 nM versus control wild-type fibres, and this is still much lower than the 
elevations observed in  p.R163C-Het (208 nM) and p.R163C-Hom (214 nM). This lack 
of resolution in the Mn2+ quench assay is compounded by fact that the RCaE is a small 
signal (i.e. has a smaller signal to noise ratio) compared with that observed during 
SOCE measurement in fully depleted cells (Kurebayashi and Ogawa, 2001; Li et al., 
2010; Wei-Lapierre et al., 2013).  
 
The effect of a gene-dose on the RCaE has not previously been investigated in other 
MHS models thus precluding the ability to make comparisons with p.G2435R results. 
Therefore, a further avenue of research would be to investigate the effect of gene-
dose on the RCaE in other KI mouse models of MH models. An additional extension of 
this study would be to investigate the RCaE in the three p.G2435R genotypes at the 
physiological temperature. The current experiments were performed at room 
temperature where the SERCA pumps are postulated to have an enhanced ability to 
compensate for a modestly increased leak which would be expected in p.G2435R 
MHS-Het. Consistent with this theory, Durham et al. (2008) found a temperature 
dependent increase in [Ca2+]i in myotubes and soleus muscle fibres using the 
p.Y522S model. At 23 ºC the [Ca2+]i in the p.Y522S-Het and wild-type fibres were not 
significantly different,  whereas they were at 37 ºC, and this temperature dependent 
increase in [Ca2+]i was antagonised by inhibitors of reactive nitrogen species (RNS). 
Furthermore, using the p.T4826I model,  Barrientos et al., (2012) also reported a 
temperature dependent enhancement in the sensitivity to [3H]Ryanodine binding 
which was deemed to emanate from a greater open probability of the mutant 
channels. 
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6.5.2.2 TRPC Channels Mediate the Enhanced RCaE 
Gadolinium is a trivalent ion which has a high charge density and a similar ionic radius 
to Ca2+. It is known to block cationic channels that allow the permeation of Ca2+, and 
has previously been shown to cause a concentration-dependent inhibition in the influx 
extracellular cations in MHS and non-MHS cells (Vandebroucka et al., 2002; Eltit et 
al., 2013). The higher concentration of 25 µM Gd3+ was utilised to help determine if 
the RCaE could be attenuated. The profound block observed with Gd3+ suggested that 
the non-specific cationic channels were indeed mediating the RCaE. The reduction 
seen in MHN was less than in p.G2435R MHS-Het and MHS-Hom myotubes which 
suggests that former are less dependent on the non-specific cationic channels than 
the latter. This may be a consequence of a genotype dependent difference in the 
expression/activity of several cationic channels. Thus, in order to determine what 
specific channels were mediating the enhanced RCaE observed in MHS-Hom, BTP2 
was used.  
 
BTP2 is a more selective blocker of CRAC and TRPC channels. In my experiments 
it was found to cause a reduction in the RCaE in MHS-Het and MHS-Hom myotubes, 
but not in MHN. This suggests that the channels blocked by this compound had a 
differential activity/expression in the three genotypes. Consistent with this were the 
results showing that treatment of MHS-Hom and MHS-Het myotubes with BTP2 
caused a decrease in the RCaE relative to untreated MHN myotubes.  The BTP2 
mediated attenuation in the RCaE was not as profound as that seen with Gd3+, and this 
suggests that other cellular cationic entry pathways that are insensitive to BTP2 were 
still functioning. Nevertheless, treatment with BTP2 was able to distinguish a 
difference between BTP2 treated MHS-Het myotubes versus non-treated MHN 
myotubes.  This latter finding supports the aforementioned theory that the Mn2+ 
quench assay is unable to distinguish between very small changes in the RCaE, but 
this is overcome with the use of a more selective blocker that was able to magnify the 
differences, and revealed a difference in the Ca2+ handling. 
 
The TRPC3/6 blocker SAR7334 caused a significant decrease in the RCaE in MHS-
Het and MHS-Hom myotubes, and this supports the involvement of these channels 
in the enhanced RCaE detected in MHS-Hom. The SAR7334 results also suggest that 
although there was no significant difference in the baseline Mn2+ quench in MHN and 
MHS-Het myotubes, application of a cation channel blocker that is more selective to 
TRPC3 and 6 channels, was able to distinguish a difference in the RCaE between the 
two genotypes (Figure 6.12 A and B). 
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The degree of blocks observed with BTP2 and SAR7334 in MHS-Het and Hom 
myotubes were quite similar at -0.109 AFU/s (BTP2) versus -0.113 AFU/s (SAR7334) 
in MHS-Het, and -0.086 AFU/s (BTP2) versus -0.081 AFU/s (SAR7334) in MHS-Hom. 
This suggests a dominance of the TRPC pathways in mediating the RCaE given that 
BTP2 antagonises both CRAC and TRPC channels whereas SAR7334 is only known 
to affect the latter. However, this postulated TRPC dominance does not preclude the 
STIM-ORAI pathway as STIM-1 and ORAI channels are known to interact with 
TRPC3/6 channels (Liao et al., 2007; Yuan et al., 2007), although others contest this 
(DeHaven et al., 2009). This conflict in the literature may emanate from the use of 
transiently transfected HEK cells in some studies; these do not have the complex 
machinery observed in skeletal muscle cells. Other reasons include less robust 
removal of proteins when employing siRNA knock-down methods instead of a 
complete knock-out. Unpublished western blot experiments undertaken by 
collaborators of the UK MH unit shows that in line with the BTP2 and SAR7334 
pharmacological data reported in this thesis, there is a genotype dependent increase 
in the expression of TRPC3 and particularly TRPC6 proteins in MHS cells. 
 
Additional investigations into the TRPC3/6 involvement in the RCaE utilised OAG, a 
membrane permeable analogue of DAG. DAG is involved in key cellular processes 
in skeletal muscle and other non-excitable cells. It is produced by the cleavage of 
phosphatidylinositol-4,5-bisphosphate (PIP2) to generate DAG and inositol-1,4,5-
trisphosphate (IP3). The later travels to the cytosol to activate intracellular receptors, 
whereas DAG remains localised to the plasmalemma where it recruits protein kinase 
C, and activates TRPC3 and 6 channels (Hoffman et al., 1999; Gudermann et al., 
2004). 100 µM OAG was found to increase the RCaE in all three genotypes to similar 
levels, but the largest increases were in both MHN (100 %) and MHS-Het (104 %) 
compared with MHS-Hom (73 %). While this is still consistent with a relatively greater 
TRPC3/6 channel activity at baseline in MHS-Hom, it was expected that the RCaE in 
these myotubes would increase much more than was observed in the experiments, 
particularly at the concentration of OAG used. 
 
The application of 250 nM SAR7334 returned the OAG mediated increased in RCaE 
back to baseline which is consistent with TRPC3/6 channels mediating the effects of 
OAG. It is interesting to note that the OAG-SAR7334 experiment revealed a genotype 
selective effect; in MHS-Hom SAR7334 treatment after OAG was able to reduce the 
RCaE by 18 % relative to the untreated MHS-Hom myotubes, however in MHN and 
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MHS-Het myotubes the RCaE post SAR7334 was actually 13 % and 23 % greater than 
their respective baseline RCaE.  
 
SAR7334 is known to be both a TRPC3 and TRPC6 antagonist, it has IC50 of 9.5 nM 
for the latter and 282 nM for the former (Maier et al., 2015). At 250 nM, SAR7334 
would be expected to have a greater effect on channels containing TRPC6. 
Consequently, in order to further assess whether TRPC6 channels were influencing 
the RCaE, hyperforin a TRPC6 agonist was used (Leuner et al., 2007). Hyperforin 
induced a significant increase in the RCaE in all three genotypes, with the greatest 
effect in MHS-Het. Although the results suggest this TRPC6 agonist is able to 
enhance the RCaE, the data were not consistent with the initial hypothesis for several 
reasons. The first is that one would expect the RCaE to be greater in MHS-Hom, 
however in this set of experiments it was greater in MHN. This may simply emanate 
from the aforementioned large variability observed when utilising the Mn2+ quench 
method to assess the RCaE. Another unexpected finding was that the largest increase 
was seen in MHS-Het, it would have been expected this increase would be more 
prominent in either MHS-Hom or if in this genotype the TRPC6 channel activity was 
close to its saturation, then MHN cells. Consequently, further experiments are 
necessary to assess whether the hyperforin results are reproducible with newer 
TRPC3/6 agonists such as GSK1702934A as well as the novel antagonists 
GSK417651A and GSK2293017A (Xu et al., 2013). Molecular biological tools such 
as siRNA or ideally CRISPR-CAS editing to knock-down or out these TRPC channels 
would be a useful future direction for assessing the effect of these channels on the 
RCaE as well as on SOCE.  
 
6.5.2.3 RYR1 Leak Drives the Enhanced RCaE 
It is well accepted that MH variants cause an increased RYR1 leak of Ca2+ in MHS 
cells (Tong et al., 1999; Brini et al., 2005; Yang et al., 2007; Eltit et al., 2013; Cully et 
al. 2018). This leak can be blocked by tetracaine an ester local anaesthetic that 
reversibly inhibits RYR1 with an IC50 of between 100 µm and 1 mM. (Shannon et al., 
2000). Application of 1 mM tetracaine had a relatively rapid effect in significantly 
reducing the RCaE in both MHS-Hom and MHS-Het myotubes but not in MHN. This 
effect was more profound in MHS-Hom myotubes. The resulting RCaE in tetracaine 
treated MHS-Hom myotubes was not significantly different to that found in untreated 
MHN myotubes. Thus, blocking the RYR1 leak induces a reduction in the RCaE to 
baseline levels seen in MHN myotubes. These results complement those of Cully et 
al. (2018) who found that in human MHS, there was a greater RYR1 leak which at 
 191 
[Ca2+]i >200 nM caused the depletion of the Ca2+ from the T-system, (indicating an 
influx of Ca2+ from the extracellular space). On the other hand, at [Ca2+]i lower 
<200 nM there was an increase in the T-system [Ca2+]. Finally, a tetracaine mediated 
inhibition of the RYR1 leak led to an increase in the T-system [Ca2+]. 
 
The rapid nature of the tetracaine effect seen in this chapter needs further 
assessment with other antagonists of the leak state such as bastadin 5, and the rycals 
(S107, JTV519) which are RYR1 stabilisers. This would help determine whether they 
too also have a similar effect on the RCaE and/or the enhanced sensitivity to RYR1 
agonists such as caffeine (Bellinger et al., 2009; Andersson and Marks 2010; Eltit et 
al., 2010). Another inhibitor of SR Ca2+ release is Dantrolene, and this too would have 
value in more detailed studies into the mechanisms driving the increased RCaE in the 
p.G2435R model. Another interesting reason to investigate this compound in this 
context is that it has been shown to block ECCE (Cherednichenko et al., 2008; Eltit 
et al., 2013; Choi et al., 2017). 
 
 
 
6.6 Conclusion 
In summary, the results above demonstrate that myotubes from the novel knock-in 
mouse expressing the p.G2435R variant, which is equivalent to human p.G2434R 
have an enhanced sensitivity to the RYR1 channel activators caffeine, halothane and 
potassium chloride thus validating their use for MH research. This MH RYR1 variant 
leads to intracellular modifications which ultimately cause an enhancement in the 
entry of extracellular Ca2+ which is mediated by channels that contain TRPC3 and 
TRPC6. This extracellular entry fulfils the cell boundary theorem and allows 
maintenance of a new equilibrium with an elevated cytosolic Ca2+. The MH cells are 
now in a primed state which leads to a hypermetabolic reaction upon exposure to MH 
triggering anaesthetic agents. The entry of extracellular Ca2+ through TRPC3/6 
channels provides new targets for drug development that could be used in the 
treatment of this potentially fatal condition. 
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7. General Discussion  
7.1 Overview and Importance 
MH is a progressive, potentially fatal hypermetabolic skeletal muscle reaction that 
occurs in genetically predisposed individuals upon exposure to certain general 
anaesthetic agents. Over the last 50 years of research into MH, two tests the IVCT 
and the CHCT have been developed to help distinguish patients who are susceptible 
to MH. These diagnostic tests were established prior to the identification of the genetic 
mutations that confer susceptibility to this disorder. Since then, RYR1, CACNA1S, 
and now possibly STAC3 have been found to predispose individuals to MH, with the 
majority of the susceptibility conferred by variants in the RYR1 gene. This increased 
knowledge about MH has reduced the need for invasive diagnostic IVCT tests, 
however it has also shown that MH is a complex genetic disorder. It is not fully 
understood how the genetic predispositions lead to the variable phenotype observed 
with this disease or the cellular mechanisms that mediate this.  
 
The results presented in this thesis have focussed on enhancing our understanding 
of the mechanisms that underlie the perturbations in Ca2+ handling seen in MH, and 
whether this can explain the phenotypic diversity seen with RYR1 variants. Functional 
studies using fluorescent Ca2+ imaging were undertaken in myotubes from both 
human MHS patients and a novel knock-in mouse model of MH. This mouse harbours 
p.G2435R RYR1 variant which is equivalent to the human p.G2434R RYR1 MH 
variant.  
 
7.2 Findings and Future Progress 
7.2.1 Are the p.D1056H, p.R2355W and p.D3986E RYR1 Variants Functionally 
Pathogenic? 
The large advances in sequencing technologies have led to the identification of many 
novel RYR1 variants that’s are thought to be associated with MH, however 
developments in the systems that can be used to assess such variants have not been 
as rapid (Kim et al., 2015; Riazi et al., 2018; Miller et al., 2018). Traditional systems 
using models such as HEK cells, allow the protein of interest to be overexpressed for 
functional studies. In this thesis, two potentially pathogenic variants and one EMHG 
diagnostic variant were studied using this system. p.D1056H and p.D3986E did 
indeed enhance the sensitivity to caffeine and thus this research delivers further 
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evidence for their incorporation into the EMHG diagnostic mutations list (EMHG, 
diagnostic mutations, 2019). However, p.D2355W an EMHG diagnostic mutation, 
was not found to have an enhanced sensitivity to caffeine. This finding was 
inconsistent with other studies (Wehner et al., 2004; Schiemann et al., 2014; Merritt 
et al., 2017), and needs further experimental repeats to determine if the result was 
underpowered.  
 
In general, there are several problems with the HEK functional characterisation 
system, this traditional technique is relatively slow, cumbersome and does not 
necessarily translate into the actual system of interest, in the case of MH, skeletal 
muscle. Newer technologies particularly a recently reported version of CRISPR called 
prime editing (Anzalone et al., 2019), now provide the potential for a much higher 
throughput for the assessment of variants by the generation of multiple cells lines 
containing the variants of interest. In their study, Anzalone et al., (2019) modified the 
Cas9 endonuclease to make it catalytically inactive, and fused it to an engineered 
reverse transcriptase that was programmed with a prime editing guide. This facilitated 
both specific targeting of the enzyme complex and helped guide the edit required. As 
a proof of principle, they successfully used it in >175 edits in human cells including 
reversing disease-causing mutations, and were able to exploit it in post-mitotic mouse 
neurones. Such genome editing systems could then be multiplexed with high 
throughput fluorescent screening platforms such as the FlexStation fluorescent 
microplate reader to assess the effects of the variants on the cell responses to RYR1 
agonists (Molecular Devices, USA). 
 
7.2.2 The Immortalisation of MHS Human Myoblasts 
In this study, although some preliminary progress was made in the immortalisation of 
human MHS and MHN myoblasts, the success rate was poor, with an insufficient 
number of myoblasts differentiating into myotubes. Changing from the g-retroviral 
method to Lentiviral system is likely to assist in the successful immortalisation of 
human MHS cells, however, an alternative approach is to generate pluripotent stem 
cells using fibroblasts derived from MHS and MHN patients and differentiate these 
into myotubes (Chal et al., 2015, Lovino et al., 2015; Rovina et al., 2019; Sun et al., 
2019). An advantage of the latter strategy is that the pluripotent stem cells could be 
differentiated into other cell types, and hence facilitate studies into the effects of RYR1 
variants in other cells that also express RYR1 such as cerebellar Purkinje cells 
(Forrest et al, 2015). 
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7.2.3 RCaE in Human and Mouse MH Cells. 
Functional studies using human MH tissue, animal models of MH, and 
heterologous/homologous expression systems, have all shown that there is an 
enhanced [Ca2+]i in MH tissue which is driven by a greater RYR1 leak of Ca2+ (Lopez 
et al., 1985,, Yang et al., 2007, Eltit et al., 2013; Lopez et al., 2018). This leak occurs 
either as a function of the RYR1 variants directly affecting the RYR1 protein, or for 
the CACNA1S variants, indirectly through altering the bi-directional signalling 
between RYR1 and the Cav1.1 complex (Eltit et al., 2012). Prior to this thesis there 
was little knowledge on how the leak state is maintained in non-triggered MH cells. 
Eltit et al., 2013 suggested there was an entry of extracellular Ca2+ however the 
channels facilitating this was not fully resolved.  
 
This project has revealed that in both human and mouse MH (p.G2435R 
homozygous) myotubes there was an enhanced RCaE which was mediated by the 
TRPC3 and TRPC6 cationic channels. Further studies in the p.G2435R myotubes 
discovered that by inhibiting the RYR1 channel activity, the RCaE could be returned to 
baseline levels found in wild type myotubes. The detailed molecular pathway 
connecting the RYR1 leak to the enhanced TRPC3/6 mediated RCaE has yet to be 
elucidated. Putative mechanisms include depletion of the SR Ca2+ causes an 
activation of SOCE pathways that involve TRPC3/6 channels (Horinouchi et al., 
2012). An alternative concept is that the RYR1 leak mediated elevations in [Ca2+]i 
triggers increases in ROS/RNS, and these subsequently activate TRPC3/6 channels. 
Consistent with this hypothesis, there is increasing evidence to suggest TRPC3 and 
6 channel activity is intimately coupled with ROS/RNS levels (Miller 2006; Kitajima et 
al., 2016; Ma et al., 2016; Oda et al., 2017). There is even more compelling evidence 
for altered levels of ROS/RNS in MH which is mediated by an increased RYR1 leak 
(Durham et al., 2008). Thus, this would be an important avenue for further 
experiments trying to understand the detailed molecular mechanisms underlying how 
the MH-associated RYR1 variants on the SR, lead to changes in Ca2+ handling within 
the sarcolemma. 
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7.2.4 A Model for Enhanced RCaE in p.G2435R MHS-Hom Myotubes 
The results from chapter six from p.G2435R MHS myotubes and data from Lopez et 
al., (2018), have been used to create a putative model explaining how MH skeletal 
muscle cells establish a new equilibrium with an increased cytosolic Ca2+ whilst 
fulfilling the cell boundary theorem (Figure 7.1A-D). The [Ca2+]i is maintained at 
approximately 120 nM with wild type RYR1 (Figure 7.1A). The presence of p.G2435R 
RYR1 variant (as homozygous) causes the RYR1 channel to be “leaky” and this 
increases [Ca2+]i from 120 nM to 265 nM (Figure 7.1B). The increased leak leads to 
a reduction in the SR [Ca2+] (Figure 7.1C). The elevated [Ca2+]i plus reduced [Ca2+]SR 
lead to an enhanced expression and activity of TRPC3/6 channels on the 
sarcolemma,  this permits a larger influx of extracellular Ca2+ i.e. an increased RCaE 
that then facilitates a degree of SR store refilling and the maintenance of the new 
elevated [Ca2+]i (Figure 7.1D).  
 
 
 
  
Figure 7.1: Model for the enhanced RCaE in p.G2435R MHS-Hom myotubes. 
(A) In myotubes from MHN (wild type RYR1) mice the [Ca2+]i in the resting state is 
approximately 120 nM. (B) The presence of homozygous p.G2435R variant causes an 
increasingly leaky RYR1 channel which leads to an elevated [Ca2+]i from 120 nM to 265 nM 
and a reduction in the SR [Ca2+] (C). (D)The elevated Ca2+ plus reduced [Ca2+]SR causes an 
enhanced expression and activity of TRPC3/6 channels on the sarcolemma thus allowing a 
larger influx of extracellular Ca2+ (RCaE); this permits a degree of refilling of the SR stores and 
the maintenance of the new elevated [Ca2+]i.  
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The consequence of a chronically elevated [Ca2+]i, is that there is a potential 
requirement for intracellular organelles particularly the mitochondria to adapt their 
Ca2+ handling to tolerate the new [Ca2+]i. Indeed, changes in the metabolic activity of 
mitochondria has been observed in both mice and human MH (Giulivi et al., 2011; 
Chang et al, 2019). Chang et al., (2019) used high-resolution respirometry to study 
human MH skeletal muscle fibres at rest, they found there was evidence of greater 
mitochondrial mass and a functional deficiency that included the uncoupling of 
oxidative phosphorylation in MHS mitochondria. Others have described changes in 
the mitochondrial ultrastructure in MHS mice (Durham et al., 2012). An interesting 
path of investigation would be to assess whether there are alterations in the 
expression of splice variants of MICU1; this is part of the mitochondrial Ca2+ uniporter 
complex (MCU) and mediates Ca2+ uptake into mitochondria. The splice variant 
MICU1.1 is found to be specifically expressed in skeletal muscle (Reane et al., 2016). 
It is conceivable that this splice variant is downregulated to prevent excess Ca2+ 
uptake into the mitochondria in MH cells. Another avenue of study would be to 
investigate the role of RYR1 variants in glucose homeostasis, as Altamirano et al., 
(2019) have reported an elevated incidence of hyperglycaemia in MHS patients, and 
found the p.R163C mice had an impaired glucose tolerance. 
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7.3 Final Summary 
 
Overall this work has made a significant contribution to the MH field by enhancing our 
understanding of the altered Ca2+ handling seen in this skeletal muscle pathology.  
 
It has provided some preliminary experiments for the immortalisation of human MH 
myoblasts; however, further research is necessary before a robust platform can be 
developed. Using a HEK expression system this thesis contributes further evidence 
for the inclusion of the RYR1 variants p.D1056H and p.D3986E on the EMHG 
diagnostic mutations list.  
 
The results provide the first report for the presence of an enhanced entry of 
extracellular Ca2+ in human MHS tissue in the resting state. This RCaE was shown to 
be mediated by the cationic channels TRPC3 and TRPC6. Experiments with 
myotubes from the p.G2435R KI mouse model also confirmed an elevation of this 
Ca2+ entry pathway in homozygous p.G2435R mouse myotubes, and that it was 
mediated by TPRPC3 and TRPC6 channels. Further studies revealed that this 
enhanced RCaE could be lowered to control levels by blocking RYR1, and thus 
suggesting the increased RCaE is being driven by the RYR1 variant associated SR 
Ca2+ leak. Taken together these results suggest that the pathways underlying the 
enhanced RCaE seen in MH tissue is conserved across species and provides an 
avenue for further research, plus potential novel therapies for MH and other RYR1 
related pathologies.  
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